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ABSTRACT 
Changes in gene expression and protein levels are an important aspect of 
cardioprotection in which short non-coding RNA known as miRNA may play a key 
regulatory role. We investigated the functions of several miRNAs in the context of two 
cardioprotective stimuli, ischemic preconditioning (IPC) and mesenchymal stem cell 
(MSC) paracrine effects. We hypothesized that downregulation of a set of miRNAs 
(miR-148a/b, miR-30b, and let-7a*) augments expression of protective heat shock 
proteins during IPC, and that MSC exosomes transfer miR-21 to cardiomyocytes, 
resulting in downregulation of pro-apoptotic genes and reduction of infarct size.  
IPC increased the level of Hsp70, Hsp90, and Hsp40 family members within 6 
hours as measured by qPCR and Western blot. Luciferase reporter assays and miRNA 
mimic transfection and knockdown were used to confirm effects of miR-148a/b, miR-
30b, and let-7a* on translation. Combinations of miRNAs had more pronounced effects 
than single miRNAs alone. Pretreatment with wild type exosomes, but not those lacking 
miR-21, reduced cell death in vitro, and decreased infarct size in mice. The wild type 
exosomes, and miR-21 mimic, decreased protein levels of the miR-21 target genes Fas 
Ligand, Programmed Cell Death 4, Phosphatase and Tensin Homolog, and Pellino1.  
In conclusion, a small set of miRNAs may act synergistically as regulatory nodes 
in a heat shock protein expression network after IPC. Future studies will test whether 
manipulation of this set of miRNAs can induce cardioprotection. miR-21 plays a key 
role in pro-survival paracrine effects mediated by MSC exosomes. Future studies will 
test whether MSC exosomes mediate regeneration as well as cardioprotection.  
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CHAPTER 1 
INTRODUCTION 
THE ROLE OF MICRORNA IN ISCHEMIC PRECONDITIONING 
Myocardial Infarction and Ischemia/Reperfusion Injury 
It is estimated that 735,000 Americans experience a myocardial infarction (MI) 
each year1. MI occurs when a coronary artery is obstructed by an atherosclerotic plaque, 
clot, or vasospasm, causing the myocardium to be deprived of oxygen and nutrients, 
which is known as ischemia. Patients experience chest pain, nausea, dizziness, and 
fatigue. Most patients are admitted to the hospital 2.5 to 3 hours after onset of 
symptoms. The clinical treatment for MI is to re-open the artery through percutaneous 
intervention (PCI) or provide thrombolytic therapy. After the artery is re-opened, 
reperfusion of the myocardium occurs. While timely reperfusion is crucial to limit 
infarct size, reperfusion itself causes further injury, accounting for 30 to 50% of the 
cumulative damage2, 3, which is known as ischemia/reperfusion (I/R) injury. During the 
next hours and days, the infarcted tissue is broken down in a process known as 
coagulation necrosis, and then neutrophils and macrophages infiltrate and phagocytose 
the dead cells. Next, granulation tissue forms, ultimately giving rise to a collagenous 
acellular scar within 6 to 8 weeks4. Complications from MI include heart failure, 
arrhythmia, future MI, angina pectoris, stroke, and sudden death1. Likelihood of these 
 
	
2 
complications is directly linked to the infarct size, so treatments to reduce this are of 
great clinical interest.  
During ischemia ATP levels fall due to lack of oxygen, which is required for 
oxidative phosphorylation. Cardiomyocytes switch to anaerobic glycolysis, which leads 
to acidosis, or accumulation of H+ ions. These cause the membrane sodium-hydrogen 
exchanger to overload the cell with Na+, which in turn causes Ca2+ overload because of 
reverse operation of the sodium-calcium exchanger. Lack of ATP prevents the Na+/K+-
ATPase pump from correcting the imbalance, resulting in osmotic swelling. Likewise, 
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump can no longer efficiently 
pump Ca2+ into the sarcoplasmic reticulum (SR), leading to further cytosolic Ca2+ 
accumulation. Increases in cytosolic Ca2+ cause necrosis in cardiomyocytes through 
activation of proteases and mitochondrial damage.  
Restoration of blood flow re-introduces oxygen, and oxidative phosphorylation 
resumes. The renewed presence of ATP during cytosolic Ca2+ overload causes 
hypercontracture, and normalization of pH leads to opening of the mitochondrial 
permeability transition pore (MPTP). This causes mitochondrial uncoupling, generation 
of oxygen free radicals, and activation of apoptosis. Furthermore, due to the abundance 
of reduced metabolic substrates that accumulated during ischemia, a burst of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) are generated by the 
resumption of oxidative phosphoryation. These damage other proteins, and misfolded 
proteins accumulate, inducing the endoplasmic reticulum (ER) stress response. 
Autophagy increases during I/R injury, but it is unclear whether this is beneficial or 
detrimental. 
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Cells die from I/R injury primarily due to both necrosis and apoptosis. Necrosis 
is a form of loosely regulated accidental cell death, and occurs during ischemia from 
osmotic swelling and compromised membrane integrity. Rupture of cardiomyocytes is 
pro-inflammatory and leads to the release of biomarkers of MI, such as Troponin I and 
creatinine kinase, into the bloodstream.  
Apoptosis, on the other hand, is the tightly regulated process wherein cells die 
while breaking down their components, which remain membrane-bound. 
Morphologically, the cell shrinks and its chromatin condenses before the nucleus 
fragments. Then the cell separates into apoptotic bodies. Phosphatidylserine is exposed 
on the external leaflet of the membrane, which is a signal for the apoptotic body to be 
phagocytosed, thus no cellular contents are released and inflammation does not occur. 
Both extracellular and intracellular signals can lead to initiation of apoptosis 
during I/R injury. Extrinsic apoptosis is caused by the binding of a death inducing 
ligand, for example, Fas ligand (FasL) to a cell surface receptor such as Fas, leading to 
receptor trimerization, which recruits adapters such as Fas-associated death domain 
protein (FADD). FADD organizes the death inducing signaling complex by recruiting 
procaspase-8 or -10, causing them to be cleaved and thus activated5. FasL/Fas signaling 
is well accepted to play a role in apoptosis in the contexts of MI and post-infarction 
remodeling6-8. 
Intrinsic apoptosis can be initiated in the heart by I/R injury due to prolonged 
activation of the ER stress response9-13 or mitochondrial damage, or Ca2+ overload. It is 
regulated by the mitochondria through the MPTP and the association of pro-apoptotic 
Bcl proteins, which form channels in the outer membrane, leading to mitochondrial outer 
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membrane permeabilization (MOMP). Cytochrome c leaks from these channels and 
together with the adaptor protein Apaf-1, caspase-9, and ATP forms the apoptosome. 
This activates caspase-9, leading to cleavage of downstream caspases and execution of 
apoptosis. It is also regulated by the endoplasmic reticulum through activation of 
caspase-12 during the ER stress response, which can activate caspase-9 independently of 
the apoptosome14. Both extrinsic and intrinsic apoptotic pathways begin with the 
activation of apical caspases and converge upon activated “executioner” caspases-3 and -
7.  
Ischemic Preconditioning 
Ischemic preconditioning (IPC) is an endogenous cardioprotective response to 
brief, non-lethal bouts of ischemia and reperfusion. Initially discovered in 1986 by 
Murry et al. in dogs15, it was subsequently demonstrated in many species, including 
rodents16, 17, rabbits18 and pigs19. Together with the risk associated with repeatedly 
occluding the culprit artery (which is likely to be atherosclerotic and fragile), the 
unpredictable nature of MI has limited the direct translation of IPC to the clinic for this 
condition, despite clinical trials supporting that it is protective in the context of planned 
cardiac surgeries such as coronary artery bypass grafting and elective PCI20. 
Furthermore, it led to the investigation of ischemic post-conditioning, in which a 
blocked coronary artery is re-opened repetitively after an ischemic episode, which 
ameliorates reperfusion injury21-23. It also laid the groundwork for the study of remote 
ischemic preconditioning (RIPC), in which preconditioning occurring in one vascular 
bed confers protection to an area at risk in a subsequent I/R injury24, 25.  
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IPC consists of two phases, an early and a late phase26, 27. The early phase is 
effective immediately after preconditioning, and lasts 1 to 3 hours. It results from 
activation of G-protein coupled receptors including the opioid, bradykinin, and 
adenosine receptors, leading to kinase cascades that activate protein kinase C (PKC) and 
lead to mitochondrial KATP channel opening. These kinases, known as reperfusion injury 
salvage kinases (RISK), include Akt (also known as protein kinase B) and extracellular 
regulated kinase-1 and -2 (ERK1/2)28. Protective levels of autophagy and mitophagy, the 
autophagy of mitochondria, are also triggered29-32. Furthermore, cellular ATP levels are 
preserved during I/R injury in preconditioned cardiomyocytes33. These events act 
together to protect cells against prolonged I/R injury occurring within a few hours after 
IPC.  
By contrast, the late phase of IPC takes effect 12 to 24 hours after an IPC 
stimulus, and lasts 3 to 4 days. Late IPC relies on synthesis of protective proteins34, 35. 
PKC and the mitochondrial KATP channel appear to act as important bridges between 
early and late IPC36. Signaling that takes place during the early phase of protection 
results in the activation of transcription factors such as NF-κB37, 38, Hif-1α39, STAT-340 
(potentially STAT-5 in man41), and others, which reprogram gene expression. Proteomic 
studies have revealed several functional groups of proteins that are upregulated to allow 
the heart to adapt to ischemia. These include metabolic enzymes, anti-oxidative proteins, 
chaperones, and cytoskeletal components42, 43. The requirement for some of these 
proteins, including heat shock protein 70 (Hsp70)38, has been established through use of 
knockout mice, revealing that IPC’s reduction in infarct size cannot occur in the absence 
of that protein.  
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Chaperone expression after IPC is a key aspect of cardioprotection because it 
directly counteracts one of the mechanisms of I/R injury, the accumulation of damaged 
and misfolded proteins. The heat shock protein (HSP) family includes many genes that 
work together in the heat shock and unfolded protein response pathways to fold nascent, 
unfolded, or damaged proteins. Hsp70 and Hsp90 bind exposed hydrophobic regions of 
unfolded proteins and catalyze ATP to refold them. Hsp40 stimulates Hsp70’s ATPase 
activity, increasing the rate of refolding, and some family members can also bind 
unfolded proteins directly.  
Hsp20 The small heat shock protein family includes Hsp27, αA-crystallin, αB-
crystallin, Hsp20 and Hsp22, among others44, 45. Under normal conditions, these form 
large, inactive multimers. Under stress, phosphorylation causes them to disperse as 
homodimers, and bind to unfolded proteins, preventing aggregation. They do not 
themselves refold the proteins, but allow them to be refolded by Hsp70. Hsp20 has been 
demonstrated to be highly cardioprotective against I/R injury in mice46-49. Hsp27 and 
αB-crystallin are also protective through stabilization of cytoskeletal and sarcomeric 
structures50-52. Overexpression of Hsp27 reduced infarct size in an isolated perfused 
heart model compared with wild-type littermates53. Highlighting the importance of 
normal small HSP function, a mutation in αB-crystallin was shown to result in desmin-
related cardiomyopathy due to aggregation of unfolded pre-amyloid oligomers along 
with impaired autophagy and mitochondrial function54-56.  
Hsp40 The DnaJ/Hsp40 family has over 20 members in mammals, perhaps as 
many as 41 in man, which can be categorized into 3 groups based on their structure57. 
They all share the J domain, through which they interact with the ATPase domain of 
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Hsp70. Types I and II have the J domain and a Gly/Phe rich region which allows them to 
bind to short hydrophobic stretches of unfolded or nascent proteins. Type III DnaJ 
proteins lack the Gly/Phe region, and may or may not bind to client proteins58. In 
addition to these activities, they also assist in the process of endocytosis through 
disassembly of clathrin coats, translocation of ribosomes to the endoplasmic reticulum, 
and delivery of proteins to the proteasome for degradation. The functional diversity of 
this family derives from subtle differences in the structure of the different family 
members, which affect their cellular localization, and the Hsp70 family members and 
client proteins with which they can associate58, 59.  
Several DnaJ family members are expressed in the heart. In H9c2 cells, a cardiac 
cell line, Dnaja1, Dnaja4, and Dnajb1 were shown to be inducible by heat shock. These 
co-localize in the cytosol with Hsp70, and after heat shock, they both translocate to the 
nucleus. Overexpression of Hsp70 alone increased cell survival upon prolonged heat 
shock, and when Hsp70 and either Dnaja1 or Dnaja4 were co-overexpressed, this effect 
was increased60. The results of this study suggest that these DnaJ family members are 
co-chaperones with Hsp70 and act together to protect cardiomyocytes from stress. In a 
swine model of I/R injury, Hsp40 (pig Dnaj-like protein, pDJA1) was increased slightly 
during ischemia, and to a greater extent during the early hours of reperfusion61. 
Furthermore, expression of this protein in neonatal rat cardiomyocytes protected them 
from staurosporine-induced apoptosis. Little is known about expression of Hsp40 family 
members in the heart during IPC, but it was found to increase during cerebral IPC, along 
with Hsp7062. A previous publication from our lab identified Dnaja1 as being 
significantly upregulated at the mRNA level 3h after IPC in the mouse heart38. This 
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effect was partially reliant on NF-κB, because in the dominant negative 2M mouse 
model, which cannot activate NF-κB, the increase was blunted significantly.  
Hsp70 Structurally, Hsp70 proteins consist of an N-terminal ATP binding 
domain and a C-terminal peptide binding domain connected by a flexible linker. The 
peptide domain, in turn, consists of the substrate binding domain and a helical lid region. 
The substrate binding domain interacts with hydrophobic 5 amino acid stretches of 
unfolded client proteins. When ATP is bound, the conformation is such that the peptide 
binding domain interacts loosely with client proteins, binding and releasing them 
rapidly. After ATP hydrolysis (stimulated by the DnaJ co-chaperone), Hsp70 binds 
stably to the protein, preventing aggregation58. Release of the client protein requires 
interaction with a nucleotide exchange factor (NEF), such as Hsp110, recycling Hsp70 
to the ATP bound open state. Once released, the client protein has a chance to fold 
correctly, or be re-captured by Hsp70. There are both inducible and constitutively 
expressed Hsp70 family members. The constitutively expressed proteins are known as 
Hsc70, and are continually present to fold nascent proteins in the cytosol and ER. 
Grp78/BiP has the dual role of being both a chaperone and a sensor of ER stress.  
The inducible Hsp70s were among the first proteins to be recognized as effectors 
of late IPC63. In a transgenic mouse model, overexpression of Hsp70 was shown to be 
sufficient on its own to induce cardioprotection as evidenced by reduced infarct size and 
enhanced contractile function in the isolated perfused heart64. Furthermore, targeted 
knockout of both inducible Hsp70 family members (Hsp70.1 and Hsp70.3) prevents 
infarct size reduction in late IPC38, 65, though it has no effect on early IPC65.  
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Hsp70.1 and Hsp70.3 are identical proteins in man, but in the mouse, Hsp70.1 
has the insertion of a proline residue in the lid region of its peptide binding domain. The 
effect of this change on the function of the protein is unknown, but our group has shown 
that Hsp70.1 is not required for IPC, and that Hsp70.1 knockout mice have significantly 
smaller infarcts compared with wild-type mice, indicating that murine Hsp70.1 is 
injurious in the context of I/R injury38. However, we also showed that in the context of 
permanent occlusion, Hsp70.1 is protective66. It remains to be seen whether this is a 
unique aspect of murine Hsp70.1 amino acid sequence, or is due to differential 
regulation, and whether this extends to other mammals.  
Hsp90 Like Hsp70, Hsp90 can hydrolyze ATP and actively refold misfolded 
proteins. Hsp90 has two family members, Hsp90A and Hsp90B, which are constitutively 
expressed and further increase upon heat shock. Hsp90 has an N-terminal ATPase 
domain, followed by a stretch of charged residues, and a C-terminal dimerization 
domain. The exact features of the client proteins that Hsp90 binds are under 
investigation. Like Hsp70, Hsp90 functions through cyclical ATP/client protein binding, 
hydrolysis, and release. The ATP bound form of Hsp90 is closed and tightly binds the 
client protein. The cofactor P23 stabilizes the ATP bound state and assists in folding. 
Then Hsp90 hydrolyzes ATP and releases the protein, which can be re-bound if 
necessary. Hsp90 and Hsp70 can work together; the protein Hop can transfer substrates 
from Hsp70 to Hsp90.  
Hsp90 was shown to increase after heat shock or metabolic preconditioning 
(consisting of exposure to lactic acid and 2-deoxy D-Glucose at pH 6.8), which was 
protective in cultured adult rat cardiomyocytes upon prolonged heat shock or ischemia 
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67. Other than enhancing protein homeostasis, one proposed mechanism for 
cytoprotection is that Hsp90, along with Hsp70 and αB-crystallin prevent the release of 
apoptotic factors such as SMAC/Diablo from the mitochondria68. Furthermore, Hsp90 
has been shown to be required for proper functionality of other cardioprotective proteins. 
For example, it was shown to target the mitoKATP channel to the mitochondrial 
membrane in order to mediate hypoxic preconditioning in vitro69, and to co-localize with 
eNOS after anesthetic preconditioning and IPC in a rabbit model, which was required for 
eNOS function70.  
Regulation of HSP expression in IPC HSP expression is controlled by the 
activation of the heat shock factor (HSF) family of transcription factors, which includes 
HSF-1 through -4. Other transcription factors are now known to play important roles as 
well, including NF-κB. Using a cardiac-specific dominant negative mouse model of NF-
κB activation, mediated by overexpression of inhibitor of κB α (IκBα) which cannot be 
phosphorylated, we showed that Hsp70 protein does not increase in the heart during late 
IPC, which was associated with failure of IPC to reduce infarct size in these mice38. It is 
also becoming clear that microRNA (miRNA) plays a role in gene expression during late 
IPC in general, and in the expression of HSPs specifically. 
MicroRNA 
MicroRNAs (miRNAs) are short 19-22 base RNA molecules that influence 
transcription and translation of mRNA in many circumstances. Most often, they exert 
their activity by binding to the 3’ untranslated region (3’-UTR) of target mRNAs and 
cause translational silencing and degradation. The first miRNA was discovered in C. 
elegans in 199371. Since that time, the number of miRNAs and their predicted targets 
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have expanded until now it is believed that most protein-coding genes are subject to 
regulation by miRNA72.  
Like mRNAs, miRNA genes are transcribed by Pol II, producing a precursor 
known as the pri-miRNA. This is then cleaved by Drosha within the microprocessor 
complex into a hairpin structure known as pre-miRNA, and exported from the nucleus. 
Subsequently, it is cleaved by Dicer into a short double stranded RNA duplex, which is 
incorporated into the RNA-induced silencing complex (RISC), and one strand is 
removed73. The mature miRNA within the RISC is associated with Argonaute-2 (Ago-
2), which has endonuclease activity, and regulates its mRNA targets through 
complimentary base pairing, in a process known as RNA interference. A few simple 
rules form the basis of much accurate target prediction72. Nucleotides 2-7 of the miRNA 
are known as the seed sequence. These nucleotides pair perfectly, or nearly perfectly, 
with a sequence in the 3’-UTR of the target mRNA. Predicted targets that are conserved 
across multiple species are more likely to be functional. Lastly, effective repression 
usually occurs at sites that are away from the middle of long UTRs, and that have higher 
local AU content, which affects accessibility72, 74. It is believed that whether the mRNA 
will be degraded or only silenced is based on the extent of base pairing that occurs 
outside of the seed sequence75.  
Because miRNAs are so short, and because base pairing does not have to be 
perfectly complimentary, each miRNA is predicted to have numerous mRNA targets, 
and likewise, most mRNAs are predicted to be regulated by numerous miRNAs. This 
suggests the interesting possibility that miRNAs could act as nodes in a network of gene 
regulation, such that changes in the level of one miRNA could affect the expression of 
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many functionally related genes. Indeed it has been suggested that this is the case76, 77. If 
miRNAs can be identified that regulate groups of protective genes, manipulating one or 
more of them could have strong protective effects, which would be of interest clinically. 
Synergistic physiological effects between two or more miRNAs in the heart have been 
reported. For instance, Pisano et al. showed that miR-499 and miR-133 synergistically 
induced differentiation of embryonic stem cells to cardiomyocytes78, and Zhu et al. 
demonstrated that miR-21 and miR-1 act synergistically to reduce cell death from 
oxidative stress79.  
The roles of a few miRNAs in IPC have been identified. For instance, the miR-
144/451 family was shown to be required for IPC, when increased expression 
downregulates Rac-1. This downregulation reduces the activation of NADPH oxidase, 
reducing the generation of reactive oxygen species80. Similarly, miR-21 has been found 
to increase in multiple forms of cardioprotection, including ischemic pre- and post-
conditioning as well as isofluorane-induced preconditioning81, 82, downregulating the 
expression of pro-apoptotic genes such as Programmed Cell Death 483, PTEN84 and 
FasL85.  
Meanwhile, other miRNAs have been found to decrease during IPC, in order to 
derepress protective genes. For example, miR-199 is downregulated by IPC, allowing 
the transcription factor HIF-1α to accumulate and activate pro-survival gene 
expression86. We have shown that miR-711 and miR-378* both decrease after IPC to 
allow increased expression of their target, Hsp7087. Three hours after IPC, miR-711 and 
378* were both found to be decreased in heart tissue, whereas Hsp70.3 mRNA was 
increased ~25-fold. Through use of the 2M dominant negative IκB mouse, we 
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determined that the increase in Hsp70.3 as well as the decrease in miR-711 are 
dependent on NF-κB activation. Luciferase assays confirmed that these miRNAs target 
the 3’-UTR of Hsp70.3, and transfection of synthetic miRNA mimics confirmed that 
both of these miRNAs can downregulate Hsp70.3 protein87. It was further demonstrated 
that transfection of HL-1 cells with an inhibitor of miR-378* could induce expression of 
Hsp70 (unpublished data). However, it is not known whether a set of miRNAs regulates 
the expression of related sets of genes, such as HSPs, in IPC. A goal of this work is to 
identify miRNAs that could act as regulatory nodes for numerous heat shock protein 
family members during IPC (Results p67). This was accomplished through use of 
mRNA and miRNA sequencing, in vitro targeting analysis, 3’-UTR reporter assays, and 
gain- and loss-of-function techniques to test miRNA effects on expression of HSPs.  
MIRNA AS A PARACRINE MEDIATOR FROM MYOCARDIUM TO TRANSPLANTED 
MESENCHYMAL STEM CELLS 
Endogenous Regenerative Potential of the Myocardium 
In the mammalian heart during cardiac development, cardiomyocytes increase in 
number after birth for a short time (a few days in mice, a few months in humans), and 
then further growth of the heart is achieved by increases in cell size88. During the very 
early postnatal period of cardiomyocyte cell division, it was demonstrated in mice that a 
surgical wound to the apex of the heart could heal completely, whereas a similar wound 
occurring one week after birth causes fibrosis and permanent damage89. Using a fate 
mapping approach, the source of the cells that regenerated the wound was shown to be 
neighboring cardiomyocytes, indicating that early on, cardiomyocytes are capable of 
proliferation.  
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After the postnatal period of cardiomyocyte proliferation, cardiomyocytes 
increase dramatically in size but cease dividing. In order to accomplish this 
physiological growth, it appears that mammalian cardiomyocytes must replicate their 
DNA90. In rodents, cardiomyocytes undergo karyokinesis but not cytokinesis, leading to 
a predominant population of binucleate cardiomyocytes (wherein each nucleus is 
diploid), beginning at approximately 4 days of age through adulthood91. In humans, 
cardiomyocytes also replicate their DNA during the pre-adolescent growth phase (8-12 
years of age), but undergo neither karyokinesis nor cytokinesis. Thus the majority (60%) 
of cardiomyocytes in the healthy heart over age 7 are tetraploid but mononucleate92, 93, 
with about 25% of cardiomyocytes being binucleate, and very small percentages of tri- 
and tetranucleated cells94. In hypertrophied hearts, ploidy increases such that octaploid 
nuclei predominate, with a small fraction of nuclei observed to be up to 32-ploid. 
Increases in myocyte cell number have also been documented in grossly hypertrophied 
hearts, weighing over twice the normal heart weight95.  
After development, there is limited capacity for further cell division. The degree 
of cell turnover within the heart is debated within the field, because different methods 
suggest different rates of turnover96. Genetic approaches in combination with “pulse-
chase” experiments have provided some insight into the rate of proliferation in mice. 
One such experiment labeled cardiomyocyte nuclei with transgenic expression of β-
galactosidase (driven by the cardiomyocyte-specific α-myosin heavy chain promoter) 
and newly synthesized DNA with radioactive thymidine. These researchers found a low 
baseline level of cell division of 0.0005%, which increased to 0.0083% after 
cryoinjury97. In another study98, cardiomyocyte nuclei were permanently labeled, and 
 
	
15 
then mice were infarcted or subjected to pressure overload. In the control mice, the 
percentage of cardiomyocytes with labeled nuclei remained constant at 83%, while in the 
injured mice, the percentage decreased to 68% in the border zone after MI and 76% in 
the remote region or under pressure overload, indicating that new myocytes had arisen 
from a non-cardiomyocyte source. This may have been resident cardiac stem cells 
(CSCs) or circulating multipotent stem cells mobilized from the bone marrow. By 
performing in situ hybridization for Y-chromosomal DNA in combination with 
immunohistochemistry for cardiomyocyte markers in sex-mismatched heart transplant 
patients, it has been demonstrated that cells from the host become cardiomyocytes in the 
transplanted heart, albeit at low levels (≤1% of cardiomyocytes)99, 100. In man, relying on 
environmental levels of 14C that have fluctuated over time to label the DNA of 
cardiomyocytes, Bergmann et al. found that turnover does occur in the adult heart at 
estimated rates of 1% in young adulthood, decreasing to 0.4% in the aging heart101. The 
fact that regeneration can occur in neonatal and even adult hearts, albeit to a very limited 
extent, raises the possibility that this endogenous capacity could be enhanced 
experimentally and perhaps therapeutically.  
Stem Cell Therapy for Regeneration of the Myocardium 
It is clear that the endogenous potential for repair is insufficient to replace the 
millions of cardiomyocytes lost during MI. This was the rationale for the first 
experiments using stem cell transplantation as a therapeutic. It was hypothesized that the 
stem cells would engraft and differentiate into cardiomyocytes, replacing the lost cells 
and helping to improve heart function. A number of different types of cells have been 
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explored for their regenerative potential, including embryonic and adult stem cells. The 
first of these was the skeletal myoblast.  
Skeletal Myoblasts In 1992, Marelli et al.102 transplanted autologous skeletal 
satellite myoblast cells into cryoinjured canine hearts. In this and other subsequent 
studies, researchers found that the skeletal myoblasts remained viable and gave rise to 
grafts of striated muscle tissue in the recipient heart. In fact, studies in animal models 
showed that these grafts had the capacity to become quite large, affecting the shape and 
function of the heart. Furthermore, they failed to express gap junction proteins after 
transplantation, indicating that they did not establish functional electrical coupling with 
neighboring cardiomyocytes103. Clinical trials initially reported improvements in ejection 
fraction and heart function104, but these were not sustained, while the risk of arrhythmia 
persisted at 4 year follow-up105. It is thought that the initial improvements may have 
been due to remodeled scar formation or improved elasticity of the ventricular wall in 
the area of injury.  
Bone Marrow Mononuclear Cells (BMMNC), a heterogeneous population that 
includes hematopoietic stem cells (HSC) and endothelial progenitor cells (EPC), as well 
as other types of precursors, have also been explored in the context of transplantation for 
MI. In 2001, Piero Anversa’s group isolated c-kit positive (c-kit+) bone marrow stem 
cells from enhanced green fluorescent protein (EGFP) expressing donor mice, and 
injected them into recipient mice’s myocardium 3-5 hours after infarction. Nine days 
later, they found that these stem cells had formed new myocardial tissue which occupied 
68% of the infarct zone and was comprised of mainly cardiomyocytes, with GFP+ 
endothelial cells and smooth muscle cells also noted106. Fernandez-Aviles et al. also 
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showed that human bone marrow cells isolated from patients post MI could engraft and 
differentiate into cardiomyocytes when cultured on slices of cryoinjured mouse heart 
tissue107. In the same study, they transplanted the autologous bone marrow cells into the 
patients’ hearts approximately 2 weeks after MI. This resulted in reduction of ventricular 
remodeling and improvements in regional and global left ventricular function. Other 
studies pointed to angiogenesis as the main benefit of BMMNC transplantation in animal 
studies108, 109. In light of these encouraging results, clinical trials were quickly initiated, 
and showed modest functional benefits in man110. Even as clinical trials were underway, 
debate arose about the mechanism of the observed benefits.  
At issue were both the persistence and capacity of the transplanted stem cells to 
differentiate into cardiomyocytes or other therapeutically relevant cell types. Scherschel 
et al. injected a series of different bone marrow derived stem cell populations, including 
one that matched those used by Anversa’s group in their 2001 publication, into infarcted 
mouse hearts. As before, these cells were tracked by EGFP expression. After 9 to 10 
days, they sacrificed the mice and used two-photon laser scanning microscopy to detect 
intracellular Ca2+ currents in the host and donor cells, which were found in clusters 
within the infarct and border zone. None of the >3000 donor cells tested exhibited Ca2+ 
transients111. In this study and others112-114, engrafted HSC failed to express cardiac 
tissue markers or adopt cardiomyocyte morphology. Furthermore, while engraftment 
was consistently detected at day 9, by week 4 after injection most of the cells were 
gone112, 113.  
In light of the growing body of data that showed convincing improvements in 
heart function, without a corresponding amount of engraftment or transdifferentiation115, 
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the paracrine hypothesis became widely accepted as an important mechanism of 
action116. This hypothesis suggests that stem cells release factors that exert effects on the 
injured myocardium including cardioprotection, angiogenesis, and decreased scar size. It 
is unclear whether paracrine effects also result in myogenesis, and if so whether the 
source of new myocytes is cell division of existing cardiomyocytes or differentiation of 
resident cardiac stem cells.  
Cardiac Stem Cells and Cardiosphere Derived Cells Evidence for resident 
cardiac stem cells (CSCs) was initially presented in 2002 by Hierlihy, et al.117. They 
isolated a population of cells with stem-cell like properties from the adult mouse 
myocardium by fluorescence assisted cell sorting (FACS). This population, which 
constituted ~1% of the total cells sorted, could be expanded through colony formation 
and differentiated into cardiomyocytes in vitro. Beltrami et al.118 further described CSCs 
as small, immature cells that could be found in clusters within the normal aging rat heart. 
They express c-kit as well as some genes involved in cardiac development and 
differentiation including Nkx2.5 and MEF2C. Some also expressed mature 
cardiomyocyte markers such as α-sarcomeric actin. In culture, the CSCs formed 
multicellular spheroids in suspension. When media was changed to differentiation media 
(containing dexamethasone), the spheroids attached and cells differentiating into 
cardiomyocytes, smooth muscle cells, and endothelial cells migrated out of the 
spheroids. Furthermore, over 20 days after injection into infarcted rat hearts, the CSCs 
persisted and appeared to contribute new myocytes throughout the infarct zone, 
generating an average 48 mm3 of tissue that reduced the size of the infarct from 70% of 
the ventricle to 48%118.  
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Similarly, Messina et al. found that CSCs emigrated from small pieces of human 
and mouse heart tissue and formed so-called “cardiospheres” in suspension culture, and 
that the cardiospheres could give rise to new cardiomyocytes and other cardiac cell types 
when transplanted into the infarcted myocardium. Immediately after permanent ligation 
of the LAD, cardiospheres were injected at 4 left ventricular sites. Eighteen days later, 
mice were sacrificed and the hearts sectioned and analyzed. Bands of regenerating 
myocardium with varying degrees of organization and thickness were observed 
throughout the infarcted area, which stained positive for a human nuclear marker 
(indicative of the human source of the cardiosphere derived cells) and cardiomyocyte 
markers myosin heavy chain, connexin-43, or the capillary markers α-smooth muscle 
actin and platelet endothelial cell adhesion molecule119. Scar size, as assessed by H&E 
staining after 18 days, was not reduced significantly, but the anterior wall was 
significantly thicker and fractional shortening was improved as assessed by 
echocardiography. 
Based on preclinical data showing regeneration as well as capacity for ex vivo 
expansion, cardiosphere derived cells (CDCs) presented an opportunity to transplant 
autologous stem cells after MI. The Phase I CADEUCEUS trial120, conducted by 
Marban and colleagues, showed that this procedure was safe, and that after 1 year scar 
size was decreased, while muscle mass increased121. However, data from animal studies 
later supported that CDCs act primarily through paracrine mechanisms without long-
term engraftment122, 123. Regeneration, which persisted long after the transplanted cells 
were cleared, was observed to result from proliferation of existing cardiomyocytes as 
well as recruitment of endogenous CSCs to differentiate124. Because the transplanted 
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cells do not remain in the heart, and have low immunogenicity, it may be possible to 
transplant allogeneic CDCs as a readily available “off the shelf” therapeutic, for which 
the ALLSTAR Phase I/II clinical trial is currently recruiting (identifier, NCT01458405).  
Mesenchymal Stem Cells (MSCs) are another population of cells that reside in 
the bone marrow as well as many other organs and tissues125, including the heart126. 
They were originally identified as a rare population of bone marrow stromal cells with 
the capability to adhere to tissue culture plastic and differentiate into different lineages 
when transplanted in vivo127. Their role in the bone marrow is to support hematopoietic 
stem cells by maintaining the population of osteoblasts, adipocytes, and reticular cells 
which comprise their niche125. Their role in other organs is not completely understood 
because their low numbers make labeling and tracking them technically challenging. 
Other than plastic adherence and the capacity for self-renewal and differentiation into 
mesodermal lineages (adipogenic, osteogenic, and chondrogenic), the International 
Society for Cellular Therapy defines MSCs by the expression of certain cell-surface 
epitopes. In man these are CD73, CD90, and CD105 in the absence of CD34, CD45, 
HLA-DR, CD14 or CD11b, CD79a, or CD19. In mice, MSCs are positive for Sca-1, 
CD29, CD44, CD105, and/or CD106, without CD11b, CD45, Flk1, CD31, CD34, CD90, 
or c-kit128-131. 
In 2000, Wang et al.132 were the first to transplant MSCs into the heart using a rat 
model. In the absence of ischemia or other injury, they injected ex vivo expanded MSCs 
labeled with DAPI into the right ventricle, and looked 4 days to 12 weeks later to 
determine whether they survived and differentiated into cardiomyocytes. At 4 days, they 
observed numerous DAPI+ cells with an immature stem cell like phenotype. After 4 
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weeks, they found a few labeled cells remaining, which had incorporated within the 
myocardium and adopted the same appearance as the surrounding cardiomyocytes. 
Immunohistochemistry of 6 week frozen sections showed the expression of sarcomeric 
myosin heavy chain and connexin 43 proteins in the DAPI labeled cells, suggestive of 
differentiation and functional electromechanical coupling. That MSCs could differentiate 
into cardiomyocytes in vitro by exposure to the DNA demethylating agent 5-azacytidine 
had been recently reported133, and in vivo differentiation was noted subsequently in 
healthy and infarcted myocardium134, 135. Studies in animal models over the next 5 years 
indicated that transplantation of MSCs into hearts with I/R injury resulted in 
improvements in heart function, reduced remodeling, and angiogenesis135-140. In these 
studies, MSCs were transplanted 1 week after MI, with the exception of Shake et al.,135 
who transplanted them 2 weeks after, and Kinnaird et al.,137 whose model was a 
hindlimb ischemia model of angiogenesis.   
MSCs from bone marrow and adipose tissue have been used in clinical trials for 
treatment of acute MI as well as ischemic and non-ischemic heart failure. Bone marrow 
derived MSCs have been tested in phase I and phase II trials with administration within 
1 week of MI. These studies show decreased arrhythmias, improved ejection fraction 
(EF), reduced hypertrophy, heart failure, and rehospitalizations for cardiac 
complications141, 142. Adipose derived MSCs have been tested in a small trial for acute 
MI, and showed reduced scar formation and improved perfusion143. More commonly, 
MSCs have been investigated in the setting of ischemic cardiomyopathy. In clinical trials 
such as POSEIDON, TAC-HFT, and PROMETHEUS, it has been shown that even after 
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chronic ischemia, MSCs can reduce scar size by 30-50%, and enhance contractility, 
angiogenesis, and functional capacity of the patients (reviewed in 144).  
The Mechanism of Action of MSC Transplantation is now understood to 
involve a number of different processes. As with BMMNCs and CSCs, permanent 
engraftment and retention in the myocardium occur at very low levels134, and numerous 
studies support that release of paracrine factors is an important component of MSCs’ 
effects116. Firstly, angiogenesis leading to improvement of myocardial perfusion and 
contractile function is well recognized to occur. MSCs release angiogenic cytokines such 
as vascular endothelial growth factor (VEGF), which act on endothelial cells to form 
new capillaries136. Preconditioning with hypoxia for 24h prior to transplantation of 
MSCs further enhanced their angiogenic properties through upregulation of VEGF, the 
VEGF receptor Flk1, and erythropoietin. The preconditioning treatment also increased 
expression of the pro-survival proteins Bcl-2, Bcl-xL, and Hif-1, which protected the 
MSCs from apoptosis after transplantation, enhancing their effects145.  
MSCs also reduce fibrosis via paracrine mechanisms. In an isoproterenol-
induced heart failure model, transplantation of MSCs almost completely restored heart 
function after 1 month, and reduced fibrosis. This may have been mediated through the 
release of hepatocyte growth factor (HGF) from the MSCs, as supported by the finding 
that HGF was expressed in the MSCs and that MSC transplantation increased HGF 
mRNA and protein levels in the heart146. The MSCs also mediated reduction of mRNA 
levels of collagens I and III, and MMP-2 and -9 in the myocardium. This group then 
showed data in support of a similar role for the antifibrotic protein adrenomedullin in the 
same animal model. Additionally, they showed inhibition of cardiac fibroblast 
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proliferation in vitro and decreased expression of collagen I and III by exposure to MSC 
conditioned medium147. Another experiment on fibroblasts exposed to MSC conditioned 
medium148 showed that it enhanced the expression of matrix metalloproteinases (MMP) -
2 and -9, while downregulating tissue inhibitor of metalloproteinase 2 (TIMP2) and 
confirmed the decrease in fibroblast viability. Based on the paracrine roles of VEGF and 
HGF in angiogenesis and anti-fibrosis, a recent study149 tested whether adenovirally-
mediated overexpression of these factors in transplanted MSCs would enhance these 
beneficial effects in a porcine model. The results showed that HGF overexpression was 
more effective than VEGF overexpression at reducing scar mass and improving ejection 
fraction, and equally effective at increasing blood vessel density and perfusion. This may 
be due to slightly improved survival of the HGF-overexpressing MSCs vs. those 
overexpressing VEGF. Overexpression of either protein improved survival compared 
with the unmodified MSCs.  
Another important paracrine role of transplanted MSCs is stimulation of 
endogenous neomyogenesis by boosting cardiac stem cell function and stimulating 
existing cardiomyocytes to divide. MSC injection has been shown to increase the 
number of endogenous c-kit+ CSCs as well as mitotic cardiomyocytes150. Furthermore, 
co-culture of CSCs with MSCs increases the viability, proliferation, and differentiation 
of the CSCs150, and transplantation of a combination of CSCs and MSCs was shown to 
be more effective than either cell type alone with regard to infarct size, contractility, and 
engraftment of the transplanted cells in the infarcted myocardium151. Thus it is clear that 
MSCs and CSCs interact in a biologically meaningful way; just as MSCs support the 
HSC niche in the bone marrow, perhaps they support CSCs in the heart.  
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Lastly, MSCs may act through direct cardioprotection. Many MSC 
transplantation protocols involve transplanting the cells within hours of the experimental 
MI, thus the observed reduction in infarct size (and associated functional benefits) may 
not be myogenesis or regeneration, but prevention of cell death. This is supported by 
experiments in which MSC conditioned medium (CM), administered near the time of 
reperfusion during experimental MI, exerts cardioprotective effects. To test the paracrine 
effects of CM from regular or AKT-overexpressing MSCs, Gnecchi et al.152 exposed the 
MSCs to hypoxia for 12 hours, concentrated their CM, and injected this or either type of 
MSC into the rat heart 1 hour after reperfusion. The Akt-overexpressing MSCs and their 
CM decreased infarct size by 62% and 45% respectively, as measured by triphenyl 
tetrazolium chloride (TTC) staining at 72h. Their finding indicates that cardioprotective 
factors are secreted into the media of hypoxic MSCs, and that Akt activation increases 
this effect (regular MSCs and their CM showed only modest reductions in infarct size). 
They found that the combination of Akt overexpression and hypoxia treatment 
upregulated VEGF, HGF, insulin like growth factor (IGF-I), and thymosin-β4 (TB4). 
Binding of these factors to their receptors on cardiomyocytes leads to cardioprotection 
through activation of Akt. Other protective factors that have been identified include 
adrenomedullin, interleukin-11, erythropoietin, and fibroblast growth factor-2116. 
Timmers et al. injected CM 5 minutes prior to reperfusion in a pig model, and observed 
a 60% reduction in infarct size, which was assessed 4h after reperfusion153. Fractionation 
of the CM revealed that the protective factor was >1000 kDa in size, and subsequent 
studies showed that it was in fact exosomes.  
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MSC Exosomes Exosomes are small 60-120 nm membrane-bound vesicles that 
are produced and stored within cells in the multivesicular body (MVB). They are 
released constitutively by most cell types by exocytosis and can be taken up by other 
cells in a paracrine or endocrine fashion, through endocytosis. Within the target cell, 
they can release their contents by fusion with the membrane of the MVB. In addition to 
cytokines and trophic factors, MSCs (as well as other stem cell types) release exosomes, 
which are taken up by cardiomyocytes and contain many known cardioprotective 
proteins, bioactive lipids, and RNA154-157. MSC exosomes are the focus of Section 3. 
Preconditioning the Heart: A Technique to Enhance Stem Cell Survival? 
Enhancing MSC engraftment and viability in the host myocardium would 
doubtless extend and magnify their paracrine effects, and thus is of interest clinically. 
While techniques for preconditioning MSC prior to transplantation into the infarcted 
heart have been extensively investigated145, 158-161, less is known about communication 
from the heart to the stem cell.  
There is evidence that inducing cardioprotection at the time of MSC 
transplantation has beneficial effects on MSC survival. Hypothesizing that poor 
engraftment is caused by I/R injury to the heart, one group162 sought to reduce this 
through postconditioning, injecting GFP+ MSCs 2h later. They found that after 4 weeks, 
the number of surviving MSCs in the postconditioned hearts was twice that of the 
control hearts. Capillary density was increased, and functional parameters such as 
ejection fraction were significantly improved. They attributed these effects to 
improvement of the cardiac microenvironment, i.e., reduced release of inflammatory 
cytokines. Another method of cardiac conditioning is electroacupuncture, which appears 
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to protect the heart through both nervous system activation163 and release of soluble 
factors164. When electroacupuncture was added to MSC transplantation, Zhang et al.165 
observed better engraftment after 4 weeks, as well as reduced fibrosis, increased 
capillary density, and improved heart function compared to MSC alone. These studies 
indicate that the preconditioned heart can better support stem cell engraftment, through 
modification of factors released by the infarcted myocardium. In isolated perfused heart 
studies in which the heart is preconditioned, coronary effluent can be collected, warmed, 
reoygenated, and perfused through a naïve heart, which induces cardioprotection in this 
heart166. The identity of the factor(s) released from the heart is not known. However, it 
has been reported that IPC leads to recruitment of bone marrow stem cells via SDF-
1α/CXCR4 signaling, and that infiltration of the myocardium by mobilized bone marrow 
stem cells is an important mediator of the late phase of IPC167. Thus preconditioning of 
the heart changes the signals that it releases, and bone marrow stem cells are sensitive to 
some of these. The heart may have an important though poorly understood role in 
releasing hormones and other signals to the rest of the body. 
Cardiac exosomes, first characterized in the media of isolated rat cardiomyocytes 
by Gupta and Knowlton168, may be a key aspect of these signals. Exosomes carry protein 
and RNA cargo representative of the parent cell, but the contents can change to reflect 
its biological state in response to some stimuli. HL-1 cells, an atrial cardiomyocyte cell 
line, release exosomes that can be taken up by cardiac fibroblasts169. Using microarrays, 
the mRNA and DNA content of the exosomes was identified. Then fibroblasts were 
treated with whole conditioned medium, the exosome fraction, and the exosome-
depleted conditioned medium to examine the effects of the entire HL-1 secretome, HL-1 
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exosomes, and other soluble factors, respectively, on fibroblast gene expression. The 
exosome fraction induced more significant changes in gene expression than did the 
soluble factors (161 vs. 96 changes), including both up- and downregulated genes. 
Stimulation of the HL-1s with growth factors TGF-β2 and PDGF-BB partially changed 
the mRNA content of the exosomes170. About 40% of the transcripts remained constant 
despite the treatments, while a small number of transcripts were shared between both 
growth factor treatments, and others were unique to each growth factor. This likely 
resulted from activation of some shared transcription factors and other transcription 
factors unique to the TGF or PDGF signaling pathways, or changes in the exosomal 
packaging of transcripts may be involved.  
Previous work in the Jones lab showed that miR-711 and miR-378* decreased 3h 
after IPC87. Further experiments (Jones lab, unpublished observations) showed that these 
miRNAs were also decreased in the serum of these mice after IPC compared with sham 
controls, which suggests that the heart is the source of these miRNAs under control 
conditions. Because miRNA was analyzed from whole serum, it is currently unknown 
whether these miRNAs were contained in the exosome fraction. However, these findings 
prompted us to explore whether changes in the miRNA profile of cardiomyocytes were 
reflected in the exosomes released by them.   
Thus while cardiomyocytes are generally not considered to be secretory cells, 
they do communicate via the release of soluble factors and exosomes with many 
different cell types in a paracrine and endocrine fashion. It is not known whether IPC 
changes the profile of miRNA or mRNA found in cardiomyocyte derived exosomes, or 
whether these exosomes can be taken up by transplanted MSCs, resulting in enhanced 
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viability. One of the goals of the work presented in this dissertation was to test whether 
HL-1 exosome content changes with preconditioning and if this mediates protective 
effects in the MSCs (see Results, p102). We preconditioned HL-1 cells with a 1-hour 
exposure to hypoxia in an ischemia mimetic solution, a treatment that markedly reduces 
cell death upon a subsequent prolonged ischemia 18-24h later (see Results, Figure 8). 
Then we collected total RNA from the cells and exosomes and sequenced its mRNA and 
miRNA content to determine whether protective RNA products increased in the 
exosomes. These results shed light on the cellular mRNA and miRNA profile of Hl-1 
cells and their exosomes, and indicate that exosomal content is tightly regulated.  
miRNA in Stem Cell Mediated Paracrine Effects on the Myocardium 
While extracellular miRNA has been found within a number of different carriers, 
including ribonucleoprotein complexes, lipoproteins, and extracellular vesicles 
(including microparticles and exosomes)171, here we focus on its paracrine transfer via 
exosomes.   
Exosome Biogenesis and Transfer 
Exosome biogenesis occurs through inward budding of the membrane of an 
organelle known as the multivesicular body (MVB), forming intraluminal vesicles 
(ILVs). There are two classes of MVBs within cells: one is destined for degradation, and 
the other fuses with the plasma membrane, releasing the ILVs that then become 
exosomes. The formation of ILVs that become exosomes is not completely understood 
yet, but it may involve endosomal sorting complex required for transport (ESCRT) 
complexes, which are involved in formation of ILVs that are destined for degradation. 
ESCRT-0 associates with cargo proteins in the endosomal membrane. HRS (hepatocyte 
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growth factor–regulated tyrosine kinase substrate), a component of ESCRT-0, recruits 
TSG101 of the ESCRT-I complex, which mediates membrane budding into the MVB. 
Then ESCRT-II or another protein, Alix, recruits the ESCRT-III complex, which 
pinches off the vesicle, releasing it into the MVB containing a small amount of cytosol 
and its cargo. Then Vps4, an ATPase, dissociates the ESCRT machinery, which is 
recycled. It is interesting to note that HRS is phosphorylated after stimulation with HGF, 
known for its anti-fibrotic effects146, 149, 152, but the effect of this phosphorylation on 
exosome production has not been described. siRNA-mediated knockdown of some 
components of this pathway, such as HRS and Tsg101, decreased exosome production in 
HeLa cells172. However, there are ESCRT-independent biogenesis mechanisms as well, 
involving oligomerization of syndecan and interaction with Alix and CD63173.  
Regarding the origin of the endosome that gives rise to the MVB, Tan et al.174 
showed that in MSCs it is derived from endocytosis at lipid raft microdomains in the 
plasma membrane. Labeled transferrin was endocytosed via the transferrin receptor, a 
prototypical recycling receptor, and later released in exosomes, indicating a recycling 
endosome had given rise to the MVB in which those exosomes were produced. 
Furthermore, labeled Cholera Toxin B, which binds to lipid raft associated GM1 
gangliosides, was also found in exosomes, indicating that lipid rafts were endocytosed 
and included in the MVB. Exocytosis requires the small GTPase Rab and is likely 
mediated by as yet unidentified SNARE (soluble N-ethylmaleimide-sensitive fusion 
protein-attachment protein receptor) complexes at the plasma membrane175.  
The uptake of exosomes by target cells involves the interaction of specific 
proteins in the exosomal and cellular membrane, in a cell-type dependent fashion. For 
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example, interactions between intercellular adhesion molecule 1 (ICAM1) and integrins 
(i.e., αvβ3 or α3β5) have been shown to mediate exosome uptake in dendritic cells, 
endothelial cells, and pancreatic cells. CD9 and CD81 can also interact with integrins to 
mediate uptake. Other important molecules include galectins, annexin, and heparan 
sulfate proteoglycans176, 177. The potential specificity of the protein interactions involved 
in exosome uptake raises the interesting possibility that exosomes could be engineered to 
deliver therapeutic cargo to targeted cell types. Indeed one group showed that they could 
modify a protein normally found in exosomes (Lamp2b) to include a neuron-specific 
peptide that could target them to the brain, where they delivered siRNA directed against 
a gene product potentially involved in Alzheimer’s disease178. Exosomes are taken up by 
endocytic processes, including clathrin mediated endocytosis, macropinocytosis, 
phagocytosis, and lipid raft endocytosis179, 180, and then trafficked to different locations 
within the cell, including phagolysosomes, late endosomes, and the nucleus. They can 
release their contents through fusion with the membranes of these structures, which is 
more likely to occur at a slightly acidic pH. Tsg101 and Alix may also mediate this 
process181. Direct fusion of exosomes with the plasma membrane of target cells has also 
been reported182.  
It should also be noted that exosome-mediated signaling also occurs at the 
plasma membrane, inducing responses independent of uptake. In a recent study, 
researchers isolated exosomes from plasma of rats and healthy human volunteers, and 
tested its effects on I/R injury models including in vitro, isolated perfused heart, and in 
vivo rat hearts. Finding that the exosomes from both rats and humans decreased infarct 
size and decreased cell death dose dependently in vitro in the absence of being 
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internalized, the authors investigated signaling pathway activation. They found a rapid 
and transient increase in ERK1/2 phosphorylation, as well as phosphorylation of Hsp27 
at a p38 site. They determined that TLR4 on the cardiomyocyte cell surface was 
activated by Hsp70 on the cell surface of the plasma exosomes, resulting in activation of 
Hsp27 as the effector of cardioprotection183. Another group found that MSC exosomes 
bear enzymatically active CD73, which forms extracellular adenosine from adenine 
nucleotides; this adenosine activates adenosine receptors on cardiomyocytes, causing 
Akt activation155. 
Exosomal Protein Content 
Many proteomic and genomic studies have been performed on exosomes of 
various sources, and much of this data is now available on a public resource website 
known as ExoCarta184. Exosomes are enriched in the proteins required for their 
biosynthesis, such as components of the ESCRT machinery, as well as tetraspanins. 
Other proteins include cytoskeletal proteins, ribosomal proteins, metabolic enzymes, and 
lipid bound proteins such as annexin177. The manner in which cells distribute specific 
protein cargo to exosomes is an area of active investigation. In the case of the metabolic 
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Hsc70 associates with a 
specific amino acid sequence of the cargo protein (KFERQ), as well as 
phosphatidylserine on the MVB outer membrane, thus delivering GAPDH as the ILVs 
form185. Other reports stress the importance of tetraspanins in sorting proteins to 
exosomes. For example, in CD81 knockout mice, the exosomal proteome lacked a set of 
proteins known to interact with CD81186. Likewise, CD9 and CD63 have been shown to 
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mediate the loading of metalloproteinase CD10 and LMP1 (latent membrane protein), 
respectively187, 188.  
The protein content of exosomes has been shown to counteract several hallmarks 
of myocardial injury. First, exosomes contain all of the ATP-producing glycolytic 
enzymes including GAPDH, phosphoglycerate kinase, phosphoglucomutase, enolase, 
and pyruvate kinase. These enzymes are depleted after I/R injury189, slowing metabolic 
recovery after ischemia, but treatment with MSC exosomes administered intravenously 5 
minutes prior to reperfusion increased ATP and NADH levels, presumably through 
transfer of glycolytic enzymes155. Furthermore, proteomic data from this group and 
others showed that exosomes contain antioxidant enzymes such as glutathione S-
transferase and peroxiredoxin, which reduce oxidative stress, another mechanism of I/R 
injury. Furthermore, it is well known that exosomes contain Hsp70, the transfer of which 
could assist cardiomyocytes with the response to damaged proteins.  
Exosomal RNA content 
mRNA Content It is clear that mRNA transported from one cell type to another 
can be translated and gives rise to a functional protein in the recipient cell. In 2007 
Valadi et al. showed that when human mast cells took up murine mast cell exosomes, the 
murine mRNAs were translated into proteins190. This mRNA transfer may have 
therapeutic implications, as the transfer of growth factor receptor mRNA via exosomes 
was later found to be a mechanism by which MSCs induce regeneration in damaged 
renal epithelial cells156.  
The process of mRNA and miRNA incorporation into exosomes appears not to 
be random, based on many studies of expression in parent cells and their exosomes. For 
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example, Valadi et al. characterized mRNA and miRNA in mouse and human mast cells, 
and showed that some sequences are enriched in exosomes, while others, despite high 
expression in the parent cells, are excluded190. Selective RNA incorporation in exosomes 
may be a combination of the nucleotide sequence and tertiary structures formed by the 
mRNA, through which RNA binding proteins with the capacity to interact with the 
MVB could mediate exosome loading. Sequences known as “zipcode sequences” are 
found in the 3’-UTR of mRNAs; ribonuclear protein complexes bind them and transport 
the mRNA to the correct cellular location, where it is released and translated191-193, 
implying that there may be a zipcode sequence that directs mRNAs to the MVB for 
incorporation in exosomes. Through comparison of the mRNA profile of glioblastoma 
multiforme cells and their exosomes, Bolukbasi et al. identified the top 20 most enriched 
transcripts in exosomes. By aligning their 3’-UTRs, they found a concensus zipcode 
sequence, which is 25 nucleotides in length, and forms a stem-loop structure with the 
core nucleotide concensus sequence “CTGCC.” They cloned the zipcode sequence into 
the 3’-UTR of enhanced green fluorescent protein (EGFP), and found that its presence 
caused EGFP mRNA to be incorporated into exosomes. They noted the presence of a 
miRNA binding site within the zipcode sequence, miR-1289, and found that 
overexpression of this miRNA further increased loading of the EGFP mRNA into 
exosomes, suggesting a cooperative role for this miRNA in binding to the (as yet 
unidentified) ribonuclear protein which transports it. Furthermore, overexpression of 
miR-1289 enhanced the loading of endogenous mRNAs bearing the zipcode sequence, 
confirming this synergy194.  
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miRNA Content As with mRNA, miRNA may be loaded into exosomes by 
proteins that bind to certain motifs. Alignment of miRNA sequences enriched in 
exosomes vs. cells identified two such motifs present in the exosomal-enriched miRNA 
(GGAG and CCCU), which induced sorting to exosomes regardless of changes in 
cellular activation state in T cells195. Heterogeneous ribonuclear protein A2B1 
(hnRNPA2B1) mediated the exosomal loading. Another group showed that when 
macrophages are activated, a subset (5%) of miRNAs within exosomes is significantly 
changed. They showed that this was due to changes in their target mRNA levels upon 
activation196. Comparing exosomes from transfected HEK293T cells overexpressing 
miR-146a vs. untransfected cells, sequencing data showed that despite marked increases 
in this miRNA, the rest of the exosomal miRNA profile was maintained197. Even 
comparing exosomes from different cell types, several commonalities among the most 
exosomal-enriched miRNAs were noted, implying that some miRNAs are universally 
exported. For example, miR-451 was among the most exported miRNA in the majority 
of the datasets. In the case of miR-451 and several other preferentially exported 
miRNAs, Ago2 rather than Dicer plays an important role in biogenesis of the mature 
miRNA, as shown by reduction in their level in Ago2 knockout mice. This implies that 
this type of processing somehow targets them to exosomes. miRNA-bound Ago2 has 
been shown to localize within GW bodies at the MVB membrane. GW182, the protein 
within GW bodies from which they take their name, is sorted into MVBs. A fraction of 
miRNA/Ago2 complexes may also be sorted into MVBs for lysosomal degradation or 
secretion in exosomes, but Ago2 was detected at low levels within exosomes198. More 
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research is needed to elucidate how Ago2 and other miRNA binding proteins connect 
miRNA processing to its loading into exosomes.  
Stem cell exosomes from various types of stem cells contain miRNA with 
protective or regenerative effects on I/R injured myocardium. Two recent studies on 
exosomes derived from cardiac stem cell sources, CDCs and CSCs, showed they contain 
miRNAs that decrease apoptosis and increase vessel density after I/R injury. In the CDC 
exosomes, miR-146a had a key role through suppression of components of the toll like 
receptor and tumor growth factor-β pathways, as well as a pro-oxidative stress protein, 
NOX4. Treating the infarcted heart with a miR-146a mimic reproduced some, but not 
all, of the effects of CDC-derived exosomes, and exosomes lacking miR-146a (by anti-
sense knockdown in the parent cells) could still suppress apoptosis199. Thus miR-146a is 
an important contributor to their benefits, but not the only factor involved. In human 
CPC exosomes, several miRNAs were enriched compared with non-therapeutically 
active fibroblast exosomes, including miR-210, miR-132, miR-146a, and miR-181200. 
The authors focused on miR-210, a well-known cardioprotective miRNA, and miR-132 
through overexpressing the miRNAs in vitro, performing functional assays for apoptosis 
and tube formation (an indicator of angiogenic activity) as well as analysis of expression 
of their target genes. MiR-210 downregulated ephrin A3 and PTP1 in HL-1 cells and 
decreased apoptosis; miR-132 downregulated RasGap-p120 in HUVECs and induced 
tube formation. Human CD34+ stem cells have also been shown to mediate cardiac 
repair through release of exosomes. The exosomes contain angiogenic miRNA including 
miR-126 and miR-130a201, though their targets and contribution to angiogenesis have 
not yet been tested. Like CSC exosomes, exosomes from iPSC were also shown to 
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contain miR-210 as well as miR-21, and to reduce markers of I/R injury such as TUNEL 
staining and cleaved Caspase-3 when injected into the mouse heart just after induction of 
ischemia. Changes in expression of the target genes of miR-210 and miR-21 were not 
investigated, but incubation of H9c2 with iPSC exosomes did show that the levels of 
these miRNAs increased, indicating that the exosomes delivered these cardioprotective 
miRNAs202.  
Two studies have investigated cardioprotective miRNA within MSC exosomes. 
The first tested the effect of preconditioning the source MSCs with hypoxia on the 
miRNA profile and beneficial effects of their exosomes. They found a 4.5-fold 
enrichment of miR-22 in the exosomes after hypoxic preconditioning and went on to 
show that miR-22 targets methyl CpG binding protein (Mecp2)203. In support of a role 
for Mecp2 in I/R injury, they showed that knockdown of Mecp2 via siRNA or miR-22 
mimic in the heart decreased apoptosis after I/R injury. Lastly, they showed that the 
exosomes from preconditioned MSCs decreased infarct size and fibrosis in a mouse 
model, and miR-22 knockdown in the MSCs and their exosomes partially abrogated this 
effect, indicating an important role for miR-22 (though Mecp2 levels in the heart after 
exosome treatment were not shown and the role in I/R injury of Mecp2 is unknown). 
The second study compared the protective effects of MSC exosomes from MSCs 
overexpressing the transcription factor GATA4 with null-transfected MSCs, and found 
the former to be more protective, possibly through enhanced content of miR-19 and 
miR-451204. Specifically, both types of exosomes were found to downregulate PTEN and 
Bim, but the exosomes from GATA4-MSCs were more effective.  
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In summary, miRNA within stem cell exosomes is increasingly recognized to 
mediate well known aspects of stem cell paracrine effects, including decreased apoptosis 
of cardiomyocytes and angiogenesis. A number of protective miRNAs have been 
researched within stem cell exosomes, and some of their mRNA targets and associated 
mechanisms have been elucidated. However, cardioprotective miRNA in MSC 
exosomes has not been extensively investigated and there is currently no data regarding 
exosomal mRNA in the context of paracrine cardioprotection or regeneration. The goal 
of this part of the project (see Results p109) was to characterize the mRNA and 
miRNA profiles of MSC exosomes and test the functional contribution of miR-21, a 
promising candidate which emerged from this profile, to cardioprotection. As discussed 
in Section 1, it downregulates a number of proteins involved in cell death in 
cardiomyocytes and other cell types, including PDCD4, FasL, PTEN. It is also predicted 
to target Peli1, which may be injurious in the context of I/R injury205.  
We found miR-21 to be the most highly expressed miRNA in MSC exosomes, but 
this is not the first description of its presence there. Wang et al.202 described it as being 
enriched in iPSC exosomes vs. non-therapeutically active fibroblast exosomes, and Feng 
et al.203 noted both its presence in MSC exosomes at baseline and a significant 3.3-fold 
increase after hypoxic preconditioning. However, whether miR-21 within MSC 
exosomes contributes significantly to their protective effect, and the proteins targeted by 
exosomally-delivered miR-21 are unknown. To test this hypothesis, we isolated MSCs 
from miR-21a knockout (miR-21a KO) mice and compared their exosomes with those of 
WT MSCs. Subsequently, we examined gene expression in vitro and in vivo after 
treatment with miR-21, WT exosomes, and miR-21 KO exosomes.  
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SUMMARY OF GOALS AND HYPOTHESES 
Due to the prevalence and poor prognosis associated with myocardial infarction, it is 
important to find new cardioprotective strategies that could lead to therapeutic advances. 
There are two philosophies about how to improve outcomes after myocardial infarction. 
The first is to trigger endogenous cardioprotective pathways such as that active in IPC, 
to prevent the loss of cells. The other is to regenerate the myocardium by boosting its 
endogenous limited regenerative potential, or replace the lost cells with differentiated 
stem cells. However, there may be more mechanistic overlap between these two 
approaches than is currently appreciated. For example, stem cells and their exosomes 
may act to trigger endogenous cardioprotection, and IPC may boost the capability of 
stem cells (both endogenous and transplanted) to regenerate the myocardium. Thus it is 
useful to investigate both of these approaches together and seek commonalities, such as 
key roles for miRNA in mediating and communicating protective effects.  
Goal 1 
To identify miRNAs that could act as regulatory nodes for numerous heat shock 
protein family members during IPC. We know that individual miRNAs are regulated by 
IPC, contributing to protective gene expression during late IPC, and that miRNAs can 
act to regulate functionally related sets of genes, so the first section is driven by the 
hypothesis that certain miRNAs act to regulate the expression of HSPs including 
Hsp40/Dnaj proteins, Hsp70, and Hsp90 in response to preconditioning. 
Goal 2 
To test whether HL-1 exosome content changes with preconditioning and if this 
mediates protective effects in the MSCs. Evidence suggests that preconditioning causes 
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the release of protective factors from the myocardium, and that changes in secreted 
factors may mediate improved stem cell engraftment. The hypothesis of this section was 
that preconditioning of cardiomyocytes leads to increased exosomal loading of 
protective miRNA, which exerts pro-survival effects on transplanted MSC.  
Goal 3 
To characterize the transcriptome of MSC exosomes and test the functional 
contribution of their highly enriched miRs to cardioprotection. Because mRNA and 
miRNA transferred by exosomes have been shown to be functional in recipient cells, and 
MSC exosomes are known to be cardioprotective, we hypothesized that a significant part 
of their cardioprotective effects are mediated through transfer of protective mRNA 
and/or miRNA, specifically miR-21, which we found to be the most highly represented 
miRNA in the exosomes.  
 
	
	
 
	
40 
 
 
 
CHAPTER 2 
 MATERIALS AND METHODS 
METHODOLOGY 
Animals 
The following types of mice were purchased from Jackson Labs (Bar Harbor, 
ME): C57Bl/6J (stock # 000664), B6;129SF2/J (stock # 101045), and miR-21 null 
(B6;129S6-Mir21atm1Yoli/J, stock # 016856) and were maintained according to the 
guidelines set forth by the NIH in the Guide for the Care and Use of Laboratory Animals 
(GCULA) and Loyola University Chicago’s Institutional Animal Care and Use 
Committee.  
Ischemic Preconditioning and Ischemia/Reperfusion Injury 
Ischemic preconditioning was achieved by reversible ligation of the left anterior 
descending (LAD) coronary artery as previously described206. Mice were anesthetized by 
intraperitoneal injection of sodium pentobarbital (90 mg/kg) and intubated to maintain a 
respiratory rate of 100±5/minute using a mini-ventilator (Harvard Apparatus, Cambridge 
MA). A lateral thoracotomy was performed between the 2nd and 3rd ribs to access the 
heart, and the LAD artery was occluded 2-4 mm from the tip of the left auricle by 
tightening a suture (8-O nylon) against a short, thin piece of silicon tubing. Six cycles of 
4-minute occlusion and 4-minute reperfusion were performed. The heart was monitored 
by ECG and visual changes (blanching) to confirm that ischemia occurred. 
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Subsequently, the chest was closed and mice were allowed to recover until the time point 
of interest for investigation of gene expression changes.  
 To induce ischemia/reperfusion injury, similar procedures were performed, with 
the LAD being occluded for 45 minutes, followed by reperfusion and recovery 
overnight206. Characteristic ECG changes included widening of the QRS complex, T 
wave inversion, and ST segment changes characteristic of myocardial infarction. The 
suture used to occlude the LAD was left in place.  
TTC Staining and Infarct Size Assessment 
As previously described206, 24 hours after I/R injury, mice were euthanized using 
sodium pentobarbital, the chest was re-opened, and the aorta was cannulated with 
polyethylene-10 tubing. Triphenyltetrazolium chloride (TTC) 1% solution in PBS was 
perfused through the heart and coronary arteries including the LAD. Enzymes active in 
viable tissue reduce TTC to a formazan compound with a red color, while dead tissue in 
the infarct zone remains unstained. To determine the area at risk, the suture on the LAD 
was tightened once again, and a 5% solution of phthalo blue pigment (Heucotech, 
Fairless Hills PA) in PBS was perfused through the heart, staining only the areas of the 
heart that were not at risk.  
After staining, hearts were frozen and sectioned into 1 mm slices from just below 
the suture to the apex of the heart (4 to 5 slices total). These slices were imaged using a 
Nikon camera and the total area, infarct area, and area at risk were determined digitally 
in NIH ImageJ by tracing the entire heart section, white area, and red area (including 
white areas within), respectively. Then, using the weight of the slices, the percent of the 
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heart at risk as well as the percent of the risk area that was infarcted were calculated 
according to the accepted method of Fishbein et. al207.  
Pericardial Sac Injections 
Mice were anesthetized and the chest opened as previously described in Section 
2.2. Injections into the pericardial sac were performed using a 50µl Hamilton syringe 
(Hamilton Company, Newport Beach CA)208 with a custom removable needle (25 gauge, 
1” length with a tip beveled at 45º). The chest was then closed and mice were 
periodically re-positioned until they recovered from the anesthesia, to ensure the injected 
solution reached all areas of the heart equally. The volume of the injection was based on 
the mouse’s weight to control for proportional differences in the size of the heart, and 
was 1 µl/g of body weight. 
Culture of Cardiac Cell Lines 
HL-1 transformed murine atrial cardiomyocytes were cultured according to 
established conditions209 with approval for use granted by Dr. Claycomb. They require 
the specially formulated Claycomb growth medium (Sigma-Aldrich, St. Louis MO), 
containing 10% FBS (of particular pre-tested lots) and norepinephrine (100 µM), and 
must be grown on a gelatin-fibronectin coated substrate. Furthermore, it is recommended 
that they be passaged at a 1:3 ratio and not be allowed to become underconfluent 
(personal communication, Dr. May Lam). Under these conditions, HL-1s maintain a 
differentiated contractile phenotype and can be serially passaged and recovered from 
frozen stocks209.  
H9c2(2-1) rat cardiac myoblast cells210 were purchased from ATCC and cultured 
according to ATCC’s recommendations. They were maintained in Dulbecco’s Modified 
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Eagle Medium (DMEM) supplemented with 10% FBS, penicillin (100 U/mL), 
streptomycin (100 ug/mL), and L-glutamine. All cells were maintained at 37ºC in 
humidified incubators with 5% CO2. 
Culture of Primary Neonatal Mouse Ventricular Myocytes 
Neonatal mouse ventricular myocytes (NMVM) were obtained from 1 to 3 day 
old wildtype or miR-21 null pups as described by Ehler et al.211. In accordance with 
institutional guidelines, the pups were cooled on ice prior to decapitation with a sharp 
scalpel and removal of the heart. Hearts were then washed in phosphate buffered saline 
(PBS) without Ca2+ or Mg2+ containing 20 mM 2,3-Butanedione monoxime (BDM, 
Sigma-Aldrich, St. Louis). BDM prevents the myocytes from contracting during the 
isolation procedure, enhancing viability and yield. Then the hearts were minced into 
small pieces and incubated in 10 mL isolation medium (Hank’s buffered salt solution 
without Ca2+ or Mg2+ containing 20 mM BDM, 0.0125% trypsin) overnight at 4ºC on a 
rocking platform.  
The next day, the hearts were digested using a collagenase/dispase enzyme mix 
(Roche #10269638001, 15 mg in 10 mL L15 Medium containing 20 mM BDM) for 25 
minutes at 37ºC. The fragments were then gently triturated to release the cells. Any 
fragments that didn’t disperse were then enzymatically digested once more. The cell 
suspension was then pipetted over a 100 µm cell strainer and centrifuged at 100xg to 
pellet the cardiomyocytes. These were resuspended in plating medium (65% DMEM 
high glucose, 19% M-199, 10% horse serum, 5% fetal calf serum, 1% penicillin-
streptomycin). Then cells were plated for 1-2 hours on uncoated plastic to allow 
attachment of endothelial cells and fibroblasts, before plating the cardiomyocytes into 
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12- or 6-well plates pre-coated with gelatin-fibronectin or collagen at a density of 1.5 x 
105 cells per cm2. The next day, medium was changed to maintenance medium (78% 
DMEM high glucose, 17% M-199, 4% horse serum, 1% penicillin/streptomycin, 1 µM 
AraC, 1 µM isoproterenol). Cardiomyocytes became adherent and began to 
spontaneously contract. They were then cultured for an additional 1 to 5 days.  
In order to test the purity of the cardiomyocyte population, 
immunocytochemistry was performed for Troponin I, a myocyte-specific protein. Cells 
were fixed in paraformaldehyde, rinsed in PBS, and then permeabilized using Triton-
X100 (0.1% in PBS) for 10:00. Cells were then washed again and blocked using 3% 
BSA, 0.1% Tween20 in PBS, for 30:00. Cardiomyocytes were then labeled using a 
rabbit anti-mouse antibody to Troponin I (Abcam, San Francisco, CA #ab47003) diluted 
1:400 in blocking buffer for 1 hour. After washing, the cells were then incubated with 
goat anti-rabbit secondary antibody labeled with Alexa Fluor 594 (Thermo Fisher 
Scientific, Waltham MA, #R37117) as well as DAPI to label nuclei. After washing, cells 
were imaged using the Cytation3 with the DAPI and Texas Red filters. The isolation 
procedure resulted in 89±7% Troponin I+ cells (Figure 1).  
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Figure 1. Primary Neonatal Cardiomyocytes 
 
Three days after plating, immunocytochemistry was performed to determine the 
percentage of cells positive for Troponin I (red fluorescence) out of the total number of 
cells, labeled with DAPI. 
 
After day 3, the NMVMs were treated with MSC exosomes overnight to assess exosome 
uptake by flow cytometry and exosomes’ effects on gene expression and viability upon 
OGD challenge.  
Culture of Primary Mesenchymal Stem Cells 
Mesenchymal stem cells were obtained from mouse bone marrow as well as bone 
chips of the femur and tibia. Female wildtype B6;129 and miR-21 null mice (on a 
B6;129 background) were used at age 8-10 weeks. The bones were cleaned of muscle 
and connective tissue, and the ends were clipped to expose the marrow, which was 
flushed from the bone using a 27-gauge needle as described previously129 in isolation 
medium consisting of RPMI-1640 with 9% FBS, 9% horse serum, 100 U/mL penicillin, 
100 µg/mL streptomycin, and 12 µM L-glutamine (Thermo Fisher Scientific, 
Waltham)128. RPMI discourages the expansion of hematopoietic stem cells. Each long 
bone was flushed with 5 mL of isolation media into a 50 mL conical tube. The cell 
suspension was strained over a 70 µm cell strainer, and then plated into T75 flasks. Non-
adherent cells were removed by rinsing with PBS and medium was replaced. This 
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washing was repeated every 3 to 4 days for 4 weeks or until cells became confluent. 
They were released from the flask with 0.25% Trypsin-EDTA for 2 minutes and re-
plated into a new flask. Cells that remained attached were discarded. The passage 1 cells 
were then allowed to grow, with media replacement twice per week. Over 2 to 4 weeks, 
colonies of rapidly multiplying cells became evident. When these became numerous 
and/or large in size, the cells were again passaged and plated in expansion media, 
consisting of Iscove modiﬁed Dulbecco medium (IMDM) with 9% FBS, 9% horse 
serum, 100 U/mL penicillin, 100 µg/mL streptomycin, and 12 µM L-glutamine.  
Because MSCs have also been described to reside within compact bone as well 
as bone marrow130, the flushed bones were cut into small pieces and placed in 10 cm2 
culture dishes containing isolation medium. By the next day, cells began to migrate out 
of the chips and attach to the plastic. The bone chips were left in the dishes for 1 week, 
and then removed. These cells were then cultured in the same way as the bone marrow 
derived MSCs; MSCs derived from bone marrow and bone chips showed no differences 
in morphology, surface marker expression or proliferative potential in our hands.  
 To validate the isolation procedure as generating a pure population of MSCs, 
three assays were performed. First, their capacity for self-renewal and proliferation was 
assessed by the colony forming unit (CFU) assay, in which 100 cells are plated in 
expansion media in a 60 mm culture dish. These were incubated for 3 weeks, and then 
colonies were stained in 3% crystal violet in methanol for 20:00 at room temperature128. 
Then the colonies were counted to determine how many of the original 100 cells could 
give rise to a rapidly dividing colony. This number increased with passaging until by 
passage 10, over 100 colonies had formed.  
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Figure 2. Mesenchymal Stem Cell Colonies 
 
100 cells were plated in expansion media and incubated for 3 weeks. Colonies were then 
stained with Crystal Violet solution and counted. At passage 3, there were an average of 
62 colonies. At passage 7, there were >200 colonies, indicating that the proliferative 
potential of the cells increased with passaging. 
 
Next we assessed their capacity to differentiate into three different lineages: 
adipocytes, chondroblasts, and osteoblasts. This was done using commercially available 
kits from Cyagen (Santa Clara, CA) according to the manufacturer’s instructions 
(adipogenic differentiation, GUXMX-90031; chondrogenic differentiation, GUXMX-
90041, and osteogenic differentiation GUXMX-90021). Briefly, adipogenic 
differentiation is induced by the addition of insulin, 3-isobutyl-1-methylxanthine 
(IBMX), rosiglitazone, and dexamethasone to the basal culture media. Chondrogenic 
differentiation is induced by dexamethasone, TGF-β, and ITS+ supplement (insulin, 
transferrin, and sodium selenite) in media containing sodium pyruvate, ascorbate, and 
proline. Osteogenic differentiation was induced by adding β-glycerophosphate to basal 
media containing ascorbate. We confirmed that the MSCs could differentiate into all 
three lineages (Figure 3). 
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Figure 3. Differentiation of MSCs 
 
Passage 5 MSCs were differentiated to three different mesodermal lineages, adipogenic, 
chondrogenic, and osteogenic. Specific stains were used to confirm differentiation. 
Adipocytes were stained with Oil Red O, which stains lipids. Chondrocytes formed a 
cartilaginous matrix pellet within the culture tube, which was stained with toluidine blue. 
Calcium deposits produced by osteocytes were stained with Alizarin red.  
 
 Lastly, we examined the surface epitopes of the cells to confirm the presence of 
known MSC markers and the absence of hematopoietic and leukocyte markers. The cells 
were detached using Accutase (which preserves surface proteins better than trypsin), and 
counted. 1x106 cells were labeled with the antibodies in Table 1 for 45:00 on ice in flow 
cytometry buffer (PBS with 1% BSA, 25 mM HEPES, and 10 U/mL DNAse). The 
negative control was unstained cells. 
Table 1. Antibodies to Cell Surface Markers 
Marker Fluorescent label Wavelength 
(ex/em) 
Dilution/106 
cells 
Associated cell type 
CD44 Allophycocyanin 645/660 1 µl MSC 
Sca-1 Pacific Blue 410/455 5 µl MSC 
CD-29 Phycoerythrin 496/575 1 µl MSC 
CD45 Phycoerythrin-
Cy7 
496/565 1 µl Hematopoietic stem 
cell 
CD11b Brilliant Violet 
510 
405/510 5 µl Leukocyte 
 
After labeling, cells were washed twice, re-suspended in 1 mL of flow cytometry buffer 
and passed over a 70 µm cell strainer into Falcon tubes for sorting. The live single cell 
population was gated and 10,000 events were counted. The results were analyzed in 
FlowJo and displayed as overlaid frequency histograms of stained vs. negative control 
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cells to show the percentage of cells positive for each surface marker. The resulting 
immunophenotype was CD29+, CD44+, Sca1+, CD45-, CD11b-, (see Figure 4) which is 
consistent with the mesenchymal phenotype and the absence of hematopoietic stem 
cells128-130.  
In Vitro Models and Viability Assays: Hypoxic Preconditioning (HPC) and 
Simulated Ischemia Reperfusion Injury (simI/R) 
HL-1 cells were preconditioned by exposure to ischemia mimetic solution (in 
mM: 125 NaCl, 8 KCl, 1.2 KH2PO4, 1.25 MgSO4,1.2 CaCl2, 6.25NaHCO3, 5 sodium 
lactate, 20 HEPES, pH 6.6 at 37ºC)29 for 1 hour in a hypoxic chamber (Biospherix, 
Parish NY). Oxygen was replaced by nitrogen until the oxygen level reached ≤0.5%, 
while CO2 was maintained at 5%. After 1 hour cells were reoxygenated and the ischemia 
mimetic solution was replaced with growth media. Simulated ischemia reperfusion 
injury (simI/R) was induced by exposure to glucose and serum free DMEM and 
placement in the hypoxic chamber for 1.5 to 3 hours (Figure 5). The optimal time for 
each experiment was estimated based on a series of time courses performed with the 
cells plated at different densities.  
Then growth medium was replaced and cells were returned to normal growth conditions. 
For H9c2 cells, simI/R was performed by incubation in the hypoxic chamber for 15 to 18 
hours in ischemia mimetic solution; a longer ischemia time was required to induce cell 
death in H9c2 cells than in HL-1s.  
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Figure 4. Surface Epitopes of MSCs 
 
Passage 10 MSCs were released with Accutase and labeled with fluorescently 
conjugated primary antibodies for the surface markers CD29, CD44, Sca-1, CD11b, and 
CD45. Unlabeled cells were used as negative controls (red line), and the fluorescence 
intensity of the labeled cells was compared to this (blue line). A shift to the right 
indicates increased fluorescence intensity, signifying that that the antigen is expressed by 
the cells.  
CD44
Sca-1
CD11b
CD45CD29
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Figure 5. Time to 50% Cell Death from SimI/R Changes with Confluence in HL-1 Cells 
 
The optimal duration of simI/R was determined to be a function of confluence of the 
cells because as HL-1 cells become more confluent, the time needed to kill 
approximately 50% of them decreases. HL-1 cells were plated at different densities and 
grown overnight. The following day, simI/R time courses of 0, 60, 120, 180, and 240 
minutes were performed, and viability was determined by Hoechst/PI uptake assay (see 
section 2.9), allowing determination of the time to 50% cell death. N=6/condition. 
 
 Three methods were employed to assess cell death after simI/R: (1) lactate 
dehydrogenase (LDH) release into the media, (2) uptake of Hoechst 33342 (Life 
Technologies H3570) and propidium iodide (PI, Life Technologies p3566) fluorescent 
dyes, and (3) GF-AFC fluorescence (Promega Madison WI, Cell-titer Fluor kit, 
#G6080), an indication of cellular metabolic activity. LDH release was assessed using a 
kit from Clontech (Palo Alto CA, #630117) according to the manufacturer’s instructions 
with the modification of using a standard curve of 0 to 25 U/mL LDH (Sigma-Aldrich, 
St. Louis, #L3888-500UN). The principle of the assay is that NAD+ is reduced to 
NADH/H+ by the LDH catalyzed conversion of lactate to pyruvate. In the second step, a 
catalyst included in the reaction mixture (diaphorase) transfers H/H+ from NADH/H+ to 
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the tetrazolium salt INT, which is reduced to a formazan dye which can be detected at a 
wavelength of 490 nm.  
Cells were re-oxygenated after simI/R in phenol red free DMEM containing 
glucose and serum. Because serum contains a baseline level of LDH activity, a media 
blank must also be included when serum is present in the reperfusion media. Phenol red 
in the media interferes with reading of the assay because it contributes to absorbance 
readings at 490 nm. Culture medium was diluted 1:10 in a final volume of 100 µl per 
well in a 96-well plate in duplicate. Then 100 µl of freshly prepared reaction mixture 
was added and the plate was incubated for 30:00 at room temperature, protected from 
light. Then absorbance at 490 nm was measured using the Cytation3 and units of LDH 
activity were calculated based on the standard curve and dilution factor.  
 Another measure of cell death is the labeling of dead cells with PI. Live cells 
exclude PI, but it enters dead cells and stains DNA. All cells take up Hoechst 33342, 
which also stains DNA. Using these dyes in combination provides the ratio of dead cells 
to all cells. After post-simI/R reoxygenation for at least 1 hour (we found similar results 
between 1 hour and 18h after reoxygenation), cells were exposed to reperfusion media, 
containing PI and Hoechst diluted to 2 µg/mL and 0.2 µg/mL respectively, and allowed 
to take up the dyes for 30 min in the incubator. Then the cells were imaged using the 
Cytation3 with the Texas Red filter to detect dead cells (PI+) and the DAPI filter to 
detect all cells (Hoechst+). The Gen5 software for the plate reader was programmed to 
count these cells and export the count for each well to Excel. To determine the 
percentage of cells that survived the simI/R challenge, this assay can be performed prior 
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to the simI/R to determine the number of cells present in the well at the beginning, 
allowing one to control for differences in plating or growth kinetics.  
Exosome Preparation and Quantification of Uptake 
Exosomes were pelleted from conditioned media of MSC and HL-1 cells by 
centrifuging the media at three different speeds as described in Table 2 according to the 
protocol described by Thery et al.212. Expansion media (per section 2.7) was made with 
exosome depleted serum when exosomes were being isolated. Exosome depleted serum 
was made by ultracentrifugation of FBS for 90:00 at 100,000 x g.  
Table 2. Centrifugation Procedure for Exosome Isolation 
Step Type of tube Volume/tube 
Speed 
(xg) 
Time 
(min) Component pelleted 
1 Falcon Conical 50 mL 2000 20 Cells 
2 Oak Ridge High Speed 30 mL 10,000 30 Microvesicles 
3 Beckman Ultra Bottle assembly 60 mL 100,000 70 Exosomes 
 
After the exosomes were pelleted, they were resuspended in PBS and re-pelleted to 
wash. If multiple tubes of media were used in step 3, the exosomes were pooled prior to 
washing. After pelleting them once more, a protein assay was performed so that a 
consistent concentration of exosomes could be used in subsequent experiments. The size 
of the pelleted vesicles was 70 to 105 nm, as determined using dynamic light scattering 
on a Zetasizer. Furthermore the vesicles were positive for the exosomal marker proteins 
Tsg101 and CD9212, 213 by Western blot.  
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Figure 6: Characterization of MSC Exosomes 
 
Western blot shows the presence of CD9 and Tsg101, and dynamic light scattering 
shows the size of the vesicles to be consistent with that of exosomes. Note, the peak at 
10 nm was also present in the PBS used to re-suspend the exosomes. 
 
To count the exosomes and confirm that various cell types take them up, 
exosomes were labeled with PKH26 (Sigma-Aldrich, St. Louis) according to the 
manufacturer’s recommendations. The exosome pellet was re-suspended in 1 mL of 
diluent provided with the labeling kit, and an equal volume of PKH26 dye in diluent was 
added (4 µl in 1 mL). This was mixed well by pipetting up and down, and labeling 
carried out for 3 minutes with gentle agitation once per minute. Then an equivalent 
volume of exosome free FBS was added to stop the reaction and the labeled exosomes 
were washed in 50 mL PBS to remove excess unbound PKH26 dye. After this wash, the 
exosome pellet appeared pink. Exosomes were resuspended in PBS and diluted into the 
growth media of the cells being studied (HL-1, H9c2, MSC, and NMVM cells were 
tested). Cells were incubated overnight, then lifted with Accutase Cell Detachment 
Solution (Thermo Fisher Scientific, Waltham), pelleted, and re-suspended in cell sorting 
buffer for analysis by traditional flow cytometry or Amnis Image Stream.  
Protein Isolation and Quantification 
Protein was extracted from cells in RIPA buffer (Santa Cruz Biotechnology, 
Santa Cruz CA, #sc-24948A) containing freshly added PMSF, Na3VO4, and a protease 
Tsg101
CD9
55 
	
inhibitor cocktail, according to the manufacturer’s recommendations. Medium was 
removed and cells were washed twice in cold PBS. Then 100-200 µl of RIPA buffer 
were added per well (depending on confluence of cells) and cells were lysed for 15:00 at 
4ºC on a rocking platform. Next cells were scraped and lysates were incubated for 30 to 
60 minutes on ice before centrifuging to pellet debris at 10000 x g for 15:00 at 4ºC. 
Lysates were transferred to a new tube and frozen at -80ºC or further analyzed by protein 
concentration assay and western blotting.  
 To extract protein from the mouse heart, the heart was removed and washed well 
in ice cold PBS to remove blood. The left ventricle was dissected, rinsed once more, and 
snap frozen in liquid nitrogen. It was then powdered using a tissue crusher (also cooled 
in liquid nitrogen) and suspended in 300 µl RIPA buffer. The homogenate was then 
processed using a dounce homogenizer until uniform. Lysates were then incubated 30 to 
60 minutes on ice, and the remainder of the protein extraction carried out as previously 
described. Lysates were stored in aliquots of 100 µl each at -80ºC.  
 Protein concentration was determined using the bicinchoninic acid (BCA) 
method (kit from Thermo Fisher Scientific, Waltham). Cell lysates were diluted 1:4, 
while heart tissue samples were diluted 1:20 in RIPA buffer. Standards were also diluted 
in RIPA buffer ranging from 125 to 2000 µg/mL and a RIPA buffer blank was 
performed. The BCA working reagent was added to 20 µl diluted sample or standard, 
and the 96-well plate was incubated covered at 37ºC for 30:00. It was then allowed to 
cool to room temperature and absorbance was read at 562nm.  
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Western Blotting 
Ten to fifteen µg of protein were heated at 95ºC for 10:00 in 2x or 4x Laemmli 
buffer before separation on a 10 or 12% polyacrylamide gel. Proteins were then electro-
transferred to nitrocellulose membranes and transfer was confirmed by Ponceau staining. 
Membranes were blocked in 5% dry milk (w/v) in tris buffered saline containing 0.1% 
Tween20 (TBS-T) for 1 hour. Then they were incubated with primary antibody (see 
Table 3) diluted in blocking buffer overnight or for 2 hours at room temperature, 
washed, and then incubated in HRP conjugated secondary antibody, also diluted in 
blocking buffer, for 1 hour at room temperature. After washing, chemiluminescent bands 
were digitally detected using the Bio-Rad ChemiDoc imager using ECL or SuperSignal 
West Dura reagent kits (Thermo Fisher Scientific, Waltham). A series of images were 
acquired and the exposure just prior to oversaturation was used for quantitation. Images 
of the membranes were exported as TIF files from the Image Lab software, and 
densitometry was performed in ImageJ to assess relative band intensities.  
Table 3. Primary Antibodies 
Antibody Source & cat# Dilution Appropriate secondary antibody 
Hsp70 Santa Cruz 
Biotechnology, Santa 
Cruz, sc-24 
1000 Mouse (1:2000) 
Hsp90 Thermo Fisher Scientific, 
Waltham, PA3-013 
2000 Rabbit (1:5000) 
Dnaja1 Thermo Fisher Scientific, 
Waltham, ms-225-p0 
2000 Mouse (1:2000) 
Dnajb4 Santa Cruz 
Biotechnology, Santa 
Cruz, sc-100711 
1000 Mouse (1:2000) 
Actin Sigma-Aldrich, St. Louis, 
A2066-.2ML 
2000 Rabbit (1:5000) 
β-actin Thermo Fisher Scientific, 
Waltham, MA5-15739 
2000 Mouse (1:2000) 
PDCD4 Cell Signaling, D29C6 1000 Rabbit (1:5000) 
57 
	
PTEN Cell Signaling 1000 Rabbit (1:5000) 
FasL Abcam, ab68338 500 Rabbit (1:5000) 
Peli1 Abcam, ab13812 1000 Rabbit (1:5000) 
TSG101 Santa Cruz 
Biotechnology, Santa 
Cruz, sc-7964 
500 Mouse (1:2000) 
CD9 Santa Cruz 
Biotechnology, Santa 
Cruz, sc-9148 
1000 Rabbit (1:5000) 
 
RNA Isolation 
Three hours after IPC, mice were euthanized by CO2 inhalation. Hearts were 
removed, washed in PBS, and the ischemic zone was dissected out and snap frozen in 
liquid nitrogen. It was then homogenized using a tissue grinder in 1 mL Qiazol and 
extracted using the miRNEasy mini kit (Qiagen, Germantown MD) according to the 
manufacturer’s instructions, including DNAse digestion.  
 RNA was extracted from cells in Qiazol (Qiagen, Germantown) and isolated by 
phase separation and isopropanol precipitation, DNAse treated, and re-isolated. 
Alternatively, the miRNEasy kit (Qiagen, Germantown) was used. For exosomes 
resuspended in PBS, Trizol LS (Thermo Fisher Scientific, Waltham) was used to isolate 
RNA by phase separation and isopropanol precipitation according to the manufacturer’s 
recommendations, with DNAse treatment and re-isolation.  
Reverse Transcription 
RNA concentration and purity was determined using a NanoDrop or Take3 plate 
on the Cytation3. A consistent amount of RNA was used for each cDNA synthesis 
reaction, with a maximum amount of 2 µg. For analysis of miRNA, the miScript II RT 
kit (Qiagen, Germantown, #218161) was used; for analysis of mRNA, the High Capacity 
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RNA-to-cDNA kit was used (Thermo Fisher Scientific, Waltham, #4387406). For either 
kit, the reaction consisted of input RNA, water, enzyme, and nucleotide mix, in a 20 µl 
total volume. This was held at 37ºC for 60 minutes, heated to 95ºC for 5 minutes, and 
then cooled to 4ºC. For short-term storage, cDNA was kept at -20 ºC, and for long term 
storage at -80ºC.  
Real-Time PCR 
Separate protocols were used to analyze mRNA and miRNA expression. For 
mRNA analysis, primers were designed in house for the gene of interest; the sequences 
are listed in Table 4. The reaction consisted of 5 µl cDNA (diluted 1:10 in nuclease-free 
water), 0.25 µl each of forward and reverse primers, 4.5 µl water and 10 µl 2x SYBR 
Green Master Mix in a total volume of 20 µl. The SYBR Green Master Mix also 
contained ROX dye as a passive reference. For analysis of miRNA, miScript primers 
were purchased from Qiagen (Germantown). The reaction, in a 22 µl volume, consisted 
of 2 µl cDNA (diluted 1:10 in nuclease free water), 2 µl universal primer, 4 µl water, and 
10 µl 2x SYBR Green Master Mix.  
Real-Time PCR was performed on an AriaMX instrument using the following 
thermal cycling parameters: hot start 10:00 at 95ºC, followed by 40 cycles of denaturing 
for 15s at 95ºC, annealing for 30s at 55ºC, and extending for 30s at 70ºC with 
fluorescent data collection occurring at this step. After the 40 cycles of amplification, a 
melt curve was performed to ensure the synthesis of a single product (one peak). Data 
analysis was performed as previously described 87, 214 with normalization to U6 for 
miRNA and 18S for mRNA. Primers were designed using Vector NTI, and ordered from 
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IDT (Coralville, IA), with the exception of Hsp90aa1 and Dnajb4, which were purchased 
from Qiagen (Germantown).  
Table 4. Sequences of Real-time PCR primers 
Gene Sense primer Anti-sense primer 
Hsp70.1 GAAGACATATAGTCTAGCT
GCCCAGT 
CCAAGACGTTTGTTTAAGA
CACTTT 
Hsp70.3 GGCCAGGGCTGGATTACT GCAACCACCATGCAAGATT
A 
Dnaja1 3’ GGTGAAGGAGACCAAGAAC
CAGGA 
TTGACAATCTGACCTGGAT
GAGAGG 
Dnajb1 3’ ATGTTTGCTGAGTTCTTCGG
TGGC 
CCGCTGTAGATCTCTTCAAG
GGAGAC 
18S AGTCCCTGCCCTTTGTACAC
A 
CCGAGGGCCTCACTAAACC 
PTEN GGCCAACCGATACTTCTCTC
C 
CTGGATCAGAGTCAGTGGT
GT 
PDCD4 
total, 
mouse 
TGGTGGGCCAGTTTATTGCT CCAGATCCCCACACACTGT
C 
PDCD4 
total rat 
TACCGCATTTCCACCACGA
G 
GCACAGAGTATGAGTGTGG
GAC 
PDCD4 v1 
mouse 
GCACAGCAACTCTTACAGT
CTTAG 
CGGTGGTTCCTCTTCTGTCC 
PDCD4 v3 
mouse 
CAAGAACAGATCTCAACTG
GAACAT 
ACCGGGTTCGTTTTTCCAGT 
PDCD4 v1 
rat 
GAAGGAGATGGAGGTCGTC
TTAAACC 
AGGTGGTTACTCTTCGGTCC
CT 
PDCD4 v3 
rat 
CCAAGAACAGATCTCAATT
GGAACGT 
GTAGAAAAATAGATGTTCC
AGCCACC 
Peli1 GTGAATGTCCTATGTGTAG
GTCTGTT 
CCTTGTTCACCAGCCAACTG
AT 
FasL GGCTCCTCCAGGGTCAGTTT
TT 
CATTCCAACCAGAGCCACC
AG 
 
Generation of Luciferase Reporter Plasmids 
Luciferase reporter plasmids were constructed as previously described87. Using 
primers to murine genomic DNA, the 3’-UTR of the gene of interest was amplified. See 
Table 5 for the sequences of cloning primers for each plasmid. Then the pGL4 plasmid 
(Promega, Fitchburg, Wisconsin) was linearized using appropriate restriction enzymes to 
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create the desired overhang sequences. The pGL4 plasmid expresses luc2 (a modified 
luciferase with mammalian codon replacement) driven by the constitutively active 
cytomegalovirus (CMV) promoter. The 3’-UTR sequence was ligated into the plasmid 
immediately following the luc2 sequence and the plasmid was re-circularized. E. coli 
bacteria were transformed with the plasmid by standard heat shock protocol, allowed to 
recover for 1 hour, and plated on agarose. Several colonies were transferred to Terrific 
broth (Sigma-Aldrich, St. Louis) and grown overnight under penicillin selection (100 
µg/mL) at 37ºC in a rotary shaker. DNA was extracted using a DNA isolation kit 
according to the manufacturer’s instructions. Each plasmid was tested by restriction 
analysis and sequencing.  
The resulting construct provides high expression of luc2 that is regulated by the 
3’-UTR of the gene of interest. When co-transfected with miRNA that binds to the 3’-
UTR, translational repression and reduced luciferase activity occur, confirming that the 
miRNA regulates the target gene through interaction with its 3’-UTR.  
Table 5. 3’-UTR Cloning Primers 
3’-UTR Forward primer (5’- to 3’) Reverse primer (5’- to 3’) 
Hsp70.3 GGTGGATTAGAGGCCTCTG
CTGGCTCTCCCGGTGCT  
GGTGGTACCCGGCCGGCCT
GTTGTCAGTTCTCACCT 
Hsp70.1 GGTGGATTAGAGGCCTCTG
CTGGCTCTCCCGGTGTG 
GGTCCTGAGTGGCCGGCCC
AGGAACCACATGGTGGCT 
Hsp90aa1 AAGATCGCCGTGTAGGTCA
CCAGAACTATGTGTTTGCTT
ACCTT 
GTCTGCTCGAAGCGGGTGT
GCTGGGGAAGAGAGGATGT
C 
Dnajb4 AAGATCGCCGTGTAGGATG
AGAAGAACCTTGCTATCCA
TAGTTTGA 
GTCTGCTCGAAGCGGCTGG
GCACAGCTCCACGGTG 
PDCD4 AAGATCGCCGTGTAGGCAC
AGCAACTCTTACAGTCTTAG
G 
GTCTGCTCGAAGCGGAGCA
GGTTCTGTCTCAAGAAGCA 
FasL AAGATCGCCGTGTAGAAGA
AAAAGCATTTTAAAATGAT
GTCTGCTCGAAGCGGGAGG
AAAGAAACTAGACAGAAGA
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CTACTATTCTTTATCATGGG
CA 
GAGGGGAAA 
 
Dnaja1 has a very long 3’-UTR (>2000 bp) that proved difficult to clone into the pGL4 
reporter plasmid. Therefore, we outsourced the purchase of this reagent from 
GeneCopoeia. 
Transfection and Luciferase Assay 
H9c2 cells were plated at a density of 1x104 cells/well in 96-well plates. The next 
day, they were incubated in Opti-MEM (Thermo Fisher Scientific, Waltham) without 
FBS (serum starved) for 1 hour and then co-transfected with plasmid DNA and RNAi 
(miRNA mimics, negative control or positive control siRNA) using Lipofectamine 2000 
(Thermo Fisher Scientific, Waltham). RNAi and lipofectamine were complexed using 
the recommended ratio of 1 µl lipofectamine per 20 pmol RNAi. When dose curves of 
miRNA were being performed, the total molarity was held constant, with negative 
control siRNA used to compensate. DNA was complexed separately from the RNA, at 
the recommended ratio of 2.5 µl lipofectamine per µg of DNA. The final volumes of 
complexed RNA and DNA were 25 µl each per well. The Opti-MEM used to starve the 
cells was removed, the RNA and DNA were combined, and 50 µl were added to each 
well. The transfection was carried out for 4 hours, followed by addition of 50 µl per well 
of DMEM containing 20% FBS for a final FBS concentration of 10%, and recovered 
overnight. The next day, 100 µl per well of Steady Glo Luciferase Reagent (Promega) 
were added, the plate was incubated at room temperature for 5 minutes to ensure 
complete lysis of cells. The contents of each well were transferred to corresponding 
wells of an opaque white plate for reading of luminescence on the Cytation3.  
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RNA and miRNA-Sequencing 
Sequencing was performed on two sets of samples, (1) IPC vs. sham mouse 
hearts; (2) HPC vs. normoxic HL-1 cells and their exosomes as well as wildtype MSCs 
and their exosomes. For the first set, three hours after sham or IPC, mouse hearts were 
removed and the ischemic zone dissected as described previously38. Total RNA was 
isolated by phase separation, and purity and concentration determined by absorbance 
readings at 260 and 280 nm using a NanoDrop. For the second set of samples, HL-1 
cells underwent HPC and were allowed to recover for 18h. RNA was isolated by phase 
separation from the cells and exosomes pelleted from the conditioned media. To increase 
the yield of RNA from the exosomes, 5 µl Glyco Blue (Thermo Fisher Scientific, 
Waltham) were added during the isopropanol precipitation step. RNA was also isolated 
from untreated wildtype MSC and their exosomes for sequencing.  
The first two sets of samples were provided to the University of Cincinnati 
genomics core facility for miRNA-Seq and RNA-Seq. Quality control was performed to 
ensure RNA integrity and presence of small RNA by Agilent Bioanalyzer, and cDNA 
libraries were prepared using the NEBNext Small RNA Library Prep Set for Illumina. 
Then the libraries were analyzed on an Illumina HiSeq 2000 instrument to yield 50 base 
pair single end reads. 
Bioinformatic Analysis of Sequencing Data 
Raw data from the Illumina in the FASTQ file format was uploaded to Galaxy, 
an open source web-based platform for data-intensive biomedical research, and 
“groomed” to prepare it for downstream analysis. Quality control was performed using 
the application FastQC. This program provides the quality of the data for each 
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nucleotide read in the form of a Phred quality score. Because this score is 
logarithmically related to the probability of an error, quality scores over 30 are predicted 
to result in 99.9% accuracy of reads (the probability of an incorrect base call is 1 in 
1000). An example from our data is shown in Figure 7. 
Figure 7: Example of Phred Quality Score Data 
 
 
After ensuring that the quality scores were consistently over 30, adapters were 
trimmed and the resulting sequencing reads were aligned to the mouse genome (build 
GRCm38) to determine their identity using TopHat2, which has the advantage of being 
able to map reads that span exon junctions215, producing a BAM file containing the read 
alignments which mapped to genes. Reads were counted using the Python package 
HTSeq, then analyzed by making a series of pairwise comparisons between the groups 
using a Bioconductor package called DESeq216. For the mRNA experiments, information 
about the function of the genes was provided by GO term analysis.  
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For miRNA, quality control and grooming were carried out as for the mRNA 
files. Then they were aligned to the mouse genome using BowTie (v. 0.12.8) and 
analyzed by DESeq.  
In silico Targeting Hypothesis Generation Using Cytoscape 
MicroRNAs that are predicted to target each protein of interest were identified 
using the MiRanda targeting algorithm217 on microRNA.org74. Stringent parameters 
were used for the prediction, such that only conserved sites with good mirSVR scores (a 
model to predict efficiency of sites218) were included. Noting that some microRNAs had 
common targets, we visualized the network as follows using Cytoscape, an open-source 
biological network visualization program. For the heat shock proteins, each microRNA 
was entered into an Excel spreadsheet formatted with the microRNAs in one column and 
gene targets in the next column. In Cytoscape, the “Import Network From File” dialog 
was opened and this Excel file was chosen. The microRNA (column 1) was chosen as 
the “source,” the interaction was left as Default, and the protein (column 2) was chosen 
as the “target.”  
The resulting network showed all of the heat shock proteins and 414 miRNAs 
predicted to target them. Because we are interested in miRNAs that act as nodes in a 
network, regulating numerous genes, we eliminated miRNAs that only targeted 1 or 2 
genes, and kept those that targeted 3 or more. Of these, 3 miRs were chosen for follow-
up based on reasonable expression levels in the heart and HL-1 cells (some were 
expressed very low or not at all), as well as a decrease in the expression level being 
noted after protective stimuli such as IPC83, 219, 220 or HPC (herein).  
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Statistical Analysis 
For normally distributed data with equal variance, comparisons between two 
conditions were made using student’s T test, and between 3 or more conditions using the 
ANOVA test with Bonferroni’s correction for multiple comparisons. Group size was 
determined by performing power analysis with a desired β of >0.8. Differential 
expression in the sequencing data was analyzed by determining the dispersion and the 
mean of each gene’s reads within groups and between groups in the application DESeq.  
EXPERIMENTAL LIMITATIONS 
Luciferase Assay Limitations 
Luciferase reporters expressing the full length 3’-UTR are useful for determining 
whether the miRNA binding site is accessible within the 3D structure formed by the 
RNA of the 3’-UTR, but because the sequence for luciferase is substituted for the actual 
gene, the structure of the mRNA may be different than it is for the endogenous 
transcript. Also, expression of the reporter is driven by a constitutively active promoter, 
leading to production of a very high number of copies of the mRNA/3’-UTR. In such 
cases, the machinery responsible for splicing and alternative polyadenylation which can 
occur in the 3’-UTR, affecting the presence of miRNA binding sites, could be 
overwhelmed, and the 3’-UTR may not be processed the same as it would be with 
endogenous levels of gene expression. Furthermore, the number of copies of the miRNA 
which are transfected is also extremely high, which could affect how endogenous 
miRNAs are loaded within RISC complexes. As such, reporter assays can answer the 
question of whether it is possible for a miRNA to repress a gene through its 3’-UTR, but 
whether the endogenous transcript is a true target must be determined empirically. 
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Limitations of Mimic Transfection and miRNA Knockdown Assays 
After transfection, the change in miRNA level is much greater in magnitude (as 
measured by real time PCR) than that which occurs endogenously in response to 
cardioprotective stimuli. The results can also be affected by transfection efficiency. 
Furthermore, the transfection process can affect cell viability, and recovery from 
transfection could be a stressor that induces heat shock protein expression. This is why 
we always used a negative control siRNA rather than non-transfected cells as controls. 
However, to get around these concerns, stable cell lines would need to be generated.  
Imaging-based Viability Assay Limitations 
With the overnight exosome pre-treatment in vitro, we often noted a mild 
proliferative effect on the H9c2 cells. This was the rationale for counting viable cells 
immediately before and after OGD. If they had been only counted after OGD, the greater 
number present would have led to an overestimation of the protective effect because the 
greater number present before OGD wouldn’t be taken into account. Instead we used the 
viable count before and after to calculate the percent survival, and found that a smaller 
percentage were lost after the WT exosome treatment. This conclusion is based on the 
assumption that under conditions of oxygen and glucose withdrawal, the H9c2 cells no 
longer divide. It is possible that the same fraction of cells was killed by the OGD 
challenge, and what we have termed a protective effect here is actually the result of 
increased cell division, which compensated for those lost. Without experiments that used 
proliferation inhibitors in the media, or pulse-chase experiments to label newly 
synthesized DNA, it is not possible to discern between the two. 
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CHAPTER 3 
RESULTS 
THE ROLE OF MICRORNA IN ISCHEMIC PRECONDITIONING 
Preconditioning and I/R Injury In Vivo and In Vitro  
Late ischemic preconditioning results in reduction of infarct size from 40.6% in 
sham controls to 21.4% of the area at risk38. Previous work from the Jones lab 
established a role for miR-711 and miR-378* acting in conjunction with alternative 
polyadenylation to regulate the expression of Hsp70.3, a cardioprotective gene that is 
required for late IPC38, 87. Using Hl-1 cells, we established in vitro models of hypoxic 
pre-conditioning (HPC) and simulated ischemia/reperfusion injury (simI/R) in order to 
test the roles of other miRNAs and heat shock protein family members. When HPC was 
performed 24h prior to simI/R, cell death was dramatically reduced. Furthermore, the 
amount of lactate dehydrogenase (LDH) released into the media was decreased (Figure 
8).  
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Figure 8. Simulated Ischemia/Reperfusion Injury and Hypoxic Preconditioning 
 
A. Confluent 6-well plates of HL-1 cells were preconditioned by 1 hour of hypoxia in 
ischemia mimetic solution and then returned to normal culture conditions overnight. 
The next day they were subjected to simI/R by exposure to hypoxia for 2.5 hours 
followed by 1h reoxygenation. All and dead cells were then counted by staining with 
Hoechst and PI, respectively, to obtain the viable cell count (n=6). *P<0.001 vs. Ctrl. B. 
Cells were treated as in part A and culture media from ischemia and reperfusion steps 
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was assayed for LDH released from cells (n=3). #P<0.001 vs. Ischemia Ctrl, •P=0.029 
vs. Ctrl, ••P<0.001 vs. Reperfusion Ctrl. C. Representative 4x images used to calculate 
the values in A. Hoechst labels all nuclei blue, while PI labels nuclei of dead cells red. 
Double-labeled dead cells appear purple.  
 
Gene Expression after IPC 
Previous work in the Jones lab established a profile of genes that are regulated 
3h after IPC through microarray analysis. We built upon this data set by performing 
deep sequencing for mRNA and miRNA on new sham and IPC heart tissue samples, 
also collected at 3h post IPC (n=2/group). Table 6 shows a comparison of the fold 
changes detected in the microarray data and the sequencing data for those genes that 
were significantly differentially expressed in both assays. In general, the fold changes 
are in agreement in direction (i.e., expression increases or decreases in both) but the 
magnitude was greater in the RNA-Seq data. Seven out of the 61 genes were heat shock 
protein family members, including Hsp40 (Dnaj family members), Hsp70, Hsp90 
(Hsp90aa1), and chaperonin (Hspd1), underscoring the importance of this group of 
proteins in IPC. For the complete list of significant mRNA changes in the sham vs. IPC 
sequencing data, see Appendix A.  
Table 6. Comparison of Microarray and Sequencing Data on Mouse Heart Tissue 3h 
Post-IPC 
Symbol Gene Name Array RNA-Seq 
Adamts1 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 
motif, 1 
2.83 4.10 
Akap2 A kinase (PRKA) anchor protein 2 1.55 1.92 
Atf3 activating transcription factor 3 3.37 17.08 
Bag3 Bcl2-associated athanogene 3 1.38 4.09 
Cnksr1 connector enhancer of kinase suppressor of Ras 
1 
1.33 2.82 
Cnksr3 Cnksr family member 3 1.43 1.99 
Ctps cytidine 5'-triphosphate synthase 1.28 1.75 
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Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 2.48 7.09 
Dnaja4 DnaJ (Hsp40) homolog, subfamily A, member 4 1.39 2.32 
Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 2.1 8.38 
Dnajb4 DnaJ (Hsp40) homolog, subfamily B, member 4 2.72 3.50 
Ell2 elongation factor RNA polymerase II 2 2.2 3.79 
Entpd5 ectonucleoside triphosphate diphosphohydrolase 
5 
-1.77 -1.74 
Errfi1 ERBB receptor feedback inhibitor 1 1.79 1.84 
Fgl2 fibrinogen-like protein 2 2.26 3.46 
Frat2 frequently rearranged in advanced T-cell 
lymphomas 2 
2.78 5.23 
Frmd6 FERM domain containing 6 1.52 2.45 
Gadd45b growth arrest and DNA-damage-inducible 45 
beta 
-1.35 2.09 
Gp49a glycoprotein 49 A 1.49 1.88 
Hmox1 heme oxygenase (decycling) 1 1.77 3.09 
Hsp90aa1 heat shock protein 90kDa alpha (cytosolic), 
class A member 1 
3.08 9.14 
Hspa1b heat shock protein 1B 8.53 690.66 
Hspd1 heat shock protein 1 (chaperonin) 1.75 1.67 
Il1r1 interleukin 1 receptor, type I 1.4 1.68 
Il1r2 interleukin 1 receptor, type II 1.46 3.66 
Il4ra interleukin 4 receptor, alpha 1.45 2.04 
Kcnb1 potassium voltage gated channel, Shab-related 
subfamily, member 1 
1.34 -1.81 
Kcnq1 potassium voltage-gated channel, subfamily Q, 
member 1 
-1.37 -1.72 
Kctd6 potassium channel tetramerisation domain 
containing 6 
1.38 2.74 
Klf6 Kruppel-like factor 6 1.39 1.94 
Ky kyphoscoliosis peptidase -2.06 -2.40 
Lilrb4 leukocyte immunoglobulin-like receptor, 
subfamily B, member 4 
2.02 2.03 
Maff v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein F (avian) 
1.35 3.01 
Mum1l1 melanoma associated antigen (mutated) 1-like 1 2.65 5.92 
Nfil3 nuclear factor, interleukin 3, regulated 1.62 2.00 
Nle1 notchless homolog 1 (Drosophila) 2.31 4.47 
Nt5e 5' nucleotidase, ecto 2.21 2.55 
Nts neurotensin 1.58 2.53 
Odc1 ornithine decarboxylase, structural 1 1.88 1.84 
Paqr7 progestin and adipoQ receptor family member 
VII 
-1.53 -2.03 
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Pde4b phosphodiesterase 4B, cAMP specific 1.66 2.24 
Pgm1 phosphoglucomutase 1 1.4 2.11 
Phlda1 pleckstrin homology-like domain, family A, 
member 1 
1.76 6.16 
Ptx3 pentraxin related gene 2.36 5.68 
Rassf1 Ras association (RalGDS/AF-6) domain family 
1 
1.25 2.39 
S100a8 S100 calcium binding protein A8 (calgranulin 
A) 
1.43 4.40 
Sat1 spermidine/spermine N1-acetyl transferase 1 1.45 1.93 
Sbno2 strawberry notch homolog 2 (Drosophila) 1.77 3.90 
Sema6d sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D 
1.35 1.90 
Serpinh1 serine (or cysteine) peptidase inhibitor, clade H, 
member 1 
1.78 4.66 
Slc20a1 solute carrier family 20, member 1 1.32 1.68 
Slc35b2 solute carrier family 35, member B2 -1.39 -1.84 
Smad1 MAD homolog 1 (Drosophila) 1.42 1.85 
Sphk1 sphingosine kinase 1 2.61 12.52 
Stip1 stress-induced phosphoprotein 1 1.47 2.80 
Tcta T-cell leukemia translocation altered gene -1.83 -1.67 
Tec cytoplasmic tyrosine kinase, Dscr28C related 
(Drosophila) 
1.49 2.68 
Thbd thrombomodulin 1.45 1.99 
Tpm3 tropomyosin 3, gamma 1.44 1.80 
Txnrd1 thioredoxin reductase 1 1.42 2.01 
Unc45b unc-45 homolog B (C. elegans) 1.34 2.55 
Fold changes between sham and IPC. Array data are a pooled n of 3, while sequencing 
data n=2 mice/group. The above genes are those that were significantly different in both 
assays. Bold-faced genes are heat shock protein family members.  
 
Gene ontology analysis of the upregulated genes suggested a number of 
regulatory themes, many of which are known to be important contributors to ischemic 
preconditioning (Table 7). For example, sets of genes that are regulated by NF-κB and 
heat shock factors 1 and 2 are increased; these transcription factors are well known to 
mediate protective gene expression in IPC37, 38, 70, 221, 222. Additionally, genes related to 
nitric oxide biosynthesis are upregulated; NO is well known to be an important 
cardioprotective factor27, 70, 223, 224. There was also enrichment of general categories such 
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as response to wounding, and inflammation/immune response. Many of the upregulated 
gene sets were associated with GO terms related to chaperone function, such as “protein 
refolding” and “response to heat” which is consistent with literature published about 
IPC since shortly after its discovery33, 63, 64.  
Table 7. Functional Enrichment from RNA-Seq Analysis 
Description #Genes P Value 
Genes upregulated by NF-kappa B (Human) 97 1.38E-29 
protein refolding 11 8.79E-28 
response to unfolded protein 50 1.41E-25 
positive regulation of protein import into nucleus, translocation 12 3.99E-24 
Genes with promoter regions [-2kb, 2kb] around transcription 
start site containing the motif NGAANNWTCK which 
matches annotation for HSF2: heat shock transcription factor 2 
201 5.15E-23 
positive regulation of nitric oxide biosynthetic process 29 2.26E-23 
Up-regulated at any timepoint following TNFa treatment, only 
with functional NF-κB (Human) 
17 1.34E-22 
chaperone mediated protein folding requiring cofactor 14 1.70E-22 
immune response 532 6.77E-22 
chaperone-mediated protein folding 22 2.62E-21 
Genes with promoter regions [-2kb, 2kb] around transcription 
start site containing the motif RGAANNTTC which matches 
annotation for HSF1: heat shock transcription factor 1 
375 8.63E-21 
response to wounding 505 7.40E-21 
inflammatory response 316 7.30E-20 
regulation of cytokine production 287 4.77E-18 
regulation of nitric oxide biosynthetic process 37 9.29E-18 
'de novo' posttranslational protein folding 17 1.37E-17 
nitric oxide biosynthetic process 44 1.75E-15 
nitric oxide metabolic process 48 5.28E-15 
unfolded protein binding 80 6.91E-15 
Protein processing in endoplasmic reticulum 159 1.48E-14 
response to heat 50 2.53E-13 
intracellular protein kinase cascade 633 4.84E-13 
The 20 most significantly enriched gene ontology (GO) terms are shown. The heat 
shock response and protein folding constitute major aspects of the heart’s response to 
IPC. 
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Based on the list of heat shock protein family members (HPSs) that were 
significantly increased in Table 6, we validated their expression in the heart after IPC 
through qPCR (Figure 9) and Western blot (Figure 10). The pattern of expression of the 
genes correlated closely with that of the sequencing data, with low Hsp70 expression at 
baseline that was highly inducible after IPC, while comparatively higher expression of 
Hsp90aa1 and Dnajb4 were observed at baseline, which also increased after IPC. 
Western blot showed that 6h after IPC, expression of Dnaja1 and Dnajb4 were 
increased by 4.9- and 6.5-fold respectively, while Hsp70 (antibodies currently available 
cannot discern between Hsp70.1 and Hsp70.3) increased by 12.5-fold. Hsp90 showed a 
trend towards an increase which did not reach statistical significance (Figure 10). By 
24h after IPC, Hsp70 was the only protein that remained elevated.  
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Figure 9. Validation of HSP RNA-Seq Data by qPCR  
 
A. The average read count of the HSPs from Table 6 chosen for follow-up, in sham and 
IPC samples. B. Expression of the HSPs normalized to GAPDH, n=4-5 mice/group. 
*P<0.05 vs. sham **P <0.001 vs. sham by t-test.  
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Figure 10. HSP Protein Levels 6 and 24h after IPC 
 
Protein was extracted in RIPA buffer from the ischemic zone of the LV 6 and 24h after 
IPC (n=4 mice/group). Ten µg of protein were analyzed by Western blot for the above 
proteins. Band intensities were normalized to Actin and are displayed as the fold change 
vs. Sham. *P<0.05 vs. Sham by t-test.  
 
Comparison of Gene Expression After IPC and HPC 
HL-1 cells generally express a similar profile of heat shock protein family 
members to that of heart tissue; Hsp90 was the highest, followed by Hsp40, and Hsp70 
as the lowest expressed (Figure 11A). Preconditioning in HL-1 cells has been reported 
to be similar to IPC in the heart with regard to the role of extracellular adenosine 
interacting with the adenosine receptor, triggering the activation of PKCε225. Because 
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IPC and HPC are both induced by brief periods of hypoxia and nutrient withdrawal, and 
both reduced cardiomyocyte cell death at 24h, we hypothesized that they may have 
overlapping gene regulatory mechanisms. However, when RNA from HPC HL-1 cells 
was analyzed by RNA-Seq, we did not observe comparable changes in any of the IPC-
regulated genes (see Table 11, p106). Realtime qPCR performed on HL-1 samples 3h 
after HPC showed very mild increases in HSP levels (Figure 11B). Furthermore, heat 
shock treatment, which induces the expression of heat shock proteins (Figure 11C), did 
not significantly decrease cell death from simI/R in either the HL-1 cells (Figure 12) or 
H9c2 cells (data not shown). The effect of HPC on HSP expression in vitro is much less 
than that of IPC in vivo. Because the HSPs were expressed to a similar degree in HL-1 
cells and heart tissue, (Figure 11A) we decided to use the HL-1 cell line for testing 
miRNA regulation of HSP expression with and without heat shock.  
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Figure 11. Heat Shock Protein Expression in Heart Tissue and HL-1 Cells 
 
A. Sequencing data showed that Hsp70, Hsp90, and Hsp40 family members are 
expressed in a similar pattern in control heart tissue and HL-1 cells. B. RNA was 
extracted from HL-1 cells 3h post-HPC and analyzed by qPCR with 18S as the 
housekeeping gene (n=3). C. RNA was extracted from HL-1 cells 3h post-heat shock 
(HS) and analyzed by qPCR with GAPDH as the housekeeping gene (n=3). *P=0.005, 
**P<0.001 vs. Ctrl. 
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Figure 12. Heat Shock Does Not Protect HL-1 Cells from SimI/R 
 
A. HL-1 cells were pre-treated with a 1h heat shock (HS) or 1h HPC and allowed to 
recover 18h. Then they were subjected to simI/R which consisted of 3h hypoxia and 
18h reoxygenation. LDH was assayed in media samples collected after simulated 
ischemia (blue) and reperfusion (red). B. Cells were treated as in (A) and viability was 
assayed by measuring GF-AFC cleavage which produces a fluorescent protein, 
indicative of metabolic activity (n=18). Pairwise comparisons were made of average 
fluorescence in all conditions by one-way ANOVA with Bonferroni’s correction, 
*P<0.001 vs. Control; simI/R vs. HS+simI/R, P not significant.  
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number to 15 (Figure 13). Next we looked to the sequencing data and previously 
performed miRNA PCR array data in order to identify miRNAs which target numerous 
HSP family members and are decreased in expression by protective stimuli (IPC and/or 
HPC). Table 8 shows the combination of this data. 
The miRNAs selected based on these criteria were miR-148a and b, miR-30b, 
and let-7a*. The accession numbers and sequences of the miRNAs are shown below. 
mmu-miR-148a-3p  MIMAT0000516  UCAGUGCACUACAGAACUUUGU 
mmu-miR-148b-3p  MIMAT0000580  UCAGUGCAUCACAGAACUUUGU 
mmu-miR-30b-5p  MIMAT0000130  UGUAAACAUCCUACACUCAGCU 
mmu-let-7a-1-3p  MIMAT0004620   CUAUACAAUCUACUGUCUUUCC 
miR-148a and b were predicted to target both Hsp70’s and Dnaja1, miR-30b 
was predicted to target both Hsp40’s and Hsp90, and let-7a* was predicted to target 
both Hsp40’s and Hsp70.1. In order to validate these targeting predictions, we 
performed luciferase reporter assays as previously described87.  
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Figure 13. Generation of miRNA-Heat Shock Protein Targeting Network 
 
A. All miRNAs targeting Hsp70, Hsp90, and Hsp40 family members are shown. B. 
miRNAs that targeted only 1 or 2 HSPs (shown in white ovals, middle) were 
eliminated, resulting in 29 miRNAs remaining. miRNAs were then removed if they had 
less than 32 reads to remove potential artifacts or very low-expression miRNAs. Gray 
circles indicate expression of 33 to 100 reads in heart tissue, and yellow color indicates 
expression greater than 100 reads but no decrease in response to IPC or HPC. Green 
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represents miRNAs expressed over 400 in the heart and HL-1 cells which do show 
decreases after IPC and/or HPC. Dnajb1 was removed from the network because there 
were no miRNAs left that target it once those that targeted only 1 or 2 HSPs were 
filtered.  
 
Table 8. Expression Data for miRNAs That Target 3 or More Heat Shock Proteins 
miR HSPs targeted 
Array fold 
change in 
IPC 
Counts in heart Countsl in HL-1 
Sham IPC Ctrl HPC 
let-7a*  
Hsp70.1, Dnaja1, 
Dnajb4 -1.51 409 522 449 279 
let-7b*  
Hsp70.1, Dnaja1, 
Dnajb4 1.18 60 68 14300 14300 
let-7c-2*  
Hsp70.1, Dnaja1, 
Dnajb4 1.05 126 161 227 155 
miR-128a 
Hsp70.1, Dnajb4, 
Hsp90aa1 -1.35 1605 1933 2238 2162 
miR-132-3p 
Hsp70.1, Dnajb4, 
Hsp70.3 1.09 44 55 65 90 
miR-148a-3p 
Hsp70.1, Dnaja1, 
Hsp70.3 -1.44 16000 17000 18448 12732 
miR-148b-3p 
Hsp70.1, Dnaja1, 
Hsp70.3 -1.17 934 765 4082 2246 
miR-199a-5p 
Hspb1, Dnajb1, 
Dnajb4 1.37 1018 985 4 59 
miR-224-5p 
Hsp70.1, Dnaja1, 
Dnajb4 -1.03 47 61 25 36 
miR-30b-5p 
Dnaja1, Dnajb4, 
Hsp90aa1 -1.18 1484 1180 3659 3070 
miR-322* 
(322-3p) 
Dnaja1, Dnajb4, 
Hsp90aa1 -1.05 382 401 2978 3703 
miR-335-3p 
Hsp70.1, 
Hsp70.3, Dnaja1, 
Dnajb4, 
Hsp90aa1 1.04 103 108 41 24 
miR-421-3p 
Dnaja1, Hsp70.3, 
Hsp90aa1 -1.06 9 12.5 75 72 
miR-664-3p 
Hsp70.1, Dnaja1, 
Dnajb4 ? 39 59 31 31 
miR-7a* 
Dnaja1, Dnajb4, 
Hsp90aa1 -1.18 355 447 7 13 
Data used to select the miRNAs to test came from a combination of previously 
performed array data and sequencing data, and was based on expression level in the 
heart. In instances where the protective stimulus caused a decrease detected in either the 
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array data and the sequencing data from IPC heart tissue or array data and the HPC HL-
1 cells, the miRNA was considered for follow-up.  
 
Luciferase Reporter Assays 
Hsp70.1 and Hsp70.3 Hsp70.1 (Hspa1b) was a predicted target of miR-148a/b 
and let-7a*. By co-transfecting the Hsp70.1 reporter plasmid along with a dose curve of 
these miRNAs, we tested whether there was a decrease in luciferase activity 24h later, 
compared with a non-targeting siRNA control. We found that both miR-148a and b 
repressed luciferase activity dose dependently to a similar degree, by 53 and 54%, 
respectively, while let-7a* did not decrease luciferase activity even at the highest dose 
tested (Figure 14). Because miR-148a and b differ only by the rearrangement of two 
nucleotides in the out-seed region, they appear to be functionally redundant in binding 
to the 3’-UTR of Hsp70.1. Similar to Hsp70.1, we tested the Hsp70.3 (Hspa1a) 3’-
UTR, which was predicted to be targeted by miR-148a/b. We observed a dose-
dependent decrease with both miRNAs that was less in magnitude than that of 
Hsp70.1’s 3’-UTR, reaching a maximal inhibition of 31% with 200 nM miR-148a. 
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Figure 14. Hsp70.1 and Hsp70.3 Regulation by miR-148a, miR-148b, and let-7a* 
 
A. H9c2 cells were co-transfected with the Hsp70.1 reporter plasmid (30 ng/well) and a 
dose curve of miR-148a, 148b, or (B) let-7a*. Non-targeting siRNA served as the 
negative control (0 nM refers to this control with 0 specific targeting miRNAs, but same 
concentration of non-targeting siRNA) and was also used to maintain a constant total 
quantity of RNAi in each condition. Luciferase activity was measured 24h after 
transfection, normalized to 0 nM miRNA, and expressed as a percentage (n=10). 
*P<0.001 vs. 0 nM miR-148a. #P<0.001 vs. 0 nM miR-148b by one-way ANOVA. C. 
Cells were treated as in (A) with the Hsp70.3 plasmid (n=10). *P<0.001 vs. 0 nM miR-
148a by one-way ANOVA.  
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Using luciferase assays, we also tested whether combinations of miRNAs would 
be more effective at repressing luciferase activity than a similar quantity of only one 
miRNA. In comparing the effects of miR-148a and miR-148b at the Hsp70.1 3’-UTR, 
we found that all of the combinations tested from 100% miR-148a to 100% miR-148b 
repressed luciferase activity to the same extent, which is consistent with both miRNAs 
targeting the same binding site in the 3’-UTR with equal efficacy (Figure 15A), in 
agreement with the results of Figure 14A. When we performed this experiment with two 
different miRNAs, miR-148a and miR-449c, which bind to different sites in Hsp70.1’s 
3’-UTR, we found that at 200 nM, miR-449c was more efficacious at reducing 
luciferase activity than 200 nM miR-148a (Figure 15B), reducing the activity to 38.6 vs. 
58.6%. When the two miRNAs were combined at an equal ratio, we saw a trend 
towards a reduction in luciferase activity that was greater than either miRNA alone, at 
29.8%.  
Dnaja1 was the predicted target of all 4 miRNAs. However, at 200 nM of each 
of them, significant decreases in luciferase activity were not observed (Figure 16).  
Dnajb4 was the predicted target of miR-30b and let-7a*. We observed a 
significant decrease in luciferase activity after transfection with let-7a* but not miR-30b 
(Figure 17).  
Hsp90 (Hsp90aa1) was predicted to be targeted by miR-30b, and we did 
observe a significant decrease in luciferase activity at the highest dose tested (35% 
decrease vs. 0 nM, Figure 18).  
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Figure 15. Combinations of miRNAs Targeting the 3’-UTR of Hsp70.1 
 
The Hsp70.1 reporter plasmid was transfected along with different ratios of miRNAs. 
Luc activity was assessed 24h later as in Figure 14. A. The dose of miR-148a and b was 
varied from 200 nM miR-148a to 200 nM miR-148b, while maintaining a constant level 
of total miRNA. Pairwise comparisons between all of the values were made using 
ANOVA with the Bonferroni post hoc test, but there were no significant differences. B. 
Different ratios of miR-148a and miR-449c were co-transfected, and luc activity values 
were again compared using ANOVA with the Bonferroni correction for multiple 
comparisons. The 200 nM miR-148a dose was significantly higher than all other 
conditions (*P<0.001); there were no other significant differences.  
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Figure 16. Dnaja1 Regulation by miR-148a, miR-148b, miR-30b, and let-7a* 
 
The Dnaja1 reporter plasmid (30 ng/well) was co-transfected along with a dose curve of 
miR-148a, 148b, miR-30b, or let-7a*. Non-targeting siRNA served as the negative 
control (0 nM) and was also used to maintain a constant total quantity of RNAi in each 
condition. Luciferase activity was measured 24h after transfection, normalized to 0 nM 
miRNA, and expressed as a percentage (n=10).  
 
Figure 17. Dnajb4 Regulation by miR-30b and let-7a* 
 
The Dnajb4 reporter plasmid was co-transfected along with a dose curve of miR-30b or 
let-7a* as described in Figure 14. Luciferase activity was measured 24h after 
transfection, normalized to 0 nM miRNA, and expressed as a percentage (n=10). 
*P<0.05 vs. 0 nM let-7a* by one-way ANOVA. 
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Figure 18. Hsp90aa1 Regulation by miR-30b  
 
The Hsp90aa1 reporter plasmid was co-transfected along with a dose curve of miR-30b 
as described in Figure 13. Luciferase activity was measured 24h after transfection, 
normalized to 0 nM miRNA, and expressed as a percentage (n=16). *P<0.001 vs. 0 nM 
miR-30b by one-way ANOVA. 
 
The next step was to analyze changes in protein levels in vitro in response to 
knockdown and mimic transfection of the miRNAs. We tested the effect of transient 
transfection of mimics or inhibitors on baseline levels of expression in HL-1 cells as 
well as H9c2 cells over time (24-72h) as well as after heat shock stimulation. 
Knockdown and Mimic Transfection of miRNAs In Vitro 
miR-148a and b Increasing the level of miR-148a and b by transfection of 
mimics decreased Hsp70 expression at 24h, which showed a trend towards a continued 
decrease at 72h, though variability increased at that timepoint (Figure 19A). 
Knockdown of miR-148a and b with anti-sense inhibitors induced a 1.21-fold increase 
at 72h. Transfection with 200 nM mimics or inhibitors typically resulted in a ~50-fold 
increase or decrease, respectively (Figure 19B). Because Hsp70 protein levels are very 
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low under control conditions, we also tested the effect of the mimics and inhibitors after 
a 1-hour heat shock (HS), which is known to significantly upregulate this mRNA 
(Figure 11C and 87). In so doing, we found a significant decrease in Hsp70 with mimic 
transfection of miR-148a, miR-148b, or a 50/50 mixture of both. On the other hand, we 
did not observe a significant increase in Hsp70 protein levels after HS unless both miR-
148a and b were inhibited (Figure 19C-D).  
Noting that Hsp70 protein levels were increased after HS when miR-148a/b 
were inhibited, we tested the mRNA levels to determine whether this upregulation 
occurred at the mRNA level as well. We observed a trend towards an increase when 
both miR-148a and b were inhibited, though it did not reach statistical significance 
(Figure 20).  
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Figure 19. Effect of miR-148a Mimic Transfection or Knockdown on Hsp70 
 
A. HL-1 cells were transfected with 200 nM mimics or inhibitors of miR-148a and b 
(100 nM each), and Hsp70 protein levels were assessed 24 and 72h later. B. 24h post-
transfection, RNA was extracted, and miR-148a and b were assessed by qPCR, n=3. C-
D. HL-1 cells were transfected with mimics or inhibitors of miR-148a, miR-148b, or 
both at an equal ratio. Twenty-four hours later they were heat shocked for 1h and 
allowed to recover for 6h before protein extraction to assess levels of Hsp70 (n=3). 
P<0.05 vs. Neg Ctrl by one-way ANOVA. 
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Figure 20. mRNA Levels of Hsp70.1 and Hsp70.3 after Transfection and Heat Shock 
 
Twenty-four hours after transfection with miR-148a and b inhibitors, HL-1 cells were 
heat shocked for 1h and allowed to recover 3h before RNA was extracted. Real time 
qPCR was performed for Hsp70.1 and Hsp70.3. CT values were normalized to those of 
GAPDH and expressed as average fold change vs. Neg Ctrl. 
 
Dnaja1 was also a predicted target of miR-148a and b. However, luciferase 
assays did not confirm this. To further evaluate whether miR-148a and b regulated 
Dnaja1, we tested protein levels after the same conditions we used to test Hsp70, i.e., 
changes in expression over time in unstimulated cells, and after heat shock. At 24h after 
transfection with miR-148a and b mimics, we observed a significant decrease in Dnaja1 
level, but this was not maintained at 72h. At 72h, there was a trend towards an increase 
in cells transfected with the miR-148a and b inhibitors (Figure 21A). After heat shock, 
mimic-treated cells showed a trend towards a decrease and the inhibitor-treated cells 
showed a trend towards an increase (in miR-148a or miR-148b inhibitor treated cells), 
though they were not statistically significant (Figure 21B-C). Thus miR-148a and b may 
weakly or indirectly regulate Dnaja1 expression.  
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Figure 21. Dnaja1 Protein Level Regulation by miR-148a and b 
 
A. HL-1 cells were transfected with mimics and inhibitors of miR-148a and b were 200 
nM (100 nM each), and Dnaja1 protein levels were assessed 24 and 72h later by 
Western blot. P<0.001 vs. Neg Ctrl at 24h by one-way ANOVA. B. 24h Western blot 
images. C-D. HL-1 cells were transfected with mimics or inhibitors of miR-148a, miR-
148b, or both at an equal ratio. Twenty-four hours later they were heat shocked for 1h 
and allowed to recover for 6h before protein extraction to assess levels of Hsp70.  
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miR-30b was predicted to target Dnaja1, Dnajb4, and Hsp90. At 24h, there was 
a trend towards increased expression in Dnajb4 when miR-30b was inhibited, but this 
was not maintained at 48h (Figure 22). There were no changes in Dnaja1 in accordance 
with the negative luciferase data results, or in Hsp90 protein levels.  
Figure 22. Dnaja1, Dnajb4, and Hsp90 Regulation by miR-30b 
 
HL-1 cells were transfected with mimics or inhibitors of miR-30b, and Dnaja1, Dnajb4, 
and Hsp90 protein levels were assessed 24 and 48h later by Western blot (n=3). No 
significant differences were noted in analysis by one-way ANOVA.  
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cause a decrease in expression of its predicted targets, nor did knockdown lead to 
significant increases (Figure 23).  
Figure 23. Effect of let-7a* on Dnaja1, Dnajb4, and Hsp70 Protein Levels 
 
HL-1 cells were transfected with mimics or inhibitors of let-7a*, and Dnaja1, Dnajb4, 
and Hsp70 protein levels were assessed 24 and 48h later by Western blot (n=3). No 
significant differences were noted in analysis by one-way ANOVA.  
 
Combinations of miRNAs To expand on the idea of the miRNAs acting 
together to regulate their targets, we next tested combinations of miRNAs over time and 
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miRNA mimics or inhibitors of miR-30b and let-7a*, which did not induce significant 
changes in Hsp70 and Dnajb4 on their own (Figures 22-23).  
Figure 24. Effect of miR-30b and let-7a* on Protein Levels of Hsp70, Dnaja1, and 
Dnajb4 
 
HL-1 cells were transfected with 200 nM RNAi consisting of a 50/50 mixture of miR-
30b and let-7a* mimics or inhibitors or an equal quantity of non-targeting control 
siRNA as the Neg Ctrl. Protein was extracted at 24 and 72h for analysis of protein 
levels by Western blot (n=3). *P=0.003 vs. Neg Ctrl. #P=0.009 vs. Neg Ctrl. 
 
The combination of all of the mimics together decreased Hsp70 expression 
significantly at 72h, and decreased Dnaja1 and Dnajb4 at both 24 and 72h. The 
combination of all of the inhibitors together significantly increased Hsp70 expression at 
24h, and both Hsp70 and Dnajb4 expression at 72h (Figure 25).  
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The effects of all of the mimics or inhibitors together were stronger than 
individual ones. Hsp70 showed a trend towards a decrease at 72h when cells were 
treated with miR-148a/b mimics (Figure 19), while the combination of mimics 
significantly reduced it to 0.41-fold (Figure 25). Dnaja1 expression was reduced 
significantly at 24h by miR-148a/b, and also by the combination of all mimics together 
to a similar extent (Figure 21 and 25); miR-30b and let-7a* did not show this effect 
singly or in combination (Figures 22-4), supporting a regulatory role only for miR-
148a/b. Dnajb4 was the predicted target of miR-30b and let-7a*. Individually, its 
expression was not significantly affected by their mimics or inhibitors (Figures 22-3). 
When miR-30b and let-7a* inhibitors were used in combination, expression increased 
significantly to 1.48-fold at 72h (Figure 24). Interestingly, when miR-148a/b inhibitors 
were added (i.e., all inhibitors together), expression at 72h further increased to 1.86-fold 
(Figure 25), though miR-148a/b are not predicted to target Dnajb4. The effects of 
mimics of miR-30b and let-7a* at 72h were also further enhanced by the addition of 
miR-148a/b, going from a 0.78-fold to 0.6-fold changes (Figure 24-5).  
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Figure 25. Effect of Combination of All Mimics or Inhibitors 
 
HL-1 cells were transfected with 200 nM RNAi consisting of equal parts miR-148a, 
miR-148b, miR-30b, and let-7a* mimics or inhibitors or an equal quantity of non-
targeting control siRNA as the Neg Ctrl. Protein was extracted at (A) 24h or (B) 
 72h for analysis of protein levels by Western blot (n=3). *P<0.05 vs. Neg Ctrl. 
**P<0.001 vs. Neg Ctrl by one-way ANOVA. 
 
To confirm our findings in the HL-1 cells, we also tested the combination of all mimics 
and inhibitors in the H9c2 cell line. Heat shock induced expression of Hsp70 and to a lesser 
extent, Dnaja1, but not Hsp90 or Dnajb4. The mimics significantly decreased Hsp70 and Dnajb4 
expression after HS, but Hsp90 and Dnaja1 were not affected. After treatment with the 
combination of all inhibitors, Dnaja1 and Dnajb4 increased significantly after heat shock, but 
Hsp70 and Hsp90 were not changed (Figure 26).  
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Figure 26. Effect of Combination of All Mimics or Inhibitors in H9c2 Cells 
 
A. H9c2 cells were transfected with Neg Ctrl siRNA or the mimic mix. 24h later, they 
were heat shocked and allowed to recover for 5h. Hsp70 and Hsp90 levels were 
assessed by Western blot (n=3-4). For Hsp70, #P<0.001 vs. HS, **P<0.001 vs. Ctrl by 
two-way ANOVA. B. Cells were treated as in (A) and Dnaja1 and Dnajb4 were 
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analyzed by Western blot (n=3-4). For Dnaja1, *P<0.05 vs. Ctrl. For Dnajb4, #P=0.004 
vs. Neg Ctrl transfected (Ctrl and HS). C. H9c2 cells were treated as in (A) but with 
inhibitor mix instead of mimic mix (n=3). *P<0.05 vs. Ctrl. 
 
Inhibitor Effects on Viability Upon OGD in HL-1 and H9c2 Cells 
We next tested the combination of inhibitors on viability of HL-1 cells and H9c2 
cells exposed to hypoxia. In the HL-1 cells, HPC increased viability when performed 
24h prior to OGD, as shown in Figure 8 (untransfected cells). Transfection of the 
inhibitors (Figure 27A) did not increase the viable cell count after OGD only. HPC 
alone, with or without the inhibitors, did not affect viability. HPC increased viability 
after OGD (compare with OGD alone) and this was not enhanced by the transfection of 
inhibitors. Transfection of mimics (Figure 27B) did not negatively affect viability after 
OGD, with or without HPC.  
In H9c2 cells, transfection of inhibitors did increase viability after OGD (Figure 
27C). We tested miR-148a/b, miR-30b and let-7a* as well as the combination of all of 
the inhibitors together at 0, 50, and 200 nM. Cells were transfected 72h prior to OGD 
challenge, because previous experiments showed that when the miRNAs were inhibited, 
their target proteins’ levels tended to increase over time. With miR-30b, let-7a*, and the 
combination of all inhibitors, we noted a significant increase compared to 0 nM, and a 
trend towards an increase over the same dose of miR-148a/b. Though the assay was 
repeated six times, variability remained high.  
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Figure 27. Effect of Inhibitors on Viability in H9c2 Cells after OGD 
 
A. HL-1 cells were transfected with 200 nM Neg Ctrl siRNA or a mixture of all of the 
mimics in equal parts miR-148a/b, miR-30b, and let-7a* (All Mim) in 12-well plates. 
The next day two plates had HPC and two served as controls. The following day, plates 
were subjected to simI/R or time-matched normoxic incubation as noted (n=6). Analysis 
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by three-way ANOVA found significant effects of HPC and simI/R (P<0.001), but no 
significant effect for transfection (P=0.445 for All Mim vs. Neg Ctrl) on viability after 
HPC, simI/R or both. B. Cells were treated as in (A) except a mixture of all inhibitors 
was tested, instead of mimics. Analysis by three-way ANOVA showed that inhibitors 
did not have a significant effect (P=0.1 for All Inh vs. Neg Ctrl) on viability after HPC, 
simI/R or both. C. H9c2 cells were transfected with miR-148a/b, miR-30b, let-7a*, or or 
all inhibitors (equal mix), relative to Neg Ctrl siRNA (i.e., 0 nM is 200 nM Neg Ctrl, 50 
nM is 150 nM Neg Ctrl and 50 nM of inhibitors). Seventy-two hours later, cells were 
counted by labeling all and dead cells with Hoechst and PI, respectively. Then they 
were subjected to OGD, and all and dead cells were again counted 1h after after 
reoxygenation, to obtain the % survival for each well. These were averaged for each 
condition (n=4); error bars represent SEM. P≤0.025 vs. Neg Ctrl.  
 
Summary of Findings 
Ischemic preconditioning upregulates heat shock proteins in the myocardium. 
While it was previously established that Hsp70 is significantly increased by IPC at 24h, 
here we show that at 6h, not only is Hsp70 increased, but also Hsp40 family members 
and Hsp90 as well. Hypothesizing that changes in expression of miRNAs could 
contribute to this increased expression, we identified a set of miRNAs that decreased 
after IPC, which could function to derepress their protective target genes (Figure 28). 
Luciferase assays confirmed that miR-148a and b directly target Hsp70.1 and Hsp70.3, 
that miR-30b targets Hsp90, and that let-7a* targets Dnajb4. Through transfection with 
mimics and inhibitors of the miRNAs, singly and in combination, we established that 
miR-148a/b can affect Hsp70 and Dnaja1 protein levels, and the combination of miR-
30b and let-7a* can affect Hsp70 and Dnajb4 levels. The combination of all of the 
miRNAs together affected protein levels of Hsp70, Dnaja1, and Dnajb4. No changes in 
Hsp90 were observed in any of the experiments.  
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Figure 28. Predicted and Experimentally Validated Targeting 
 
 
In the heart, IPC strongly induces the expression of heat shock proteins within 6 
hours. In the HL-1 cells, heat shock strongly induces their expression, while hypoxic 
preconditioning as well as transfection of inhibitors of the miRNAs slightly induce their 
expression. However, both the strong induction after heat shock and the moderate 
induction that occurs with transfection of inhibitors do not induce cytoprotection from 
simI/R. Though the miRNAs selected to investigate in this Aim decrease after HPC, 
preventing this decrease by transfecting the HL-1 cells with mimics does not prevent 
the protection afforded by HPC. In H9c2 cells, the inhibitors slightly boosted expression 
of Hsp40 family members, but not Hsp70 or Hsp90. Transfection of the H9c2 cells with 
inhibitors dose-dependently increased viability in the OGD model.  
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EXOSOMAL MIRNA AS A PARACRINE MEDIATOR FROM MYOCARDIUM TO 
TRANSPLANTED MESENCHYMAL STEM CELLS 
As shown in the previous section, hypoxic preconditioning (HPC) exerted a strong 
protective effect on the HL-1 cells (Figure 8). Because of studies showing that MSCs 
have improved engraftment in preconditioned hearts, which could be mediated by 
paracrine factors released by cardiac cells162, 165, we wanted to test whether 
preconditioning of HL-1’s would affect their exosomes’ RNA content, and whether 
protective mRNA or miRNA could be transferred to MSCs, resulting in protection.  
Mesenchymal Stem Cells Internalize HL-1 Exosomes 
We began by confirming that MSCs internalize HL-1 exosomes, which would 
be a key first step for RNA transfer. We fluorescently labeled the exosomes using the 
lipophilic dye PKH26, and exposed the MSCs to the labeled exosomes over a time 
course of 30 minutes to 18h. Flow cytometry and analysis using the imaging flow 
cytometer Amnis ImageStream showed that MSCs readily take up HL-1 exosomes, 
becoming 80% positive after 30 minutes and 98.9% PKH+ after 18h (Figure 29).  
  
103 
	
Figure 29. MSCs Internalize HL-1 Exosomes 
 
HL-1 exosomes were labeled with the fluorescent dye PKH26, and exposed to MSCs 
over a time course. (A) MSCs rapidly became PKH26+ as shown by an increase in 
fluorescence intensity in the PE channel. (B) Imaging showed the accumulation of 
numerous labeled spots (yellow) within the cells. The membranes of the MSCs were 
labeled with an antibody to CD-44 (red) to confirm exosome internalization.  
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miRNA-Seq Results 
To determine whether the miRNA content of HL-1 exosomes changed after 
HPC, exosomes were isolated from the following sources: control HL-1 cells, control 
HL-1 exosomes, HPC HL-1 cells, and HPC HL-1 exosomes. Figure 30 shows the 
number of total, filtered, and aligned reads for each sample analyzed. Overall alignment 
averaged 44%.  
Figure 30. miRNA-Seq Read Counts 
 
HL-1 cellular and exosomal miRNA was sequenced, and low quality reads were filtered 
out. The remaining sequences were aligned to the mouse genome for differential 
expression analysis.  
 
Then we performed differential expression analysis using the DESeq package to 
compare control vs. HPC cells, and control exosomes vs. HPC exosomes. Table 9 shows 
the significant differences in miRNA between the control and HPC cells. According to 
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the sequencing data, HPC treatment increased the cellular levels of miR-20b and miR-
19a/b, with moderate increases in miR-501, 3062, 340, and 465a/c. There were 
decreases in miR-326, miR-1a*, and miR-184.  
Table 9. Differentially Expressed miRNAs Between Control and HPC HL-1 Cells 
Gene ID Name 
Reads, 
Control 
Cells 
Reads, 
HPC 
Cells 
Fold 
Change 
Adjusted 
P Value 
MIMAT0003187 mmu-miR-20b-5p 21.4 92.4 4.33 0.00005 
MIMAT0000559 mmu-miR-326-3p 63.3 19.3 0.31 0.00501 
MIMAT0000513 mmu-miR-19b-3p 135.6 502.2 3.70 0.01961 
MIMAT0003508 mmu-miR-501-5p 67.4 160.3 2.38 0.03280 
MIMAT0016979 
mmu-miR-1a-1* 
mmu-miR-1a-1-5p 27.6 8.0 0.29 0.05544 
MIMAT0014830 mmu-miR-3062-5p 18.1 50.0 2.77 0.05544 
MIMAT0000213 mmu-miR-184-3p 825.4 398.2 0.48 0.05544 
MIMAT0000706 mmu-miR-362-5p 682.1 1355.9 1.99 0.07083 
MIMAT0004651 mmu-miR-340-5p 135.3 359.7 2.66 0.07083 
MIMAT0004873 mmu-miR-465c-5p 195.6 419.4 2.14 0.07083 
MIMAT0002106 mmu-miR-465a-5p 132.0 352.9 2.67 0.07964 
MIMAT0000651 mmu-miR-19a-3p 44.3 181.9 4.11 0.09447 
Data represent the average of 3 replicates. Intensity of blue color correlates with 
magnitude of decrease in HPC vs. Control cells. Intensity of red color correlates with 
magnitude of increase in HPC vs. Control cells. 
 
A comparison of control exosomes vs. HPC exosomes revealed that, while 
changes in the miRNA profile do occur in the parent cells, the miRNA profile in 
exosomes remains relatively constant, with only two significantly different miRNAs, 
miR-3535, and miR-208a, both of which decreased independently of significant 
changes occurring in the parent cells (Table 10).  
Table 10. Differentially Expressed miRNAs Between Control and HPC HL-1 Exosomes 
Gene ID Name 
Control 
Exo 
HPC 
Exo 
Fold 
Change 
Adjusted 
P Value 
MIMAT0031410 mmu-miR-3535 245.6 68.5 0.28 0.004 
MIMAT0000520 mmu-miR-208a-3p 354.6 123.8 0.35 0.004 
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Data represent the average of 3 replicates.  
RNA-Seq Results 
Through sequencing the mRNA of control and HPC HL-1 cells, we determined 
that HPC induces many changes in their gene expression profile (Table 11). 
Interestingly, this data is substantially different than what occurs in the IPC heart as 
shown in Section 3.1.2 (Table 6), indicating that HPC and IPC operate by somewhat 
different cytoprotective mechanisms, despite the common stimuli of oxygen and 
nutrient deprivation.  
Table 11. Differentially Expressed mRNAs Between Control and HPC HL-1 Cells 
Symbol Name 
Control 
Cells 
HPC 
Cells 
Fold 
Change 
Adjusted 
P Value 
Kbtbd11 
kelch repeat and BTB (POZ) 
domain containing 11 937.2 163.2 0.17 0.0002 
Rora 
RAR-related orphan receptor 
alpha 732.6 190.7 0.26 0.0250 
Stc1 stanniocalcin 1 620.6 199.7 0.32 0.0000 
Egln3 
EGL nine homolog 3 (C. 
elegans) 1711.8 665.5 0.39 0.0001 
Ndnf 
neuron-derived neurotrophic 
factor 1292.8 511.6 0.40 0.0243 
Tshr 
thyroid stimulating hormone 
receptor 330.0 133.2 0.40 0.0250 
Rnf152 ring finger protein 152 489.0 201.0 0.41 0.0110 
Slc2a1 
solute carrier family 2 
(facilitated glucose 
transporter), member 1 3545.8 1587.9 0.45 0.0003 
Cp ceruloplasmin 1150.3 515.8 0.45 0.0023 
Ppap2b 
phosphatidic acid 
phosphatase type 2B 1640.6 745.9 0.45 0.0034 
Slc40a1 
solute carrier family 40 
(iron-regulated transporter), 
member 1 1954.5 916.2 0.47 0.0156 
Ccng2 cyclin G2 1894.9 897.6 0.47 0.0073 
Mylk myosin, light polypeptide 8634.6 4112.6 0.48 0.0005 
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kinase 
Specc1 
sperm antigen with calponin 
homology and coiled-coil 
domains 1 1280.6 610.7 0.48 0.0156 
Mgarp 
mitochondria localized 
glutamic acid rich protein 1355.8 668.2 0.49 0.0181 
Hivep2 
human immunodeficiency 
virus type I enhancer 
binding protein 2 1444.4 729.7 0.51 0.0395 
Xbp1 X-box binding protein 1 1438.0 734.2 0.51 0.0230 
Slc47a1 
solute carrier family 47, 
member 1 17395.4 9361.1 0.54 0.0230 
Ttn titin 64147.2 34782.6 0.54 0.0156 
Pdia6 
protein disulfide isomerase 
associated 6 9037.5 16376.0 1.81 0.0181 
Srm spermidine synthase 566.6 1043.0 1.84 0.0395 
Atf5 
activating transcription 
factor 5 587.0 1160.7 1.98 0.0243 
Npm3 nucleoplasmin 3 681.6 1382.7 2.03 0.0243 
Cd209c CD209c antigen 572.0 1178.0 2.06 0.0442 
Cox6a2 
cytochrome c oxidase 
subunit VIa polypeptide 2 458.9 953.9 2.08 0.0110 
Fkbp11 FK506 binding protein 11 715.0 1545.5 2.16 0.0019 
Olfr1033 olfactory receptor 1033 428.4 1009.1 2.36 0.0019 
Wdr92 WD repeat domain 92 5357.2 13622.4 2.54 0.0000 
Bche butyrylcholinesterase 430.8 1098.2 2.55 0.0201 
Cmah 
cytidine monophospho-N-
acetylneuraminic acid 
hydroxylase 950.9 2541.6 2.67 0.0025 
Krt18 keratin 18 73.2 253.3 3.46 0.0019 
Data represent the average of 3 replicates. Intensity of blue color correlates with 
magnitude of decrease in HPC vs. Control cells. Intensity of red color correlates with 
magnitude of increase in HPC vs. Control cells.  
 
A comparison of the mRNA in control vs. HPC exosomes revealed few 
differences. Albumin was present to a small degree within the HPC exosomes but not 
the Control exosomes, and Collagen Type I-α2 was present in Control exosomes but 
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not HPC exosomes. The low read count of these indicates low abundance of these 
mRNAs, which could mean that the changes observed may not have an impact on the 
protectiveness of the HPC HL-1 exosomes (Table 12). 
Table 12. Differentially Expressed mRNA in Control and HPC Exosomes 
Symbol Name 
Control 
Exo 
HPC 
Exo 
Fold 
Change 
Adjusted 
P Value 
Alb albumin 0 46.51 Inf 0.001 
Col1a2 collagen, type I, alpha 2 44.36 0.00 0.00 0.021 
Data represent the average of 3 replicates. 
These data indicate that while the mRNA and miRNA profiles change in HL-1 
cells when they undergo HPC, the exosomal contents are not greatly affected by HPC. 
We had planned to determine how exosomes from HL-1 affected MSC. A limitation to 
this study was difficulty in establishing an OGD model that induced cell death in the 
MSCs, which were resistant to even long durations of hypoxia (Figure 31).  
Figure 31. MSCs are Resistant to Cell Death from OGD 
 
MSCs were plated in 6-well plates and subjected to OGD in serum free glucose free 
media. Cells were reoxygenated in growth media containing 10% serum, and labeled 
with Hoechst (all cells, blue line) and PI (dead cells, orange line) for viability analysis 
1h later.  
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MIRNA IN STEM CELL MEDIATED PARACRINE EFFECTS ON THE MYOCARDIUM 
MSC Exosomes Are Protective Against Cell Death Upon OGD Challenge 
When H9c2 cells were pre-treated with exosomes (MSC-derived) overnight in 
doses ranging from 0 to 300 µg/mL exosome protein, a dose dependent increase in 
viability was observed after OGD (Figure 32A). The percentage of cells surviving 
increased from 69 to 88%. We also tested the effect of treating H9c2s with 
microparticles (MP), which are isolated during the exosome isolation procedure. These 
did not confer protection (Figure 32A). Exosomes were also protective in HL-1 cells 
(Figure 32B), as evidenced by increased viable cell counts after OGD, and decrease in 
LDH release. Although the two time points we tested did not induce cell death in 
NMVMs compared to incubation at normoxia, treatment with exosomes did increase the 
number of viable cells at 180 min OGD (Figure 32C). 
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Figure 32. MSC Exosomes Decrease Cell Death from OGD Challenge in Various 
Cardiac Cell Types 
 
A. H9c2 cells were pre-treated with a dose curve of exosomes (Exo) or one dose of 
microparticles (MP) overnight and then stained with Hoechst and PI to count all and 
dead cells, respectively. They were then subjected to OGD challenge, after which they 
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were reperfused in growth media and counted once more. Data are expressed as viable 
cell count calculated by subtracting dead/PI+ cells from all cells/Hoechst+ (n=3). 
*P=0.029, **P=0.004 vs. No Exo. B. HL-1 cells were subjected to OGD challenge and 
treated with 300 µg/mL exosomes overnight. Viable cell count was determined as in A 
(n=11-12). *P=0.017, **P<0.001 vs. Normoxia. C. NMVMs were pre-treated with 300 
µg/mL exosomes overnight and subjected to OGD challenge for 90 and 180 min. OGD 
did not increase the cell death in our hands, but Exo pre-treatment did increase the 
viable cell count (n=4-8). *P=0.003 vs. Ctrl OGD 180 min. 
 
MSC Exosomes Are Internalized by H9c2, HL-1, and NMVM Cells 
H9c2, HL-1, and NMVM cells were incubated with PKH26 labeled exosomes 
and analyzed by flow cytometry and Amnis ImageStream. All three types of cells 
demonstrated uptake of exosomes, as evidenced by an increase in fluorescence intensity 
in the phycoerythrin (PE) channel (Figure 33A-C). Furthermore, fluorescently labeled 
exosomes were visible within the cells imaged by the Amnis (Figure 33D). To 
determine the concentration of exosomes in media at an exosomal protein concentration 
of 300 µg/mL before and after cells were treated, an aliquot of media was saved at the 
beginning and at the end of the 18h treatment and exosomes were counted by Amnis 
ImageStream. The concentration of exosomes prior to cell uptake was 3.64x106/mL 
while after the 18h treatment, the concentration decreased to 0.07x106/mL (about 2% of 
the exosomes remained in the media).  
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Figure 33. MSC Exosomes Are Taken Up by H9c2, HL-1, and NMVM Cells. 
 
Cells were treated with PKH26-labeled exosomes for 18h (A and C) or a time course 
(B). They were then analyzed by flow cytometry. (D) H9c2 cells were imaged by 
Amnis ImageStream, showing labeled exosomes within the cell. 
 
 
 
A. 18h Exo Treatment, H9c2 Cells B. Exo Time Course in HL-1 Cells
C. 18h Exo Treatment, NMVM D. Amnis Images of H9c2 Cells
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miRNA Seq Results 
To determine which miRNAs are highly expressed within MSC exosomes, total 
RNA was extracted from the MSCs and their exosomes (n=3/group from different 
passages of MSCs). The profile of miRNAs revealed that the expression pattern was 
different between the cells and exosomes, as suggested by other published comparisons 
(Table 13)195, 197.  
Table 13: Significantly Differentially Expressed miRNAs in MSCs and Their Exosomes 
Name 
MSC 
Cells 
MSC 
Exosomes 
Fold 
Change 
Adjusted P 
Value 
mmu-miR-451 0.844 3959.310 4688.5 0.000000004 
mmu-miR-150 0.312 1114.537 3570.8 0.000000005 
mmu-miR-223 0 297.663 Inf 0.000000008 
mmu-miR-494 0.100 484.685 4830.9 0.000000013 
mmu-miR-493*; 
mmu-miR-493-5p 0 324.916 Inf 0.000009727 
mmu-miR-495-3p 0.100 136.769 1363.2 0.000017907 
mmu-miR-142-5p 0 255.041 Inf 0.000039516 
mmu-miR-144*; 
mmu-miR-144-5p 0 206.204 Inf 0.000049889 
mmu-miR-409-3p 0.401 365.421 910.6 0.000058969 
mmu-miR-127-3p 1.394 1355.294 972.6 0.000097942 
mmu-miR-144-3p 0 487.572 Inf 0.000305884 
mmu-miR-122a 1.854 5308.913 2864.1 0.000377957 
mmu-miR-411*; 
mmu-miR-411-3p 0.201 62.199 310.0 0.000381352 
mmu-miR-369-3p 0.106 48.480 457.8 0.000381352 
mmu-miR-369-5p; 0 62.441 Inf 0.001097037 
mmu-miR-299a-3p 0.201 53.348 265.9 0.001292217 
mmu-miR-299b-5p 0.201 53.348 265.9 0.001292217 
mmu-miR-6236 1.335 125.464 94.0 0.001292217 
mmu-miR-433-3p 0 511.125 Inf 0.001401959 
mmu-miR-504-5p 0 86.881 Inf 0.001446907 
mmu-miR-451b 0 23.860 Inf 0.001818421 
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mmu-miR-409-5p 0.100 30.652 305.5 0.003231630 
mmu-miR-486-5p 6.352 10715.185 1686.9 0.004490330 
mmu-miR-3107*; 
mmu-miR-3107-3p 6.352 10715.185 1686.9 0.004490330 
mmu-miR-381-3p 2.043 349.147 170.9 0.005934268 
mu-miR-3107-5p 14.427 28715.119 1990.4 0.007409008 
mmu-miR-486*; 
mmu-miR-486-3p 14.427 28715.119 1990.4 0.007409008 
mmu-miR-412-5p 0 19.045 Inf 0.007821526 
mmu-miR-142-3p 0 85.318 Inf 0.009487658 
mmu-miR-411-5p 2.556 400.806 156.8 0.009772641 
mu-miR-370-3p 0.100 58.982 587.9 0.010449075 
mmu-miR-126-5p 2.447 172.365 70.4 0.012110825 
mmu-miR-434-3p 0.206 28.368 137.6 0.013274568 
mmu-miR-382*; 
mmu-miR-382-3p 0.401 146.574 365.2 0.015102170 
mmu-miR-382; 
mmu-miR-382-5p 0.106 72.811 687.6 0.018437024 
mmu-miR-6240 2.021 83.180 41.2 0.020513287 
mmu-miR-200b-3p 0.131 22.976 175.3 0.023077551 
mmu-miR-134-5p 0.100 19.640 195.8 0.023792018 
mmu-miR-2137 0.237 20.269 85.5 0.026085925 
mmu-miR-126-3p 50.245 2799.285 55.7 0.030018186 
mmu-miR-299*; 
mmu-miR-299-5p 0 11.607 Inf 0.032574692 
mmu-miR-299b-3p 0 11.607 Inf 0.032574692 
Data represent the average of 3 replicates. Intensity of red color correlates with 
magnitude of increase in exosomes vs. cells. Inf, infinite. 
 
To determine whether miRNA within MSC exosomes could mediate their 
cardioprotective effects, we also determined which miRNAs were highly expressed 
within the MSC exosomes, with read counts higher than 1024, and performed a 
literature search to determine whether any of these are known to be cardioprotective 
(Table 14). The rationale for using 1024 reads as a cutoff was based on histogram 
analysis of the log2 of the frequency of the number of reads for each miRNA in each 
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sample, in order to focus on those miRNAs within the top ~50% most highly expressed 
(see Figure 34). 
Table 14. Highly Expressed miRNAs in MSC Exosomes 
Gene ID Name Read Count Refs (if known cardioprotective) 
MIMAT0000530 mmu-miR-21a-5p 45255.27 81-85, 226-228 
MIMAT0014943 mmu-miR-486b-5p 28715.12  
MIMAT0017206 mmu-miR-486a-3p 28715.12  
MIMAT0000247 mmu-miR-143-3p 11931.92  
MIMAT0000539 mmu-miR-92a-3p 11286.39  
MIMAT0003130 mmu-miR-486a-5p 10715.18  
MIMAT0014944 mmu-miR-486b-3p 10715.18  
MIMAT0000531 mmu-miR-22-3p 9674.50 203 
MIMAT0000221 mmu-miR-191-5p 8571.52  
MIMAT0000521 mmu-let-7a-5p 8505.54  
MIMAT0000522 mmu-let-7b-5p 8193.79 229 
MIMAT0000152 mmu-miR-140* mmu-miR-140-3p 6268.33 
 
MIMAT0000136 mmu-miR-125b-5p 5680.82  
MIMAT0000533 mmu-miR-26a-5p 5528.38  
MIMAT0000655 mmu-miR-100-5p 5450.84  
MIMAT0000132 mmu-miR-99b-5p 5443.74  
MIMAT0000121 mmu-let-7g-5p 5392.06  
MIMAT0000515 mmu-miR-30d-5p 5351.18  
MIMAT0000246 mmu-miR-122-5p 5308.91  
MIMAT0000523 mmu-let-7c-5p 5290.96  
MIMAT0000131 mmu-miR-99a-5p 5158.83  
MIMAT0000383 mmu-let-7d-5p 5156.14  
MIMAT0000122 mmu-let-7i-5p 4875.94  
MIMAT0000532 mmu-miR-23a-3p 4536.37  
MIMAT0003454 mmu-miR-423-3p 4332.23  
MIMAT0004825 mmu-miR-423-5p 4156.89  
MIMAT0000666 mmu-miR-320-3p 4127.96  
MIMAT0001632 mmu-miR-451a 3959.31 80 
MIMAT0000525 mmu-let-7f-5p 3927.54  
MIMAT0000652 mmu-miR-25-3p 3785.08  
MIMAT0000516 mmu-miR-148a-3p 3433.13  
MIMAT0000135 mmu-miR-125a-5p 3246.42  
MIMAT0000138 mmu-miR-126-3p 2799.29 230 
MIMAT0000230 mmu-miR-199a*  mmu-miR-199a-3p 2449.21 
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MIMAT0004667 mmu-miR-199b-3p 2445.06  
MIMAT0000524 mmu-let-7e-5p 2310.92  
MIMAT0000125 mmu-miR-23b-3p 2223.53  
MIMAT0000661 mmu-miR-214-3p 2200.85 231, 232 
MIMAT0000669 mmu-miR-221-3p 2079.00  
MIMAT0000126 mmu-miR-27b-3p 1690.11  
MIMAT0000648 mmu-miR-10a-5p 1600.75  
MIMAT0000140 mmu-miR-128-3p 1504.61  
MIMAT0000208 mmu-miR-10b-5p 1463.62  
MIMAT0000219 mmu-miR-24-3p 1445.74 233-237 
MIMAT0014856 mmu-miR-3074-5p 1445.74  
MIMAT0000139 mmu-miR-127-3p 1355.29  
MIMAT0000384 mmu-let-7d*  mmu-let-7d-3p 1272.16 
 
MIMAT0000229 mmu-miR-199a-5p 1259.88  
MIMAT0000670 mmu-miR-222-3p 1259.57  
MIMAT0000514 mmu-miR-30c-5p 1223.28  
MIMAT0000535 mmu-miR-29a-3p 1126.91  
MIMAT0000160 mmu-miR-150-5p 1114.54  
MIMAT0000534 mmu-miR-26b-5p 1076.65  
Data represent the average of 3 replicates. Yellow highlight indicates published reports 
which support that the miRNA is cardioprotective.  
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Figure 34: miRNA Expression Histograms 
 
The frequency of the read count for each exosomal sample was plotted vs. the log2 of 
the reads. Counts below 32 (i.e., log2(5), to the left on the x axis) were considered to be 
“noise” and were not plotted. The blue highlight covers the area of reads expressed at a 
level of 1024 or higher which corresponds to ~log2(10). 
 
The most abundant miRNA in MSC exosomes was mmu-miR-21a-5p. This 
miRNA is well known to be cardioprotective, as it increases in IPC, post-conditioning, 
and anesthetic-mediated cardioprotection81-85, 226-228, 238. We thus chose to follow up on 
this miRNA, and validated its presence in MSC exosomes through qPCR, compared 
against a standard curve of commercially available miR-21 mimic (Figure 35). Based 
on the molecular weight of miR-21 and the molarity as determined by its CT, this 
correlates with 3.04x1012 copies per µg RNA in the exosomes.  
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Figure 35. miR-21 is Present in MSC Exosomes 
 
Total RNA was extracted from 4 preparations of MSC exosomes and 500 ng of RNA 
were reverse transcribed. Realtime PCR was performed and the CT was plotted (black 
circles) along with those of a standard curve of miR-21 mimic (blue circles). Primer 
efficiency was determined by plotting the CT vs. the log of the initial starting quantity 
(stock of known molarity from Qiagen). The slope of this line was used to calculate E 
as shown. The efficiency was 100%. The trendline equation was then used to calculate 
the log of the initial quantity of miR-21 in pmol. Then the quantity in pmol was 
converted to number of miR-21 molecules using Avogadro’s number.  
 
Tarbase 7.0 is a manually curated database of experimentally validated miRNA 
targets239. In order to identify potential miR-21 target genes, we searched this database 
and filtered for results that were validated by normal throughput methods including 
qPCR and Western blot. This returned 11 candidates, of which several are known to 
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play an injurious role in the context of I/R injury (Figure 36). The genes that we chose 
for follow up were Fas ligand (FasL), phosphatase and tensin homologue (PTEN), 
pellino 1 (Peli1), and programmed cell death 4 (PDCD4), based on literature which 
supports that they contribute to apoptosis after I/R injury and that reducing their levels 
is protective6, 7, 81, 83, 205, 226, 240. 
Figure 36. A Screenshot Showing the Search Results from Tarbase7 for Mir-21 Targets 
 
The search results were filtered by Method Type to include normal throughput results. 
RA, reporter assay; WB, Western blot; qP, real time PCR; IP, immunoprecipitation; 
MA, microarray. Green indicates a positive result, red indicates a negative result. 
 
mRNA Seq Results 
The mRNA profile of MSCs and their exosomes was also determined through 
RNA-Seq. As with the miRNA profile, many mRNAs were differentially expressed (see 
Appendix B). We also determined the most highly expressed mRNAs in the MSC 
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exosomes with reads higher than 2000 counts (Appendix C). Some of these may have 
cardioprotective roles, which will be the subject of future studies. 
miR-21 Knockout Exosomes Are Less Cardioprotective Than Wildtype Exosomes 
In Vitro 
Conventional full-body miR-21a knockout mice241 were obtained from Jackson 
Labs and their MSCs (KO MSCs) were isolated using the same procedure as for the 
wild-type (WT) mice. Their MSCs grew normally and released exosomes just like the 
WT MSCs. The KO MSCs still expressed a small level of miR-21, likely from other 
miR-21 family member genes which include miR-21b, and miR-21c. miRNAs are 
grouped into families based on the sequence of the mature miRNA or 
sequence/structure of the (precursor) pre-miRNA. Families of miRNAs share a 
conserved seed sequence, and thus might bind overlapping targets. The sequences of 
miR-21a, b, and c are shown in Figure 36. The miR-21 present in the KO MSCs was 
0.2% of that of WT MSCs (Figure 37).  
Figure 37. miR-21 Knockout MSCs Express miR-21 at Very Low Levels 
  
Total RNA was isolated from WT and KO MSCs, reverse transcribed, and analyzed by 
qPCR for miR-21 and U6. Data are shown as normalized fold change from WT control 
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MSCs (n=3). The sequences of miR-21a, b, and c are shown. The seed sequence is in 
bold, and differences in miR-21b and miR-21c from miR-21a are in red.  
 
We next compared the ability of exosomes isolated from cultured KO MSCs and 
WT MSCs to reduce cell death from OGD. We isolated exosomes from equivalent 
volumes of conditioned media from both cell types, assayed their protein, and adjusted 
the treatments so that the amounts of exosomes used for pre-treatment were equal. We 
found that while the WT exosomes were significantly more protective than the KO 
exosomes, improving survival from 48±4.5% to 60±5.1%, the KO exosomes were still 
more protective than no exosome treatment, increasing the survival to 56±4.5% (Figure 
38). Furthermore, the WT exosomes were noted at times (including in the experiment 
below) to exert a significant proliferative effect on the H9c2 cells after the overnight 
pre-treatment (black bars) which the KO exosomes did not demonstrate, indicating that 
miR-21 triggered cell division.  
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Figure 38. KO Exosomes Are Less Protective Than WT Exosomes 
 
H9c2 cells were pre-treated with equal concentrations of WT and KO exosomes 
overnight, and then labeled with Hoechst and PI to determine viable cell counts before 
(black bars) and after OGD (white bars) (n=20). #P≤0.001 vs. Pre-OGD No Exo **P 
≤0.001 vs. Post-OGD No Exo, §P=0.001 vs. Post-OGD WT Exo. 
 
To determine whether other time points than 24h pre-treatment would be 
protective, we performed (1) a short pre-treatment of one hour or (2) “per-conditioning” 
with exosomes present during the entire 18h OGD (Figure 39). We found that a 1-hour 
pre-treatment with either type of exosomes was not protective, and did not result in 
proliferation, while per-conditioning with either type of exosomes increased survival, 
from 34±7.0% to 63±8.6% (WT) or 57±4.6% (KO). The percent viability did not differ 
significantly between the WT and KO exosomes, indicating that the protection observed 
during per-conditioning does not require miR-21. 
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Figure 39. Preconditioning for 1 Hour Does Not Protect, While Per-Conditioning with 
Either WT or KO Exosomes Is Protective 
 
H9c2 cells were pretreated with exosomes in their growth media for 1 hour before 
OGD, or per-conditioned with exosomes in the ischemia mimetic solution during OGD. 
Viable cells were quantified before and after OGD by staining with Hoechst and PI and 
subtracting dead cell count from total cells (n=20). Error bars represent SD. **P<0.001 
vs. Post-OGD No Exo. Pre-OGD viable counts did not show any statistically significant 
difference. 
 
Reporter Assays for PDCD4 and FasL 
In order to test whether miR-21 regulates its predicted target genes PDCD4 and 
FasL through interactions with their 3’-UTR, luciferase reporter assays were performed. 
We co-transfected H9c2 cells with the reporter plasmid and a dose curve of miR-21 
mimic, and noted significant decreases in the luciferase activity (Figure 40). We also 
transfected the H9c2 cells with either reporter plasmid, and then treated them with WT 
or KO exosomes to determine whether exosomal miR-21 could repress the luciferase 
activity. Both types of exosome could decrease luciferase activity, but the miR-21 KO 
exosomes showed a trend towards less effective repression. Taken together these data 
show that miR-21 represses PDCD4 and FasL through specific interaction with their 3’-
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UTR. However, based upon the fact that the KO exosomes will exhibit some repression, 
we conclude that miR-21 is not the only exosomal factor that can downregulate these 
genes. 
Figure 40. miR-21 Reduces Luciferase Activity of PDCD4 and FasL 3’-UTR Reporters 
 
H9c2 cells were transfected with (A) PDCD4 or (B) FasL reporter plasmids and a dose 
curve of miR-21 mimic. (C-D) Cells were transfected with PDCD4 or FasL reporter 
plasmids and two doses of exosomes. After 18h, cells were stained with Hoechst and PI 
to quantify viable cells, and then luciferase activity was measured. Data are presented as 
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the raw luminescence values per viable cell, normalized to 0nM miR-21, with error bars 
representing SD (n=8-10). *P≤0.05, **P≤0.001 vs. 0 nM miR-21 or 0 µg exosomes.  
 
PDCD4 3’-UTR Variants 
A search of the NCBI database indicated that in mice and rats, PDCD4 has 
predicted alternative splicing. As shown in Figure 41E, splice variants 1 and 2 differ in 
the 5’ region of the coding sequence but have the same 3’-UTR, while variant 3 has the 
same coding sequence as variant 2, but a large portion of the middle of the 3’-UTR is 
alternatively spliced, resulting in removal of the miR-21 binding site. To determine 
which variant predominates in rat H9c2 cells, mouse HL-1 cells, neonatal mouse 
ventricular myocytes (NMVM), and mouse heart, we designed primers to amplify both 
the full-length and spliced RNA by traditional and real time PCR. We found that the 
predominant form of the 3’-UTR was the spliced form in heart and cell samples 
according to real time qPCR and traditional PCR with product size analysis on an 
agarose gel. The sizes of the bands correspond to the predicted sizes of the full length 
(F) and spliced (S) products in mouse and rat cells. In HL-1 cells, only the spliced 
product is visible. In mouse heart tissue and neonatal cardiomyocytes, there is a strong 
band at the predicted size of the spliced product, and the full length product is faintly 
visible. Its intensity does not seem to change with the treatment (control vs. MSC 
exosomes). In H9c2 cells, the full length product is again visible, though far less intense 
than the spliced product. Interestingly, the intensity of the full length product appears to 
decrease remarkably with the transfection of miR-21 mimic, supporting that miR-21 
mediates degradation of variant 3 mRNA.  
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Figure 41. The Predominant Splice Variant of PDCD4 in Cells and Mouse Heart Lacks 
the Portion of the 3’-UTR Containing a Predicted miR-21 Binding Site 
 
(A-D) RNA was isolated and reverse transcribed. Then real time PCR was performed to 
amplify the total, full length, and spliced 3’-UTR variants. Expression was normalized 
to 18S and bars represent the 2^-dCT values (n=1-2/condition). (E) A schematic of the 
structure of PDCD4 variants 1, 2, and 3. The locations of the primers within the 3’-UTR 
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of PDCD4 are shown. The total PDCD4 primers are not shown but are located in the 
coding region. The PCR products from HL-1 cells, NMVMs, heart tissue, and H9c2 
cells were run on an agarose gel. The cell lines were transfected with Neg Ctrl 
siRNA(C), or miR-21 mimic (miR21), and NMVMs and heart tissue were treated with 
saline (C) or MSC exosomes (Exo). F=full length product, expected size 681 bases in 
mouse cells and 777 in rat cells. S=spliced product, 157 bases.  
 
Despite the apparent preponderance of the mRNA lacking the miR-21 binding 
site in the 3’-UTR, miR-21 robustly downregulates PDCD4 protein (Figure 43), 
indicating that there must be other binding sites, perhaps within the coding sequence. A 
search of the DIANA microT-CDS database242 revealed two binding sites within the 
coding sequence of PDCD4 which may mediate miR-21’s effects (Figure 42). All of the 
human splice variants express the full 3’-UTR, according to NCBI.  
Figure 42. A Screenshot from DIANA MicroT-CDS Shows Two Binding Sites Within 
the Mouse PDCD4 Coding Region 
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Protein and RNA Levels of Predicted miR-21 Target Genes After miR-21 
Transfection and Treatment of Cells with Exosomes 
Transfection of H9c2 cells with miR-21 resulted in significant downregulation 
of FasL, PDCD4, and PTEN vs. treatment with negative control siRNA, with trends 
towards decreased protein levels of Peli1 at 24 and 48h which were not always 
significant (Figure 43).  
In general, miRNA may or may not mediate degradation of its mRNA targets 
(depending on the extent of base pairing outside the seed region). To test whether miR-
21 decreases the mRNA level of its target genes, we performed real time PCR 24h after 
miR-21 transfection, and found that total PDCD4 decreased significantly, while spliced 
PDCD4 showed a trend towards a decrease that did not reach statistical significance. 
Interestingly, PTEN increased significantly and FasL also showed a trend towards an 
increase, while Peli1 did not change (Figure 44).  
When cells were treated with WT exosomes, a similar effect was observed to 
that of transfection of miR-21, with significant downregulation of PDCD4 and FasL. 
However, when cells were treated with KO exosomes, these changes were not observed, 
which further supports a role for miR-21 within exosomes (Figure 45). 
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Figure 43. Transfection with miR-21 Mimic Reduced Steady State Protein Levels of 
Predicted miR-21 Target Genes in vitro 
  
H9c2 cells were transfected with 200 nM Neg Ctrl siRNA (Neg Ctrl) or miR-21 using 
Lipofectamine 2000. Total protein was extracted using RIPA buffer 24 to 48h later, and 
5-10 µg of protein were analyzed by Western blot (n=3-6). Band intensities were 
normalized to β-actin, error bars represent SD. *P<0.05 vs. Neg Ctrl. 
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Figure 44. RNA Levels of miR-21 Target Genes 24h after miR-21 Transfection 
 
H9c2 cells were transfected with 200 nM Neg Ctrl siRNA or miR-21. RNA was 
extracted from the cells 24h later and reverse transcribed for analysis by real time PCR. 
CTs were normalized to 18S and expressed as fold change vs. Neg Ctrl (n=3). Error 
bars represent SD. *P<0.05 vs. Neg Ctrl.  
 
Figure 45. Treatment of Cells with WT Exosomes Reduces Expression of PDCD4 and 
FasL 
 
A. H9c2 cells were treated with WT exosomes for 9h, followed by protein extraction 
and Western blot. B. Quantification of band intensities normalized to β-actin and 
expressed as fold change vs. Ctrl (n=6). *P<0.001. C. H9c2 cells were treated as before, 
but with KO Exo (n=6). Error bars represent SD.  
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Pericardial Sac Injection of WT and KO Exosomes 
Because the in vitro data supported that exosome uptake has protective effects in 
cells, and that miR-21 mediates these effects at least in part through downregulation of 
PDCD4 and FasL, we next tested whether WT and KO exosomes were protective when 
injected into the pericardial sac of mice 24h prior to I/R injury. We determined infarct 
size as a percentage of the area at risk 24h after I/R injury, and found a significant 68% 
decrease in infarct size after WT exosome injection (Figure 46). The KO exosomes also 
caused a trend towards a decrease, which was not significantly different from the saline 
control group (P=0.22).  
Figure 46. Injection of WT Exosomes Reduces Infarct Size in Mice 
 
A. Experimental timeline: on Day 0, mice received an injection of exosomes or saline to 
the pericardial sac and were allowed to recover overnight. They then underwent I/R 
injury, and the next day hearts were stained with TTC, frozen, and sectioned for infarct 
analysis. B. Representative hearts from each group. C. Quantification presented as the 
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average infarcted percent of the risk region, error bars represent SE (n=8). *P<0.001 vs. 
saline. 
 
Expression of miR-21 Target Genes 24h After Exosome Injection and 6h after I/R 
Injury 
To determine whether the protective effect we observed in vivo was due to 
downregulation of miR-21’s pro-apoptotic target genes, we next tested the expression of 
PDCD4, PTEN, Peli1, and FasL 24h after exosome injection. We did not observe a 
significant decrease in protein levels of these genes, though there was a trend towards a 
decrease in FasL (18% decrease vs. saline), and interestingly, a trend towards increased 
expression of PDCD4 (Figure 47A-B). This led us to question whether the miR-21 
being taken up was having a priming effect such that it bound its target mRNAs, but 
changes in target protein levels would only be apparent after a relevant stimulus such as 
I/R injury. Real time PCR analysis showed no significant changes at 24h after exosome 
injection other than a 51% decrease in PDCD4 full length mRNA with WT exosome 
injection (Figure 47C). This is in agreement with PCR data from the miR-21 transfected 
H9c2 cells, which only showed significant decreases in PDCD4 levels but not other 
target genes. We therefor tested the levels of these proteins after exosome injection 
followed 24h later by I/R injury, and we then observed significant decreases in all four 
of these proteins 6h after I/R (Figure 48). 
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Figure 47. Expression of PDCD4, Peli1, and FasL 24h after Injection of WT or KO 
Exosomes 
 
WT and KO exosomes were injected into the pericardial sac of mice, and hearts were 
removed 24h later. (A) Total protein was extracted and analyzed by Western blot (n=4). 
(B) Quantification of band intensities normalized to actin and displayed as fold change 
vs. Saline. (C) RNA was extracted and reverse transcribed for real time PCR analysis. 
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Data were normalized to 18S and are shown as the average fold change vs. Saline (n=4). 
Error bars represent SEM. *P=0.038 vs. Saline. 
 
Figure 48. WT Exosomes Decrease Expression of PDCD4, PTEN, FasL, and Peli1 6 
Hours after I/R Injury 
 
Saline, WT exo, or KO exo were injected into the pericardial sac of mice (n=5-6) 24h 
prior to I/R injury. Mice were sacrificed 6h later and protein was isolated from the 
infarct zone of the heart for Western blot analysis. (B) Band intensities were quantified 
and data were normalized to Actin. Bars represent the normalized average fold change 
vs. Saline controls with error bars representing SEM. *P<0.05; **P<0.005 vs. Saline.  
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CHAPTER 4 
DISCUSSION 
SUMMARY OF HYPOTHESES AND RESULTS 
This section briefly summarizes the central hypotheses of each research aim, and the 
results of the experiments undertaken to test them, which have contributed to our 
understanding of how miRNA is involved in cardioprotection from IPC and stem cell 
paracrine effects.  
Hypothesis 1 
We hypothesized that a network of miRNAs and heat shock proteins are 
regulated in response to preconditioning. Because each miRNA has many potential 
mRNA targets, and most mRNAs have many potential miRNA binding sites in their 3’-
UTRs, we were interested in finding miRNAs that co-regulated targets with a common 
function, which could be a powerful way to induce gene-expression mediated 
cardioprotection, such as that which occurs during IPC. To investigate this hypothesis, 
we selected a set of heat shock proteins which two preliminary datasets (array and 
sequencing data) suggested were increased by IPC, including Hsp40/Dnaj proteins, 
inducible Hsp70 family members, and Hsp90. We confirmed that indeed the mRNA 
levels of Hsp70 (Hspa1a and Hspa1b), Hsp90aa1, Dnaja1 and Dnajb4 increased 3 hours 
after IPC, leading to significant protein increases 6 hours after. We then selected a 
handful of miRNAs which were predicted to regulate them, including miR-148a/b, miR-
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30b, and let-7a*, and tested whether this regulation actually occurs at the protein level. 
We confirmed that the miRNAs act synergistically to regulate the heat shock proteins of 
interest in two cardiomyocyte cell lines.  
Hypothesis 2 
We hypothesized that preconditioning of cardiomyocytes leads to increased 
exosomal loading of protective miRNA, which exerts pro-survival effects on 
transplanted MSC. Because cardioprotection from postconditioning162 or electro-
acupuncture165 have been shown to enhance the engraftment of transplanted stem cells 
through changes in the myocardial microenvironment162, we wanted to test the role of 
exosomes, which are an important mediator of paracrine communication that have never 
been studied in this context. Preconditioning the HL-1 cells by HPC induced the 
expression of several miRNAs with known pro-survival or regenerative effects, 
including miR-19 and 20243, 244. HPC also upregulated several protective mRNAs. 
However, RNA-Seq did not detect corresponding increases in these RNAs in the 
exosomes produced by the HL-1 cells, and thus did not support Hypothesis 2. This does 
not rule out the possibility that exosomes from the preconditioned intact heart do act in 
this manner to enhance stem cell engraftment in the harsh environment of the post-I/R 
heart. 
Hypothesis 3 
We hypothesized that MSC exosome-mediated cardioprotective effects are 
mediated through transfer of protective mRNA and/or miRNA. Having found that MSC 
exosomes could decrease cell death in H9c2 cells after OGD after an 18h pre-treatment, 
a time point that is consistent with regulation of protein levels in response to the 
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exosomes, we sequenced their RNA content to reveal their profile of miRNA and 
mRNA. We determined that miR-21 was the highest expressed miRNA in the exosomes. 
Because miR-21 is a well-known cardioprotective miRNA, we fine-tuned the hypothesis 
to investigate the role of miR-21 in exosome-mediated cardioprotection. Experiments 
yielded the following major results. First, miR-21 and wildtype MSC exosomes 
regulated the expression of known miR-21 target genes in vitro and in vivo, while miR-
21 knockout exosomes did not. Second, pre-treatment of H9c2 cells or pericardial sac 
injection with wildtype MSC exosomes in vivo was protective, while miR-21 knockout 
exosomes were not. Taken together, these data support the hypothesis that miR-21 is a 
key mediator of cardioprotection from MSC exosomes.  
THE ROLE OF MICRORNA IN ISCHEMIC PRECONDITIONING 
The goals of Aim 1 were to (1) build upon previous work performed in the lab and 
further characterize the gene expression response of the heart to IPC; (2) to identify 
miRNAs that could be manipulated experimentally to induce a key aspect of this gene 
expression response by acting as nodes in a network; (3) to establish whether these 
miRNAs interact with the 3’-UTR of the genes of interest; and (4) to determine whether 
overexpression or knockdown of these miRNAs results in changes in the expression of 
these genes consistent with preconditioning. 
Gene Expression after IPC and HPC 
The IPC microarray dataset was originally published in 2010 and detected 1376 
significant differences between wildtype sham and IPC mice. The RNA-Seq experiment 
was performed in 2013, and detected 292 significant differences. These two datasets 
overlapped by 61 genes. In most cases, the array data and the sequencing data were in 
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agreement with regard to the direction of the change (up or downregulated), with the 
exception of growth arrest and DNA-damage-inducible 45 beta (Gadd45b) and 
potassium voltage gated channel, Shab-related subfamily, member 1 (Kcnb1). Nearly all 
of the genes increased after IPC, with only 6 genes that decreased in both datasets. 
Comparing these two datasets allowed us to select genes of interest for follow-up more 
confidently. We chose to focus on the heat shock proteins because there were several 
that were upregulated strongly by IPC, all of which were NF-κB dependent, and we 
validated these by real time qPCR. Additionally, we evaluated expression of Hsp70.3, 
which was not included in the microarray dataset, but which we know is required for in 
IPC from previous work in the lab38, 87.  
Knowing that Hsp70 was upregulated at 24h after IPC87, we tested whether 
Hsp90 or the Hsp40 family members were also increased at that time, and found that 
they were not. We then tested an earlier time point, 6h, and found that they were 
elevated then. Hsp70.1 and Hsp70.3 exhibited the greatest fold increases at the mRNA 
level at 3 hours after IPC, perhaps this is why Hsp70 is the only protein that is still 
elevated the next day.  
It is known that late IPC requires new protein synthesis245, but it is unclear 
whether early IPC also requires new protein synthesis. Rizvi et al.245 showed that 2 
hours after IPC, protein synthesis nearly doubled as measured by the incorporation of 3H 
leucine. Rowland and colleagues also found that in the isolated perfused rat heart, IPC 
increased myocardial protein content, and blocking translation with cycloheximide 
blocked the protection from early IPC35, a finding that was verified in the isolated rabbit 
heart34. Conversely, another group246 found that early IPC was not blocked by 
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cycloheximide in an intact rabbit model. Our data are consistent with the observed 
increase in protein synthesis in the hours after IPC. Synthesis of Dnaja1, Dnajb4, and 
Hsp70 and Hsp90 likely function to assist with the enhanced production of other 
cardioprotective late phase mediator proteins such as iNOS and COX2, in addition to 
helping to refold proteins damaged by oxidative stress in the instance of subsequent I/R 
injury.  
Studies using Hsp70.1/.3 knockout mice have shown that Hsp70 is required for 
late IPC38 but it is unknown whether the increases in Hsp40 levels that occur during 
early IPC are required, for either early or late IPC. A Dnaja1 knockout mouse was made 
but is currently unavailable for purchase (embryonic stem cells are held in the Knockout 
Mouse Phenotyping Project repository).  
In order to test miRNAs that are protective in the context of myocardial I/R 
injury, we established in vitro models of hypoxic preconditioning and simulated I/R 
injury. The HPC protocol remarkably reduced cell death upon subsequent simI/R. 
However, expression of heat shock proteins did not seem to constitute an important 
aspect of this protection, as they were not strongly upregulated after HPC, and their 
forced expression by heat shock did not protect HL-1 cells from simI/R. For a discussion 
of the genes that were regulated by HPC, see Section 4.3.2. While heat shock has not 
been established in HL-1 cells as a protective stimulus against hypoxia or simulated 
ischemia, Brundel et al.247 showed that it protected them from tachypacing-induced 
myolysis in their in vitro atrial fibrillation model. By contrast, a few publications have 
reported that overexpression of heat shock proteins mediated by heat shock or gene 
transfer is protective in H9c2 cells upon subsequent hypoxic challenge248-250. Our 
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experiments with heat shock of HL-1 cells and H9c2 cells did not reproduce these 
findings.  
Noting that the HSPs of interest in the murine heart are induced by heat shock in 
HL-1 cells, and that they express them similarly to the pattern observed in the heart, we 
decided that the HL-1 cells would be an acceptable model for testing the effects of 
different miRNAs on heat shock protein expression under control and heat shock 
conditions.  
miRNA/HSP Network 
We then set out to identify miRNAs that could be manipulated experimentally in 
order to affect the expression of Hsp70, Hsp90 and Hsp40 family members. Based on 
the concept of miRNAs as nodes in a network, we identified miRNAs predicted to target 
3 or more of the genes by creating a Cytoscape network from a database including every 
miRNA predicted (with stringent criteria) to target each heat shock protein of interest. 
By cross-referencing all of the available datasets within the lab describing miRNA in 
cardioprotection, including a PCR array, miRNA-Seq on IPC heart tissue, and miRNA-
Seq on HPC HL-1 cells, we selected 4 miRNAs for follow-up. miR-148a, which was 
predicted to target Hsp70 and Dnaja1, was of interest because its expression is very high 
in both the heart tissue and HL-1 cells, and in HL-1 cells it decreases with HPC. miR-
148b showed moderate expression, but decreases with IPC/HPC in both datasets. The 
array data also showed that miR-148a and b decrease after IPC. The genes for miR-148a 
and b are located within the introns of other genes, and their expression is regulated by 
methylation state of their promoters251. Two recent studies have identified miR-148a as a 
regulator of NF-κB signaling through regulation of RelA252 (Bao 2014), and IκB kinase-
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β (IKK-β, 253). Thus a reduction in miR-148a would support enhanced NF-κB signaling, 
the activation of which is known to be protective in the context of IPC.  
miR-30b was predicted to target Dnaja1, Dnajb4 and Hsp90aa1. All three 
datasets showed a decrease in miR-30b expression after IPC, which has also been 
observed by others83. MiR-30b has an intergenic location on chromosome 15, and its 
expression is regulated by NF-κB254. Inhibition of miR-30b has been shown to be 
cardioprotective through de-repression of its target gene cystathione γ-lyase 255, which 
produces the protective mediator H2S. Furthermore, it has been confirmed to target the 
important anti-apoptotic protein Bcl-2254, so decreases in miR-30b would be expected to 
be cardioprotective. On the other hand, it has also been reported to target Cyclophilin D, 
a component of the mitochondrial permeability transition pore, and thereby to be 
protective in a cardiac-specific overexpression mouse model 256. Mimic transfection of 
miR-30b in H9c2 cells was also shown to decrease apoptosis in a model of hypoxia-
reoxygenation257.  
Lastly, let-7a-1-3p (let-7a*) was predicted to target Hsp70.1, Dnaja1, and 
Dnajb4. Let-7a* is the passenger strand of the let-7a transcript, which has an intergenic 
position on chromosome 13 in the mouse. In HEK and HeLa cells, overexpression of 
Argonaute3 (Ago3) but not other Argonaute family members 1, 2, or 4, was shown to 
increase the expression of let-7a* over its relatively low baseline expression. This effect 
appears to be selective for the passenger strand of let-7a*, because overexpression of 
Ago3 did not increase expression of 33 other miRNA passenger strands tested258. Ago2 
is the canonical active enzyme in RISC complexes, but Ago3 has an intact catalytic 
motif259, and let-7a* was shown to be a functional miRNA in that it repressed luciferase 
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activity and downregulated a target gene, Rab10258. Little is known about its role in the 
heart. 
Reporter Assays in Support of 3’-UTR Targeting 
The next step was to confirm whether the predicted targets were bona fide targets 
of each miRNA by using luciferase 3’-UTR reporter assays. miR-148a/b was confirmed 
to target Hsp70.1 and Hsp70.3, miR-30b targeted Hsp90aa1, and let-7a* targeted 
Dnajb4. A key aspect of our hypothesis is that miRNAs act synergistically to regulate 
expression of their target genes. We tested this idea through use of luciferase assays in 
which we compared the decrease in luciferase activity observed with two different 
miRNAs with different efficacies at reducing luc activity. Transfection of 200 nM of 
miR-449c reduced activity to about 40%, while the same dose of 148a reduced it to 
about 60%. If no synergy occurred, when cells were transfected with a 50/50 mix (100 
nM of both) we would expect the reduction in luc activity to be intermediate between the 
two, about 50%. However, what we observed was repression that was greater than either 
mimic alone, down to 29.8%. This suggests that two or more miRNAs can act additively 
to repress protein levels in the heart as has been reported, for example, miR-451 and 
miR-144, which synergistically target CUGBP2260.  
Luciferase 3’-UTR reporter assays have some limitations (see Chapter 2 p64). 
They are useful for determining whether a miRNA can interact with a predicted binding 
site in a given 3’-UTR, but ultimately effects on protein levels must be determined 
experimentally.  
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Knockdown and Mimic Transfection of miRNAs: Effect on HSP Levels 
We next tested the effect of transfection of mimics and inhibitors on protein 
levels. Based on the luciferase data, we expected to find that Hsp70 would be regulated 
by miR-148a and b, and this was the case. While mimic transfection of either miRNA 
was sufficient to reduce Hsp70 protein levels after heat shock, inhibition of both 
miRNAs led to a significant increase in Hsp70 expression. This, together with the 
luciferase data from the Hsp70.1 reporter assay, supports that miR-148a and b are 
functionally redundant (they will therefore be referred to as miR-148a/b hereafter). It 
should also be noted that while the 3’-UTR of Hsp70.3 is known to be alternatively 
polyadenylated in response to heat shock87, the miR-148a/b binding site is retained.  
The luciferase data did not indicate that Hsp70 was a bona fide target of let-7a*, 
and indeed the Western blots did not show that Hsp70 protein levels changed when let-
7a* was overexpressed or inhibited. However, to our surprise, Hsp70 protein levels did 
change in response to the combination of miR-30b and let-7a*, though miR-30b wasn’t 
predicted to target either Hsp70.1 or Hsp70.3. The mimics downregulated Hsp70 at 24 
and 72h, while the inhibitors showed a trend towards increasing its expression. With the 
addition of inhibitors of miR-148a/b, this increase became significant at both 24 and 
72h. Hsp70 protein levels were not assayed after transfection of miR-30b mimics or 
inhibitors alone, because it was not a predicted target of miR-30b. This would be an 
interesting future study, in light of recent publications showing miR-30b to regulate 
other cardioprotective genes and signaling cascades254-257, 261.  
Because expression of miR-148a and b at baseline was high in HL-1 cells 
(18,500 and 4000 reads respectively), we expected to find that knocking it down would 
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increase the protein level of Dnaja1, which also had significant expression at baseline 
(compare to very low baseline levels of Hsp70). Dnaja1 did decrease slightly in response 
to miR-148a/b mimics, but contrary to our expectation, inhibition of these miRNAs did 
not induce upregulation at the protein level. This is consistent with the lack of interaction 
observed in the reporter assay. If the miRNAs do not bind to the 3’-UTR, they don’t 
repress expression of the protein, and their removal would not lessen such repression. It 
is possible that downregulation observed in response to miR-148a/b mimic was indirect.  
Dnaja1 was not affected by mimic transfection or knockdown of miR-30b or let-
7a* individually or together. However, Figure 25 shows that the addition of miR-148a/b 
mimics to miR-30b and let-7a* does induce significant downregulation. There was a 
trend towards upregulation of Dnaja1 at 72h in both Figure 24 and 25, which did not 
reach statistical significance.  
Luciferase data supported that Dnajb4 would be regulated (perhaps weakly) by 
let-7a* but not miR-30b. Figures 22 and 23 show that individually, neither affects 
Dnajb4 levels, but as shown in Figure 24, when the let-7a* and miR-30b inhibitors are 
combined, Dnajb4 was significantly upregulated 3 days after transfection, by 1.48-fold. 
With the addition of miR-148a/b inhibitors, this increased to 1.86-fold (Figure 25). Thus 
there is evidence of synergistic regulation of the Hsp40 family members as well as 
Hsp70.  
Hsp90 was expected to be regulated by miR-30b, but this did not turn out to be 
the case. In fact, none of the combinations of miRNAs regulated its expression, which 
was very high at baseline in HL-1 and H9c2 cells (i.e., Western blot membranes required 
very short exposure times during ECL).  
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Viability Assays 
Despite the observation that the miRNAs decreased after HPC in HL-1 cells, this 
decrease was not a key aspect of cytoprotection in this model, as shown in Figure 28A 
and B. Inducing this decrease by transfecting the inhibitors, which successfully 
diminished the levels of the miRNAs, did not increase viability after OGD, nor did it 
enhance the effect of HPC. This makes sense in light of the fact that the mechanism by 
which the inhibitors would have protected is upregulation of heat shock proteins. Heat 
shock, which strongly upregulates Hsp70, also failed to induce protection in HL-1 cells 
and H9c2 cells in our hands, so it is not surprising that upregulation of heat shock 
proteins through inhibitor transfection likewise did not protect them.  
In line with this, transfection of mimics, which maintained the miRNAs at high 
levels, and which we confirmed to downregulate heat shock protein expression, did not 
prevent the protection from HPC (Figure 28B). This further emphasizes that other 
mechanisms than HSP expression likely underlie the protection from simI/R in this 
model. Other mRNAs showed significant regulation in the RNA-Seq data as discussed in 
Section 4.3; these may play a role or the effect may be regulated by non-gene regulatory 
changes in HL-1 physiology, such as bioenergetic state or protective signaling cascade 
activation. 
Different conditions were employed for hypoxic challenges in the HL-1 and 
H9c2 cells. The HL-1 cells required relatively brief periods of 1.5 to 3 hours of hypoxia 
along with glucose and serum withdrawal to demonstrate 50%-60% cell death, whereas 
H9c2 cells did not show significant numbers of dead cells with this treatment. Instead 
they required an overnight period of hypoxia in ischemia mimetic solution to achieve 
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this degree of cell death (hence the two different names for these procedures, simI/R and 
OGD). The HL-1 cells may need a shorter time because they grow much more densely 
than the H9c2 cells, and use up energy stores more rapidly because they contract (see 
Figure 5). Perhaps owing to differences in the hypoxia time or other differences in the 
two cell lines, transfection of the inhibitors did increase viability in the H9c2 cells after 
OGD. It is unclear whether these increases in viability were dependent on enhanced heat 
shock protein expression though, because while the combination of mimics did 
downregulate Hsp70, the inhibitors did not induce upregulation of Hsp70 even after heat 
shock. The inhibitors did however boost expression of Dnaja1 and Dnajb4 after heat 
shock, so perhaps a similar effect contributed to protection from OGD.  
Conclusions: Interactions of miRNAs and Transcription Factors During IPC 
Transcription factors and miRNAs work together during IPC to regulate gene 
expression and protein levels such that protective proteins are upregulated and pro-
apoptotic proteins are downregulated, which enhances cell survival of I/R injury. 
Signaling cascades triggered by IPC result in the activation of transcription factors such 
as Hif-1α262, 263 and NF-κB37, 38, which upregulate expression of protective genes 
including HSPs, as well as miRNAs, which in turn downregulate injurious genes (Figure 
49A). For example, NF-κB and Hif-1α have both been shown to be transcription factors 
for miR-21264, 265, which protects the heart through downregulation of PDCD483, FasL85, 
and PTEN84 (for in-depth discussion of this see page 156-161). Hif-1α is also a 
transcription factor for miR-107266 and miR-210266, 267, which increase after 
preconditioning and downregulate the pro-apoptotic genes PDCD10 and Casp8ap, 
respectively, resulting in cytoprotection in MSCs.  
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Another facet of miRNA/transcription factor interaction during IPC is that the 
expression of other miRNAs is reduced, which can indirectly enhance the actions of 
transcription factors such as NF-κB by simply removing an impediment to the 
expression of the genes they upregulate (Figure 49A). This is the case for miR-711 and 
miR-378*, which were previously shown by Tranter et al.87 to downregulate expression 
of the NF-κB-dependent gene Hsp70.3; these miRNAs decrease in the heart after IPC. 
Furthermore, the decrease in miR-711 appears to be mediated by NF-κB, because this 
decrease did not occur in an NF-κB dominant negative mouse strain (2M)87.  
Likewise, the results presented herein support a repressive role for miR-148a/b, 
miR-30b, and let-7a* in expression of Hsp70 and Hsp40 family members. While miR-
148a/b was sufficient on its own to downregulate Hsp70, synergistic actions of miR-30b 
and let-7a* mimics were also observed, because transfection of the combination of 
mimics resulted in the greatest reduction of Hsp70, Dnaja1, and Dnajb4 expression 
(Figure 49B). Similarly, blocking miR-148a/b significantly enhanced Hsp70 protein 
levels after HS compared with negative control siRNA transfection, but inhibition of the 
combination of miRNAs produced the greatest increase in expression of Hsp70 and 
Dnajb4. Increases in Dnaja1 expression were not noted in HL-1 cells, but it did increase 
after HS in H9c2 cells transfected with the combination of inhibitors. 
miRNAs have also been shown to interact directly with transcription factors by 
regulating their expression or the expression of their upstream activators in IPC (Figure 
49A). For example, miR-199 targets and inhibits the translation of Hif-1α, and is 
decreased by HPC, which allows for increased levels and activity of Hif-1α. 
Furthermore miR-199 downregulates Sirtuin1, which is an element of a pathway 
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involved in the constitutive degradation of Hif-1α protein during normoxia, so decreased 
miR-199 expression by HPC contributes to increased Hif-1α by increasing its translation 
and preventing its degradation86. miR-148a has been shown to reduce NF-κB signaling 
by downregulating the expression of one of the NF-κB subunits, RelA252, as well as a 
subunit of the activating upstream kinase required for degradation of inhibitor of κB 
(IκBα), known as inhibitor of κB kinase β (IKKβ)253. Whether reductions in miR-148a/b 
by IPC are necessary or sufficient for enhanced NF-κB activation during IPC has not 
been investigated and would be an interesting future study.  
Regardless of the outcome of the in vitro viability assays, which did not show 
protection in HL-1 cells, we believe that treatment with the inhibitors in vivo would be 
cardioprotective through increased HSP expression. The combination of inhibitors 
synergistically induced increases in expression of HSPs in the HL-1 cell line, which 
expressed a similar profile of HSPs and miRNAs as is found in heart tissue. Thus 
inhibition of the miRNAs in vivo would likely also lead to increased HSP expression. 
Elevated HSP expression through a variety of means other than IPC, including whole 
body heat shock63, 248, 268, transgenic overexpression64, 269-272, and adenoviral delivery273-
275 have all been shown to be cardioprotective. Thus we anticipate that if the miRNA 
inhibitors allow the HSPs to become upregulated in the heart as expected, that infarct 
size would be reduced upon subsequent I/R injury.    
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Figure 49. IPC Regulation of Gene Expression by Transcription Factors and miRNA  
 
A. IPC activates transcription factors including Hif-1α and NF-κB, which transcribe 
protective proteins and miRNAs that downregulate proteins favoring cell death. IPC also 
reduces the expression of another set of miRNAs which leads to enhanced expression of 
their targets, which can include protective proteins and the transcription factors for them. 
miRNAs shown in blue are the subject of this dissertation, while those in black are 
examples from other publications. B. The network of miRNA/mRNA interactions is 
depicted. The arrows represent the effect of the miRNA(s) on protein levels, with the 
thicker lines representing the strongest effect of modulating the combination of all 3 
miRNAs.  
 
EXOSOMAL MIRNA AS A PARACRINE MEDIATOR FROM MYOCARDIUM TO 
TRANSPLANTED MESENCHYMAL STEM CELLS 
Hypoxic Preconditioning Regulates HL-1 miRNA 
We confirmed that MSCs could take up exosomes produced by HL-1 cells. If 
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parent cells, we hypothesized that this RNA would also increase in the exosomes, which 
would allow it to be transferred to the MSCs and potentially enhance their viability. The 
sequencing analysis showed changes in the mRNA and miRNA profiles of the HL-1 
cells, which may have resulted in their protection from OGD. For instance, miR-19, part 
of the miR17-92 cluster, has been shown to be protective in the context of I/R injury by 
reducing expression of the pro-apoptotic protein PTEN, and to induce proliferation of 
cardiomyocytes even in the adult myocardium243. MiR-20, another component of this 
cluster, is also significantly upregulated, though its target mRNAs within the heart have 
not been described. Little is known about the other miRNAs that increased. Despite 
increases within the HL-1 cells, these miRNAs did not increase in the exosomes. The 
only significant changes in miRNA expression in the HPC exosomes were 
downregulations of miR-3535 and miR-208a.  
We observed a decrease in miR-184, which has been reported to target the anti-
apoptotic genes Bcl-xL and Bcl-W276, so one would expect that a decrease in miR-184 
would be cardioprotective. However, we did not detect an increase in the expression of 
Bcl-xL in previous experiments with HPC HL-1 cells (Jones lab, unpublished 
observations).  
Hypoxic Preconditioning Regulates HL-1 mRNA  
HPC induced numerous significant changes in mRNA levels. These changes 
overlapped very little with those seen in the mouse IPC heart, suggesting that the gene 
regulatory mechanisms contributing to the protective effects from these two stimuli are 
very different. Keratin 18 (Krt18) and Activating Transcription Factor 5 (ATF5) 
increased 3.5- and 2-fold respectively; gene ontology analysis revealed that they are anti-
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apoptotic genes. Furthermore, there were increases in two proteins, FK506 binding 
protein (FKBP11) and protein disulfide isomerase associated 6 (Pdia6), which are 
isomerases that assist with protein folding. Pdia6 has been shown to be induced by the 
ER stress response in the heart and cultured cells, and to be protective when 
overexpressed in cells exposed to simI/R277. Lastly, there was upregulation of the 
enzymes cytidine monophospho-N-acetylneuraminic acid hydroxylase, 
butyrylcholinesterase, cytochrome c oxidase subunit VIa polypeptide 2, and spermidine 
synthase, which could boost cellular metabolism. However, the only mRNA that 
increased in the exosomes was albumin, which has no known cytoprotective effects.  
Several mRNAs that decreased after HPC are known to be regulated by hypoxia 
and/or hypoxia inducible factor 1α (HIF-1α), including stanniocalcin 1 (Stc-1), EGL 
nine homolog 3, solute carrier family 2 (facilitated glucose transporter) member 1, 
myosin light polypeptide kinase, ceruloplasmin, cyclin G2, and RAR-related orphan 
receptor-α. This downregulation may serve to decrease the cells’ responsiveness to 
hypoxia upon a subsequent prolonged hypoxic stimulus, which could constitute a 
protective mechanism. Furthermore, Stc-1, slc40a1, and cyclin G2 are targets of the 
miR-17/92 cluster. The aforementioned upregulation of this cluster may have mediated 
the decreases in these genes, though this has not been experimentally validated.  
Stc-1 is a secreted homodimeric glycoprotein that was shown by Zhang et al. to 
be protective against calcium overload and hypoxia in neurons278. Recently the same 
group reported that in hypoxia-preconditioned HL-1 cells, Stc-1 is remarkably 
upregulated (>50-fold increase vs. normoxia), which is in contrast to the decrease that 
we observed. However, their model of hypoxic preconditioning and time point of testing 
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Stc-1 expression were different from ours. Whereas we preconditioned the HL-1 cells 
with 1 hour at 0.5% O2 in ischemia mimetic solution, and measured RNA levels 18h 
later, this group treated their cells for 6 hours at 2% O2 and measured RNA levels 
immediately after this period. They also measured Stc-1 expression at 17 and 41 hours 
later, and found that its level had returned to baseline at both time points. Thus had we 
measured Stc-1 expression at a time point closer to the end of the HPC period, we may 
have noted an increase also. It should be noted that this publication does not show data 
that indicate that their HPC protocol actually induced cytoprotection (i.e., decreased cell 
death upon more prolonged hypoxic challenge).  
Conclusions 
Taken together these results led us to reject the hypothesis that HL-1 exosomes 
are modified by HPC to contain increased levels of anti-apoptotic miRNA and mRNA, 
reflecting protective changes in the transcriptome of the HL-1s. Our findings support the 
conclusions of Villaroya-Beltri et al., who found in T cells that changes in the miRNA 
profiles of parent cells are not reflected in the exosomes they produce195. This is in 
contrast to the findings of Genneback et al., who showed that the contents of HL-1 
exosomes were modified after the cells were exposed to the growth factors TGF-β2 or 
PDGF-BB170. Quite possibly the HPC stimulus invoked fewer or less profound changes 
in gene expression than these stimuli, and thus didn’t result in many exosomal changes. 
It should be noted that this in vitro study does not rule out the possibility that IPC or 
other preconditioning stimuli in the heart could enhance exosome-mediated paracrine 
effects, due to differences in the stimuli and between HL-1 cells and primary 
cardiomyocytes. 
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MIRNA IN STEM CELL MEDIATED PARACRINE EFFECTS ON THE MYOCARDIUM 
MSC Exosome Mediated Preconditioning 
Exosomes of various sources have been shown to induce cardioprotection in two 
different but interconnected ways: induction of pro-survival signaling, and changes in 
gene expression (i.e., transfer of mRNA and miRNA). Our data support that MSC 
exosomes act through changes in gene expression, and raise the possibility of induction 
of pro-survival signaling. Figure 32 shows that pre-treatment with exosomes overnight, a 
time point that corresponded to substantial uptake, induces protection while Figure 39 
shows that a 1-hour pre-treatment is ineffective. The need for overnight timing suggests 
a gene-regulatory mechanism. However, Figure 39 also shows that when either WT or 
miR-21 KO exosomes are present during OGD, cell death is decreased, which may 
indicate the rapid activation of pro-survival signaling pathways, which don’t require 
miR-21. However, changes in gene expression over the time course of the OGD 
treatment cannot be ruled out, because the hypoxic period is 18h, which is long enough 
for gene expression changes to occur.  
Pre-treatment with MSC microparticles (MP) did not show a protective effect 
(Figure 32A). This suggests that MSC exosomes are the more important type of 
extracellular vesicle released by MSCs for paracrine communication of cardioprotection 
in this model, though a full dose curve of MP was not performed, nor was PKH26 
uptake analysis.  
Sequencing revealed that many miRNAs are enriched in the exosomes compared 
with the parent cell population, and even some which were read exclusively in the 
exosomes but not the MSCs (Table 13). Notably, miR-451 was the most enriched in the 
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exosomes compared with the cells, which is in agreement with other published studies195, 
197. Looking for highly expressed miRNAs within MSC exosomes (regardless of parent 
cell expression) revealed numerous ones with known cardioprotective roles (Table 14). 
The most highly expressed of these was miR-21, with nearly twice as many reads as the 
next most abundant miRNA. After validating its presence through real time PCR (Figure 
35), we chose to investigate this miRNA and determine whether its presence in MSC 
exosomes contributes significantly to their cardioprotective effects.  
We employed a loss-of-function approach using a commercially available KO 
mouse. This is a conventional full-body knockout in which miR-21a-5p was deleted 
from its locus within the 3’-UTR of the gene TMEM49. The expression of TMEM49 
was not affected by the deletion of miR-21a-5p241. Other than miR-21a, there are also 
miR-21b and miR-21c family members. These are found in other locations of the 
genome, and how the knockout of miR-21a affects their expression is not known (i.e., if 
they undergo compensatory upregulation). However, real time PCR showed very low 
levels of miR-21 are present in the cells of miR-21 KO mice (Figure 37). A feature of 
the most recent version of the miRBase database (the primary microRNA sequence 
repository, v21, June 2014) is the inclusion of “confidence” criteria for each miRNA. 
While miR-21b and miR-21c are included in the database, they do not meet the criteria 
for confidence that they are real miRNAs. The criteria are based on the number of deep 
sequencing reads from the mined datasets that map to each arm (-3p and -5p) of the 
stem-loop precursor. Specifically, to be “high confidence” a miRNA must have 10 reads 
that map to each arm, or at least 5 reads that map to each arm with 100 reads total279. 
Thus the low abundance of miR-21b and c reflected in this study are confirmed in the 
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data from many other deep sequencing studies that comprise the miRBase dataset. 
Furthermore, there are no published studies regarding cardioprotective effects of miR-
21b or c. Thus we acknowledged their presence but proceeded with experiments to 
compare WT to miR-21a KO exosomes based on the assumption that their expression is 
too low to impact the results. 
In vitro and in vivo, we found that the WT exosomes were highly 
cardioprotective, decreasing cell death upon OGD and infarct size upon I/R injury in 
vivo, while the miR-21 KO exosomes were less so (Figures 38 and 46). In the H9c2 
model, the KO exosomes were still significantly more protective than the control 
treatment (no exosomes), but in the mouse heart, there was only a non-significant trend 
towards a decrease in infarct size with the miR-21 KO exosomes compared to saline 
controls. Had we performed this procedure on a larger group of mice, we may have 
found that this decrease was also significant, but the inherent variability of the procedure 
would have necessitated the use of approximately 30 more mice per group to establish 
this, based on power analysis. However, together with the sequencing data, the residual 
protection observed in cells suggests that other miRNAs or mRNAs could be assisting 
miR-21 in beneficially regulating gene expression. These will be the subject of future 
studies. 
miR-21 Target Genes 
Having established that miR-21 is a critical component of MSC exosome 
mediated preconditioning, we sought to determine the mechanism by identifying pro-
apoptotic target genes that miR-21 downregulates. Search of the literature and online 
databases identified FasL, PTEN, Peli1, and PDCD4 as validated miR-21 target genes in 
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the heart and other tissues, and for each of these genes, there were also publications 
showing that their downregulation (by miR-21 or otherwise) was cardioprotective in the 
context of I/R injury, which strongly suggested that this was the mechanism of our 
observed preconditioning.  
Transfection of miR-21 mimic into H9c2 cells resulted in the downregulation of 
PDCD4 and FasL (Figure 43A-B). PDCD4 exhibited reductions in both mRNA and 
protein levels but FasL and PTEN mRNA levels were increased at 24h (Figure 44). This 
could represent feedback regulation of transcription in response to decreases in protein 
levels, to maintain homeostasis at under normal growth conditions. Luciferase reporter 
assays supported that downregulation of PDCD4 and FasL was mediated through the 3’-
UTR of these genes (Figure 40A-B). There was minimal change in expression of PTEN 
or Peli1 in the H9c2 cells, so reporter assays for these genes were not performed. In cells 
treated with exosomes, Western blot also showed downregulation of protein levels of 
PDCD4 and FasL (Figure 45) as well as decreased luciferase reporter activity (Figure 
40C-D), indicative of the transfer of functional miR-21.  
Because most of the 3’-UTR of PDCD4, including the binding site for miR-21, is 
spliced out in the cells and mouse heart (Figure 41), this effect on protein levels might be 
mediated through miR-21 binding sites within the coding sequence or 5’-UTR. We 
identified two sites within the coding sequence in silico using the DIANA MicroT-CDS 
software (Figure 42). Future work will be needed to demonstrate the necessity and 
sufficiency of each site for miR-21 repression.  
The reporter assays also revealed that while WT exosomes exerted a dose-
dependent decrease in luciferase activity, miR-21 KO exosomes also decreased reporter 
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activity to only a slightly lesser extent, which supports that other miRNAs or factors 
within the exosomes can target these 3’-UTRs. Indeed, the next most abundant miRNA 
after miR-21 in Table 14, miR-486b-5p, is predicted by microRNA.org to target 
PDCD4. Furthermore, the highly expressed miR-24, miR-92, and the let-7 family 
members a, c, d, f, g, and i are all predicted to target FasL. It seems that MSC exosomes 
may carry a cocktail of selective anti-apoptotic miRNAs for the purpose of paracrine 
downregulation of specific target genes, perhaps as part of their biological role in the 
bone marrow and other tissues. 
Having noted decreases in PDCD4 and FasL after exosome treatment in vitro, we 
next asked whether these genes are decreased by exosome treatment in the heart. 
Twenty-four hours after exosomes were injected into the pericardial sac, a time point at 
which the infarct size was decreased, we did not observe significant downregulation of 
PDCD4, Peli1, or FasL (Figure 47A-B). At the RNA level, we did observe a significant 
decrease in the PDCD4 splice variant with the full length 3’-UTR, which is consistent 
with the presence of a functional miR-21 binding site being retained (Figure 47C). 
However, given the relatively low contribution of this variant to the total amount of 
PDCD4 mRNA present, it is not surprising that the protein did not decrease as a result of 
this change. 
We next asked whether the levels of the proteins were changed at a relevant time 
point after the I/R injury. Western blots on protein extracted from the ischemic zone 6h 
after I/R injury showed significant downregulation of PDCD4, PTEN, FasL and Peli1 
(Figure 48). From this we concluded that miR-21 acted to prime the transcriptome of the 
cells such that expression of these genes was blunted after I/R injury.  
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Literature supports that increases in miR-21 level reduce infarct size. Increases in 
miR-21 occur endogenously in response to cardioprotective stimuli such as IPC (3.5-fold 
increase vs. sham 6 hours after IPC83), ischemic postconditioning (IPost, 3-fold increase 
vs. I/R alone at 3h reperfusion84) and anesthetic-mediated preconditioning (2.5-fold 
increase vs. control after 30 minutes81). Highlighting the role of miR-21, several studies 
have shown that overexpression, mediated by viral vectors226, 227 or a cardiac-specific 
overexpressing genetic mouse model85, can reduce infarct size to a similar degree as 
these maneuvers. Consistent with this, knockdown of miR-21 by administration of an 
antagomir83 or use of a miR-21 KO mouse81 abrogates the reduction of infarct size from 
IPC or anesthetic-mediated preconditioning, respectively.  
Regarding the mechanism by which miR-21 reduces infarct size, the data support 
that it decreases apoptosis through downregulation of PDCD4, PTEN, and FasL. The 
Zhang group noted that in cultured NRVMs, transfection of pre-mir-21 decreased 
PDCD4 protein levels by ~45%, and importantly through adenoviral overexpression and 
siRNA mediated knockdown, they confirmed a role for PDCD4 in apoptosis (as 
measured by TUNEL staining) from hypoxia/reoxygenation226. Likewise, Olson et al. 
showed that miR-21 downregulated PDCD4 by 18% in NRVMs treated with 
isofluorane, but no effect on expression of PTEN was observed. However, evidence that 
miR-21 regulates PTEN in the mouse heart is supported by other studies. For example, 
cardiac-specific overexpression of miR-21 in the mouse heart downregulated PTEN as 
well as FasL in a mouse model of permanent occlusion85. FasL has been shown to 
increase in the hours after I/R injury in mice280, in the isolated perfused heart, and in 
NRVMs281. Activation of Fas by FasL induces apoptosis, and this is been shown to 
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contribute significantly to infarct size in mice6-8. Thus, treatments that increase the level 
of miR-21 would be expected to decrease apoptosis in the heart after MI by blunting the 
expression of FasL, as supported by Sayed et al.85. Downregulation of these was 
associated with increased p-Akt and decreased caspase 6, consistent with decreased 
apoptosis. Additionally, knockdown of miR-21 using an antagomir prevented miR-21 
from increasing in response to IPost, and prevented IPost from reducing PTEN 
expression84. In this study, downregulation of PTEN increased p-Akt levels which 
coincided with increased Bcl-2, decreased Bax, and decreased cleaved caspase-3, 
leading to decreased apoptosis as measured by TUNEL staining in heart slices. That 
miR-21 contributes to a decrease in apoptosis after MI was further supported by a recent 
study in which lentiviral miR-21 was delivered to the myocardium, preventing miR-21 
expression from decreasing over from 1-2 weeks after MI. This resulted in decreased 
TUNEL staining, increased Bcl-2/Bax ratio and decreased caspase-3227.  
Our data are consistent with these reports which identify PTEN and FasL as 
target genes of miR-21 in the heart, which mediate pro-apoptotic signaling in response to 
I/R injury. Our data also extend the findings of the Zhang group which identified 
PDCD4 as a pro-apoptotic miR-21 target in vitro, by supporting that exosome-mediated 
increases in miR-21 modulate PDCD4 protein levels in vivo. An effect of miR-21 on 
Peli1 expression in the heart has not been demonstrated before. However, knockdown of 
Peli1 by adenoviral siRNA delivery was associated with reduced scar size and improved 
heart function in a mouse model of permanent occlusion205. Thus if exosomal miR-21 
acts in a similar fashion to the adenovirally delivered siRNA, to downregulate Peli1, this 
would be consistent with the protection that we observed.  
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Interconnected Regulation of miR-21 and Its Targets 
Akt is a kinase known to stimulate cellular metabolism, protein synthesis, 
proliferation, and survival. It is activated in response to a variety of receptor mediated 
stimuli, including adhesion, growth factors, cytokines, and hormones. Binding of these 
ligands leads to activation of phosphatidylinositide-3 kinase (PI3K), which 
phosphorylates the membrane lipid phosphatidylinositol to produce phosphatidylinositol 
3-phosphate (PIP3). Enriched regions of PIP3 in the membrane recruit Akt via its 
pleckstrin homology (PH) domain, which is then phosphorylated by phosphoinositide 
dependent kinase-1 (PDK-1). Akt is then active and carries out its pro-survival and 
metabolic signaling. Akt is inactivated by PTEN through dephosphorylation of PIP3, for 
example in response to growth factor withdrawal.  
  There is a regulatory loop that exists between Akt and miR-21. Akt drives the 
expression of miR-2185, 282, and miR-21 downregulates PTEN, enhancing Akt activity. 
Perhaps because of this, miR-21 appears to be required for cardioprotection that is 
driven by Akt signaling. For instance, isofluorane-mediated cardioprotection strongly 
induces expression of miR-21, and also activates Akt, as evidenced by increased 
phosphorylation. In miR-21 KO mice, Qiao et al. found that infarct size reduction by 
isofluorane was completely abrogated, as was AKT activation82.  
Akt and miR-21 also act together to block PDCD4. Akt directly phosphorylates 
PDCD4, which leads to its inactivation and translocation to the nucleus283, while miR-21 
acts to reduce its expression. These effects result in enhanced AP-1 signaling (which is 
blocked by PDCD4) and removes PDCD4’s inhibition of protein synthesis, furthering 
Akt’s role of enhancement of protein synthesis. Furthermore, PDCD4 has been shown to 
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downregulate the anti-apoptotic protein FLIP (Flice Inhibitory Protein, also known as 
Caspase 8 and FADD like Apoptosis Regulator, CFLAR) in some types of cancer 
cells284. FLIP blocks the extrinsic apoptosis pathway by displacing Caspase 8 from the 
Fas Associated Death Domain (FADD) complex. When FLIP is silenced in 
cardiomyocytes using shRNA, apoptosis is enhanced both at baseline as well as upon 
simI/R285, indicative of its protective role within the heart. By downregulating both FasL 
and PDCD4 (and possibly thereby increasing FLIP expression), miR-21 may block 
extrinsic apoptosis in at least two ways.  
Akt’s induction of miR-21 expression has been shown to require the transcription 
factors CBP/p300, CREB, and NF-κB282. Another target of miR-21, Peli1, is a ubiquitin 
ligase that acts upstream of NF-κB activation. In the regenerating liver, NF-κB is 
initially activated and miR-21 levels increase. This results in downregulation of Peli1, 
and thereby subsequent reduction of NF-κB activity286. By downregulating Peli1 in the 
heart, miR-21 could reduce NF-κB activity, and thereby blunt the feed-forward loop of 
Akt activity and its own expression. However, whether Akt’s activation of miR-21 
transcription requires Peli1 is not known. It has been shown that blocking the expression 
of Peli1 using siRNA or Cre-LoxP-mediated conditional deletion in the heart is 
beneficial in the context of post-I/R injury remodeling205.  
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Figure 50. miR-21 Targets and Signaling Pathways  
 
Akt is recruited to enriched regions of PIP3 in the membrane and phosphorylated by 
PDK-1. This results in upregulation of miR-21, which reduces the expression of PTEN, 
FasL, Peli1, and PDCD4. This may result in decreased infarct size by further increasing 
AKT activity, decreasing activation of Fas, and decreasing NF-κB signaling. 
Abbreviations: RTK, receptor tyrosine kinase. PI3K, phosphoinositide 3-kinase. PIP, 
phosphatidylinositol. PIP3, phosphatidylinositol 3-phosphate. PTEN, phosphatase and 
tensin homologue. p-AKT, phosphorylated AKT. PDK-1, phosphoinositide dependent 
kinase-1. PDCD4, programmed cell death 4. Peli1, pellino 1. FasL, Fas ligand. sFasL, 
soluble Fas ligand. FLIP, Flice Inhibitory Protein. FADD, Fas associated death domain.  
 
Conclusions 
These interactions between Akt, miR-21, and the miR-21 target genes PTEN, 
PDCD4, FasL, and Peli1 enable the understanding of how the delivery of miR-21 from 
MSCs to cardiomyocytes could act to reduce infarct size after myocardial infarction. 
These data support a key role of miR-21 within MSC exosomes in their paracrine 
effects. 
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 The results presented herein suggest a number of questions which could be 
addressed by future studies. First, while expression of PTEN was found to be decreased 
by transfer of exosomal miR-21, Akt activation was not investigated. We would expect 
this activation to increase, which is consistent with the pro-survival effect that we 
observed. Furthermore, studies in which miR-21 is administered in vivo were not 
performed, but we would expect miR-21 to recapitulate many of the effects of the 
exosomes with regard to both gene expression and infarct size.  
While the exosomes were shown to be cardioprotective in a preconditioning 
model, these studies did not address their potential regenerative or angiogenic effects, 
which would require a longer time course, and for the effects on initial infarct size to be 
controlled for. Lastly, it will be important for a follow-up study to sequence the miRNA 
content of the WT and miR-21 KO exosomes to ensure that miR-21 is the only major 
difference. The loss of miR-21 could affect the expression of mRNAs in the MSCs, such 
as transcription factors, resulting in changes to the overall profile of miRNAs present, in 
which case the lack of protective effect could not be attributed to miR-21 alone.  
Potential Significance (Basic and Medical)  
The cardioprotective properties of stem cell exosomes, including MSC 
exosomes, have recently begun to be explored155, 157, 183, 199, 200, 287-289. In particular, the 
importance of transfer of exosomal miRNA from stem cells has been recognized; our 
findings are in support of this. For example, transfer of miR-146a and miR-22 have been 
shown to be important for paracrine effects from CDCs199 and MSCs203, respectively. 
miR-21 was also observed to be enriched in these types of exosomes, but until now has 
not been directly investigated. Whether miR-21 is an important component of 
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therapeutic benefits in other types of stem cell exosomes or the exosomes of human 
MSCs is not known.  
Using the miR-21 mimic in vitro, we confirmed that PDCD4, FasL, and PTEN 
are targets of miR-21 as suggested by others83-85. Treatment of the mouse heart with the 
exosomes resulted in the downregulation of these proteins as well as Peli1, which 
strongly suggests that Peli1 is a target of miR-21 in the mouse heart. To prove this 
conclusively, experiments in which miR-21 is administered in vivo would have to be 
undertaken, because in theory another component of the exosomes could be responsible 
for the downregulation of Peli1 observed.  
If miR-21 were confirmed to target Peli1 in the heart, this would represent 
another layer of regulation of NF-κB driven gene expression. This implies that miR-21 
could affect the expression of NF-κB-dependent genes, including the heat shock 
proteins. One scenario is if miR-21 increases after IPC as shown in a number of 
publications83, 85, it would downregulate Peli1, which would reign in NF-κB activity. 
Because miR-21 expression peaks at 6h after IPC, while NF-κB-dependent genes begin 
to show regulation by 3 hours after IPC, perhaps this represents a homeostatic 
mechanism to return NF-κB activity to baseline. After prolonged hypoxia such as during 
I/R injury, miR-21 decreases85, which could allow Peli1 to increase, hypothetically 
increasing NF-κB activation, which could contribute to increased infarct size and 
expression of inflammatory cytokines205. In support of this, our previously published 
array data show HSP expression is higher after I/R than after IPC, though this has not 
been experimentally validated.  
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The results presented herein have potential translational ramifications. The 
effectiveness of stem cell exosomes in activating cardioprotection suggests a way to 
circumvent some of the limitations of cell therapy for myocardial infarction. One such 
limitation is the timing of administration of cells relative to the MI. It takes weeks to 
expand purified cultures of autologous MSCs from bone marrow biopsies to have 
enough cells for transplantation, by which time the infarcted area is replaced by scar 
tissue. Exosomes could be produced by allogeneic MSCs or other stem cell populations, 
and stored for use as needed. Of course, stem cell populations have already been 
investigated that do not require culture-expansion, such as BM-MNCs110 and adipose 
derived regenerative cells143. Data from one clinical trial (POSEIDON, as shown in144) 
support that allogeneic mesenchymal stem cells are equally effective to autologous, 
which would circumvent this limitation. But exosomes may have the additional benefit 
of being easier to preserve for later use because viability after storage is not a concern.  
 If the beneficial factor(s) that transplanted stem cells secrete could be isolated, 
it/they could be used instead of or in addition to the cells themselves. Because exosomes 
have been shown to recapitulate many of the benefits of their parent stem cells, they 
could represent one such factor. Taking this reductionist approach even further, our 
findings support the importance of miR-21 within the exosomes as a key factor of their 
mechanism of action. Thus if miR-21 could be administered after MI and recapitulate 
the effects of the exosomes and the cells, this would circumvent the need for them, 
potentially saving time and money.  
 A limitation to these reductionist approaches is that stem cells release many 
factors in addition to exosomes, including HGF and VEGF146, 149, 152; use of exosomes 
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alone would eliminate the exposure of the heart to these, potentially preventing the 
antifibrotic and angiogenic benefits of MSCs themselves. Likewise, administering miR-
21 alone would prevent the heart from being exposed to the other protective miRNAs, as 
well as mRNAs and proteins found in exosomes154-156. In support of this, while miR-
146a was found to be a key component of CDC exosome regenerative effects, its 
administration in the absence of exosomes did not reproduce all of their benefits. It 
increased viable mass, but failed to improve global function or decrease scar mass. 
Exosomes from cells depleted of miR-146a could still suppress apoptosis, though to a 
lesser extent. Thus the authors concluded that other miRNAs may be needed to 
reproduce the full repertoire of the exosomes’ effects, and that exosomal miRNAs may 
act synergistically199. Our sequencing data showed the presence of other miRNAs which 
share pro-apoptotic targets with miR-21, with expression levels that were also quite 
high, which suggests the potential for synergy with miR-21. Thus we believe exosomes 
would be more therapeutically efficacious than individual miRNAs alone. Potentially, a 
cocktail of the most enriched miRNAs could recapitulate exosomes’ effects. Future 
studies are needed to compare the benefits of stem cells, their exosomes, and the 
bioactive miRNAs within the exosomes.  
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APPENDIX A 
RNA-SEQ DATA: GENES WITH DIFFERENTIAL EXPRESSION BETWEEN 
SHAM AND IPC MOUSE HEART TISSUE 
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Symbol Name Sham IPC Fold P  
Slc5a3 
solute carrier family 5 
(inositol transporters), 
member 3 93.4 494.5 5.3 8.49E-11 
Nr4a3 
nuclear receptor subfamily 4, 
group A, member 3 9.4 107.1 11.5 1.10E-10 
Hsph1 
heat shock 105kDa/110kDa 
protein 1 860.0 3534.4 4.1 2.22E-10 
Ch25h cholesterol 25-hydroxylase 68.4 324.1 4.7 1.22E-06 
Ucp3 
uncoupling protein 3 
(mitochondrial, proton 
carrier) 692.6 183.8 0.3 1.41E-06 
Hspa1b heat shock protein 1B 14.6 
10090.
6 690.7 1.52E-06 
Akap12 
A kinase (PRKA) anchor 
protein (gravin) 12 311.9 957.7 3.1 1.52E-06 
Hsp90aa1 
heat shock protein 90, alpha 
(cytosolic), class A member 
1 
2664.
0 
24336.
4 9.1 4.08E-06 
Adamts4 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 motif, 4 17.5 94.3 5.4 8.94E-06 
Dnaja1 
DnaJ (Hsp40) homolog, 
subfamily A, member 1 642.8 4557.1 7.1 1.23E-05 
Peg10 paternally expressed 10 13.6 95.6 7.0 1.44E-05 
Icam1 
intercellular adhesion 
molecule 1 86.0 309.9 3.6 1.65E-05 
Hspa1a heat shock protein 1A 16.1 8741.7 541.6 3.54E-05 
S100a8 
S100 calcium binding 
protein A8 (calgranulin A) 26.3 115.7 4.4 6.08E-05 
Sele selectin, endothelial cell 24.2 99.9 4.1 1.06E-04 
Dnaja4 
DnaJ (Hsp40) homolog, 
subfamily A, member 4 
1745.
7 4055.4 2.3 1.14E-04 
Il6 interleukin 6 23.2 88.9 3.8 2.02E-04 
Rell1 RELT-like 1 113.5 300.2 2.6 3.28E-04 
Nuak1 
NUAK family, SNF1-like 
kinase, 1 229.4 667.3 2.9 3.85E-04 
Tiparp 
TCDD-inducible poly(ADP-
ribose) polymerase 634.0 1431.6 2.3 4.01E-04 
Bhlhe41 
basic helix-loop-helix 
family, member e41 254.9 714.9 2.8 5.49E-04 
Lhfpl2 lipoma HMGIC fusion 16.2 65.5 4.0 5.68E-04 
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partner-like 2 
Csf2rb2 
colony stimulating factor 2 
receptor, beta 2, low-affinity 
(granulocyte-macrophage) 37.2 131.1 3.5 7.74E-04 
Casp4 
caspase 4, apoptosis-related 
cysteine peptidase 74.4 209.9 2.8 8.74E-04 
Gcnt2 
glucosaminyl (N-acetyl) 
transferase 2, I-branching 
enzyme 216.3 491.0 2.3 0.001 
Spry4 
sprouty homolog 4 
(Drosophila) 147.0 334.6 2.3 0.001 
P4ha1 
procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), 
alpha 1 polypeptide 396.1 1183.2 3.0 0.001 
Slfn4 schlafen 4 34.9 103.7 3.0 0.001 
Retnlg resistin like gamma 2.0 23.3 11.6 0.001 
Pim1 proviral integration site 1 93.9 223.1 2.4 0.001 
Atp2c1 ATPase, Ca++-sequestering 844.9 1730.4 2.0 0.001 
Ankrd33b ankyrin repeat domain 33B 335.8 759.0 2.3 0.001 
Dnajb4 
DnaJ (Hsp40) homolog, 
subfamily B, member 4 
1840.
1 6440.2 3.5 0.001 
Csf2rb 
colony stimulating factor 2 
receptor, beta, low-affinity 
(granulocyte-macrophage) 27.5 91.2 3.3 0.002 
Map3k8 
mitogen-activated protein 
kinase kinase kinase 8 92.4 204.8 2.2 0.002 
Txnrd1 thioredoxin reductase 1 911.7 1830.4 2.0 0.002 
Tmem173 transmembrane protein 173 49.9 136.0 2.7 0.002 
Hspa8 heat shock protein 8 
8147.
0 
18962.
1 2.3 0.002 
Hmox1 
heme oxygenase (decycling) 
1 152.8 471.5 3.1 0.003 
S100a9 
S100 calcium binding 
protein A9 (calgranulin B) 14.5 58.8 4.1 0.003 
Sema6c 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic 
domain, (semaphorin) 6C 71.5 21.6 0.3 0.003 
Rgs16 
regulator of G-protein 
signaling 16 3.6 26.1 7.2 0.003 
Icosl icos ligand 76.6 178.8 2.3 0.003 
Cnksr3 Cnksr family member 3 201.8 402.1 2.0 0.003 
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Sat1 
spermidine/spermine N1-
acetyl transferase 1 319.8 617.5 1.9 0.003 
Lima1 
LIM domain and actin 
binding 1 104.5 242.8 2.3 0.004 
Selp selectin, platelet 43.6 141.8 3.3 0.004 
Zkscan8 
zinc finger with KRAB and 
SCAN domains 8 368.5 162.7 0.4 0.004 
Gem 
GTP binding protein (gene 
overexpressed in skeletal 
muscle) 37.2 92.2 2.5 0.004 
Fnip2 
folliculin interacting protein 
2 308.9 741.5 2.4 0.004 
Il4ra interleukin 4 receptor, alpha 314.4 641.9 2.0 0.004 
Litaf LPS-induced TN factor 154.7 326.9 2.1 0.004 
Akap2 
A kinase (PRKA) anchor 
protein 2 
1977.
2 3800.5 1.9 0.004 
Bbs10 
Bardet-Biedl syndrome 10 
(human) 37.7 7.7 0.2 0.004 
Clec4e 
C-type lectin domain family 
4, member e 10.6 45.8 4.3 0.004 
Osmr oncostatin M receptor 503.8 1644.8 3.3 0.004 
Smad1 SMAD family member 1 330.2 612.2 1.9 0.004 
Eif1a 
eukaryotic translation 
initiation factor 1A 378.8 719.3 1.9 0.004 
Gm4070 predicted gene 4070 
2933.
2 5854.6 2.0 0.004 
Gvin1 
GTPase, very large 
interferon inducible 1 
2933.
2 5854.6 2.0 0.004 
Lnx2 ligand of numb-protein X 2 114.3 246.9 2.2 0.004 
Atp8b1 
ATPase, class I, type 8B, 
member 1 131.9 284.3 2.2 0.005 
Dnajb5 
DnaJ (Hsp40) homolog, 
subfamily B, member 5 257.4 541.6 2.1 0.005 
Plac9b placenta specific 9b 141.6 64.5 0.5 0.005 
Stx11 syntaxin 11 19.3 58.0 3.0 0.005 
Ppp1r18 
protein phosphatase 1, 
regulatory subunit 18 95.1 203.2 2.1 0.005 
Banp 
BTG3 associated nuclear 
protein 12.4 45.4 3.7 0.006 
Gprc5a 
G protein-coupled receptor, 
family C, group 5, member 
A 9.0 36.4 4.1 0.006 
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Plekho2 
pleckstrin homology domain 
containing, family O member 
2 63.1 147.9 2.3 0.006 
Rassf1 
Ras association 
(RalGDS/AF-6) domain 
family member 1 122.0 291.6 2.4 0.006 
Spred1 
sprouty protein with EVH-1 
domain 1, related sequence 752.4 1348.8 1.8 0.006 
Thbd thrombomodulin 588.0 1169.5 2.0 0.006 
Nfil3 
nuclear factor, interleukin 3, 
regulated 121.8 244.1 2.0 0.006 
Esm1 
endothelial cell-specific 
molecule 1 4.2 23.0 5.4 0.007 
Serpina3f 
serine (or cysteine) peptidase 
inhibitor, clade A, member 
3F 26.9 104.2 3.9 0.007 
Ptgs2 
prostaglandin-endoperoxide 
synthase 2 48.4 112.6 2.3 0.007 
Sdc4 syndecan 4 274.8 686.2 2.5 0.007 
Sema6d 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic 
domain, (semaphorin) 6D 388.0 737.4 1.9 0.007 
Jmjd1c 
jumonji domain containing 
1C 702.8 1357.6 1.9 0.007 
Tfpi2 
tissue factor pathway 
inhibitor 2 26.3 68.4 2.6 0.007 
Serpinh1 
serine (or cysteine) peptidase 
inhibitor, clade H, member 1 410.5 1915.1 4.7 0.007 
Zfp568 zinc finger protein 568 179.7 508.3 2.8 0.007 
Art4 ADP-ribosyltransferase 4 168.4 78.2 0.5 0.008 
Gm8989 
very large inducible GTPase 
1 pseudogene 235.7 556.7 2.4 0.008 
Ttc30a2 
tetratricopeptide repeat 
domain 30A2 104.2 40.0 0.4 0.008 
Nfkbiz 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B cells inhibitor, zeta 73.2 143.0 2.0 0.008 
Kazn 
kazrin, periplakin interacting 
protein 35.8 88.1 2.5 0.009 
Car13 carbonic anhydrase 13 10.8 32.5 3.0 0.009 
Slco5a1 
solute carrier organic anion 
transporter family, member 290.1 543.6 1.9 0.009 
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5A1 
Cxcl1 
chemokine (C-X-C motif) 
ligand 1 66.6 186.3 2.8 0.009 
Tmem2 transmembrane protein 2 206.1 393.0 1.9 0.009 
Map3k1 
mitogen-activated protein 
kinase kinase kinase 1 358.8 658.6 1.8 0.009 
Slc23a2 
solute carrier family 23 
(nucleobase transporters), 
member 2 419.8 750.7 1.8 0.010 
Ets2 
E26 avian leukemia 
oncogene 2, 3' domain 748.3 1433.4 1.9 0.010 
Zfp697 zinc finger protein 697 125.8 528.9 4.2 0.010 
Fam26e 
family with sequence 
similarity 26, member E 21.5 55.5 2.6 0.010 
Tnfaip3 
tumor necrosis factor, alpha-
induced protein 3 43.2 101.0 2.3 0.010 
Tmem88b transmembrane protein 88B 24.4 96.6 4.0 0.010 
Socs3 
suppressor of cytokine 
signaling 3 169.1 393.5 2.3 0.010 
Mmp8 matrix metallopeptidase 8 5.4 28.6 5.3 0.010 
Tmem254a transmembrane protein 254a 203.6 93.1 0.5 0.010 
Rel 
reticuloendotheliosis 
oncogene 127.8 241.8 1.9 0.010 
Ell 
elongation factor RNA 
polymerase II 39.6 111.4 2.8 0.011 
Gpr176 
G protein-coupled receptor 
176 0.0 9.4 Inf 0.011 
Cxcl2 
chemokine (C-X-C motif) 
ligand 2 12.9 57.4 4.5 0.012 
Maff 
v-maf musculoaponeurotic 
fibrosarcoma oncogene 
family, protein F (avian) 124.2 373.1 3.0 0.012 
Smim5 
small integral membrane 
protein 5 94.2 38.2 0.4 0.012 
Mgat5 
mannoside 
acetylglucosaminyltransferas
e 5 39.8 97.4 2.4 0.012 
Mir24-1 microRNA 24-1 0.0 9.1 Inf 0.012 
Mir3074-1 microRNA 3074-1 0.0 9.1 Inf 0.012 
Egr1 early growth response 1 254.0 616.3 2.4 0.012 
Fgl2 fibrinogen-like protein 2 
1719.
5 5952.5 3.5 0.012 
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Frmd6 FERM domain containing 6 322.5 789.5 2.4 0.012 
Kank1 
KN motif and ankyrin repeat 
domains 1 409.1 742.6 1.8 0.013 
Kdm6b 
KDM1 lysine (K)-specific 
demethylase 6B 202.5 372.4 1.8 0.013 
Rps6ka5 
ribosomal protein S6 kinase, 
polypeptide 5 281.9 136.2 0.5 0.013 
Tpm3 tropomyosin 3, gamma 366.5 660.0 1.8 0.013 
Fam189a2 
family with sequence 
similarity 189, member A2 421.0 728.4 1.7 0.014 
Dusp16 
dual specificity phosphatase 
16 271.2 521.9 1.9 0.014 
Unc45b 
unc-45 homolog B (C. 
elegans) 
1163.
8 2972.8 2.6 0.014 
Il17ra interleukin 17 receptor A 70.2 149.5 2.1 0.014 
Tsku tsukushi 16.5 47.2 2.9 0.014 
Odc1 
ornithine decarboxylase, 
structural 1 501.9 925.2 1.8 0.014 
Trim16 tripartite motif-containing 16 45.9 113.0 2.5 0.015 
Sbno2 
strawberry notch homolog 2 
(Drosophila) 100.2 390.3 3.9 0.016 
Alkbh1 
alkB, alkylation repair 
homolog 1 (E. coli) 87.7 171.3 2.0 0.016 
Akap13 
A kinase (PRKA) anchor 
protein 13 
1350.
9 2322.6 1.7 0.016 
Tmem254b transmembrane protein 254b 198.4 89.9 0.5 0.017 
Tmem254c transmembrane protein 254c 198.4 89.9 0.5 0.017 
Kcnj3 
potassium inwardly-
rectifying channel, subfamily 
J, member 3 575.8 304.1 0.5 0.017 
Igsf9b 
immunoglobulin 
superfamily, member 9B 1.9 15.0 7.9 0.017 
Irf8 interferon regulatory factor 8 31.5 73.2 2.3 0.018 
Thbs1 thrombospondin 1 321.1 3253.6 10.1 0.018 
Ptpn21 
protein tyrosine phosphatase, 
non-receptor type 21 223.6 480.5 2.1 0.018 
Slc20a1 
solute carrier family 20, 
member 1 239.7 402.8 1.7 0.018 
Gin1 
gypsy retrotransposon 
integrase 1 213.6 105.0 0.5 0.018 
Pgm1 phosphoglucomutase 1 66.9 141.1 2.1 0.018 
Casp8 caspase 8 61.6 126.0 2.0 0.018 
174 
	
Atp7a 
ATPase, Cu++ transporting, 
alpha polypeptide 306.9 544.7 1.8 0.018 
Ugdh UDP-glucose dehydrogenase 200.1 392.6 2.0 0.019 
Ccl19 
chemokine (C-C motif) 
ligand 19 13.0 37.7 2.9 0.019 
Slc25a25 
solute carrier family 25 
(mitochondrial carrier, 
phosphate carrier), member 
25 89.9 161.2 1.8 0.019 
Jak2 Janus kinase 2 386.0 698.5 1.8 0.019 
Arrdc4 arrestin domain containing 4 104.8 186.1 1.8 0.020 
AI507597 
expressed sequence 
AI507597 31.0 9.4 0.3 0.020 
Ttc30b 
tetratricopeptide repeat 
domain 30B 364.8 138.6 0.4 0.020 
Il1r2 interleukin 1 receptor, type II 7.8 28.6 3.7 0.020 
Arid5b 
AT rich interactive domain 
5B (MRF1-like) 143.2 369.5 2.6 0.021 
Fam110b 
family with sequence 
similarity 110, member B 18.7 48.9 2.6 0.021 
Ky kyphoscoliosis peptidase 73.9 30.8 0.4 0.022 
Cacybp calcyclin binding protein 601.6 1032.8 1.7 0.022 
Lonrf1 
LON peptidase N-terminal 
domain and ring finger 1 108.7 217.5 2.0 0.022 
Kcne4 
potassium voltage-gated 
channel, Isk-related 
subfamily, gene 4 51.3 101.9 2.0 0.022 
Bag3 
BCL2-associated athanogene 
3 532.9 2181.5 4.1 0.022 
Adamts1 
a disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 motif, 1 459.5 1883.6 4.1 0.023 
Sh2d5 SH2 domain containing 5 1.2 12.1 10.5 0.023 
Olfr56 olfactory receptor 56 1.2 11.6 10.0 0.023 
Gp49a glycoprotein 49 A 118.6 223.2 1.9 0.023 
Aebp1 AE binding protein 1 29.3 72.4 2.5 0.024 
Nts neurotensin 20.5 51.8 2.5 0.024 
Zfp516 zinc finger protein 516 96.8 177.3 1.8 0.024 
Nudt18 
nudix (nucleoside 
diphosphate linked moiety 
X)-type motif 18 66.3 131.7 2.0 0.024 
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Samsn1 
SAM domain, SH3 domain 
and nuclear localization 
signals, 1 10.9 35.2 3.2 0.025 
Prrg3 
proline rich Gla (G-
carboxyglutamic acid) 3 
(transmembrane) 185.0 92.6 0.5 0.025 
Cxcr5 
chemokine (C-X-C motif) 
receptor 5 12.0 1.3 0.1 0.025 
Cyp1b1 
cytochrome P450, family 1, 
subfamily b, polypeptide 1 167.0 323.9 1.9 0.025 
Emp1 
epithelial membrane protein 
1 576.5 1264.1 2.2 0.025 
Nek6 
NIMA (never in mitosis gene 
a)-related expressed kinase 6 36.1 84.7 2.3 0.025 
Ppara 
peroxisome proliferator 
activated receptor alpha 
1466.
8 840.4 0.6 0.025 
Urb1 
URB1 ribosome biogenesis 1 
homolog (S. cerevisiae) 85.6 187.8 2.2 0.026 
Dab2 
disabled 2, mitogen-
responsive phosphoprotein 483.7 889.5 1.8 0.026 
Entpd5 
ectonucleoside triphosphate 
diphosphohydrolase 5 
2380.
5 1367.8 0.6 0.026 
Rbm18 
RNA binding motif protein 
18 637.7 1038.8 1.6 0.026 
Lilrb4 
leukocyte immunoglobulin-
like receptor, subfamily B, 
member 4 134.3 272.7 2.0 0.026 
AI593442 
expressed sequence 
AI593442 60.3 16.8 0.3 0.026 
Zfp420 zinc finger protein 420 72.0 34.0 0.5 0.026 
Ptx3 pentraxin related gene 77.2 438.5 5.7 0.026 
Sh3rf2 
SH3 domain containing ring 
finger 2 241.1 130.8 0.5 0.027 
NA NA 18.0 45.8 2.5 0.027 
Prodh proline dehydrogenase 94.8 48.0 0.5 0.027 
Zfp948 zinc finger protein 948 100.6 276.8 2.8 0.027 
Map3k5 
mitogen-activated protein 
kinase kinase kinase 5 633.9 1623.6 2.6 0.028 
Cytip 
cytohesin 1 interacting 
protein 19.1 45.7 2.4 0.028 
Ccr1 
chemokine (C-C motif) 
receptor 1 58.6 121.2 2.1 0.028 
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Hspd1 
heat shock protein 1 
(chaperonin) 
3284.
7 5474.3 1.7 0.028 
Zkscan7 
zinc finger with KRAB and 
SCAN domains 7 31.3 9.9 0.3 0.029 
Sgms2 sphingomyelin synthase 2 34.1 107.1 3.1 0.029 
Dnajb1 
DnaJ (Hsp40) homolog, 
subfamily B, member 1 112.1 939.4 8.4 0.029 
Dapk2 
death-associated protein 
kinase 2 38.0 13.1 0.3 0.029 
Ptpn12 
protein tyrosine phosphatase, 
non-receptor type 12 509.6 1113.3 2.2 0.029 
Nle1 
notchless homolog 1 
(Drosophila) 11.3 50.6 4.5 0.029 
Pde4b 
phosphodiesterase 4B, 
cAMP specific 517.2 1157.0 2.2 0.029 
Nr5a2 
nuclear receptor subfamily 5, 
group A, member 2 4.6 19.7 4.3 0.030 
Ripk1 
receptor (TNFRSF)-
interacting serine-threonine 
kinase 1 150.7 256.8 1.7 0.030 
Kit kit oncogene 33.7 73.5 2.2 0.030 
Tmem120a transmembrane protein 120A 62.8 123.7 2.0 0.030 
Gadd45b 
growth arrest and DNA-
damage-inducible 45 beta 45.7 95.8 2.1 0.030 
Ctso cathepsin O 416.2 231.4 0.6 0.030 
Swap70 SWA-70 protein 131.1 240.2 1.8 0.030 
Klf6 Kruppel-like factor 6 
1375.
1 2668.2 1.9 0.031 
Map3k14 
mitogen-activated protein 
kinase kinase kinase 14 23.3 55.2 2.4 0.031 
Arid5a 
AT rich interactive domain 
5A (MRF1-like) 43.8 124.5 2.8 0.031 
Sh3pxd2b SH3 and PX domains 2B 95.4 202.7 2.1 0.032 
Ccdc14 
coiled-coil domain 
containing 14 71.8 30.8 0.4 0.032 
Stip1 
stress-induced 
phosphoprotein 1 274.7 769.1 2.8 0.032 
Epb4.1l5 
erythrocyte protein band 4.1-
like 5 137.1 67.9 0.5 0.032 
Nt5e 5' nucleotidase, ecto 520.2 1328.0 2.6 0.033 
Ect2 ect2 oncogene 24.3 8.1 0.3 0.033 
Rasgef1b 
RasGEF domain family, 
member 1B 134.1 253.1 1.9 0.034 
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Eid2b 
EP300 interacting inhibitor 
of differentiation 2B 135.2 68.4 0.5 0.034 
Acvrl1 
activin A receptor, type II-
like 1 124.3 233.1 1.9 0.034 
Cyb5r2 cytochrome b5 reductase 2 36.5 13.3 0.4 0.034 
Gda guanine deaminase 464.2 1075.4 2.3 0.034 
Fjx1 
four jointed box 1 
(Drosophila) 1.7 14.1 8.3 0.035 
Ccng2 cyclin G2 633.2 360.9 0.6 0.035 
Apol10b apolipoprotein L 10B 19.7 50.1 2.5 0.036 
Tec tec protein tyrosine kinase 55.9 149.6 2.7 0.036 
Aloxe3 arachidonate lipoxygenase 3 0.0 7.1 Inf 0.036 
Runx1 
runt related transcription 
factor 1 55.5 110.3 2.0 0.036 
Nol10 nucleolar protein 10 108.1 193.1 1.8 0.036 
Errfi1 
ERBB receptor feedback 
inhibitor 1 307.9 565.9 1.8 0.036 
Zfp606 zinc finger protein 606 215.4 118.9 0.6 0.037 
Tmem41b transmembrane protein 41B 671.4 1121.5 1.7 0.037 
Mum1l1 
melanoma associated antigen 
(mutated) 1-like 1 27.4 162.0 5.9 0.037 
Nedd9 
neural precursor cell 
expressed, developmentally 
down-regulated gene 9 245.1 401.9 1.6 0.038 
Atf3 
activating transcription factor 
3 65.8 1124.3 17.1 0.038 
Vcam1 
vascular cell adhesion 
molecule 1 207.1 354.5 1.7 0.038 
Fam46a 
family with sequence 
similarity 46, member A 858.3 1316.8 1.5 0.038 
Sema6b 
sema domain, 
transmembrane domain 
(TM), and cytoplasmic 
domain, (semaphorin) 6B 161.6 276.9 1.7 0.038 
Bcl9l B cell CLL/lymphoma 9-like 155.5 85.2 0.5 0.038 
Ell2 
elongation factor RNA 
polymerase II 2 256.9 974.6 3.8 0.039 
Cd83 CD83 antigen 39.8 77.8 2.0 0.039 
Bambi 
BMP and activin membrane-
bound inhibitor 83.1 160.1 1.9 0.039 
Pddc1 
Parkinson disease 7 domain 
containing 1 90.0 45.9 0.5 0.039 
178 
	
Kcnb1 
potassium voltage gated 
channel, Shab-related 
subfamily, member 1 792.5 438.7 0.6 0.039 
Dhrs3 
dehydrogenase/reductase 
(SDR family) member 3 
1059.
5 625.6 0.6 0.039 
Fbxo30 F-box protein 30 518.1 903.6 1.7 0.039 
Palm2 paralemmin 2 38.5 73.5 1.9 0.039 
Paqr7 
progestin and adipoQ 
receptor family member VII 81.3 40.0 0.5 0.039 
Etv6 
ets variant gene 6 (TEL 
oncogene) 176.8 286.1 1.6 0.040 
Ctps 
cytidine 5'-triphosphate 
synthase 434.1 757.9 1.7 0.040 
Capn12 calpain 12 66.9 120.5 1.8 0.041 
Il1r1 interleukin 1 receptor, type I 758.5 1275.9 1.7 0.041 
Fam210b 
family with sequence 
similarity 210, member B 106.1 52.9 0.5 0.041 
Zfp266 zinc finger protein 266 667.3 394.5 0.6 0.041 
Has2 hyaluronan synthase 2 8.0 23.5 2.9 0.041 
Map3k13 
mitogen-activated protein 
kinase kinase kinase 13 39.7 13.7 0.3 0.041 
Elovl6 
ELOVL family member 6, 
elongation of long chain fatty 
acids (yeast) 32.9 71.9 2.2 0.041 
Slco2a1 
solute carrier organic anion 
transporter family, member 
2a1 20.2 49.1 2.4 0.042 
Fzd1 
frizzled homolog 1 
(Drosophila) 45.6 92.0 2.0 0.042 
Capn5 calpain 5 14.6 2.7 0.2 0.043 
Cnksr1 
connector enhancer of kinase 
suppressor of Ras 1 63.5 178.8 2.8 0.043 
Kif18a kinesin family member 18A 28.3 10.3 0.4 0.043 
Kcnn2 
potassium intermediate/small 
conductance calcium-
activated channel, subfamily 
N, member 2 126.6 65.1 0.5 0.043 
Inip 
INTS3 and NABP 
interacting protein 108.6 196.5 1.8 0.043 
Cpt1a 
carnitine 
palmitoyltransferase 1a, liver 539.5 272.1 0.5 0.044 
Klf7 
Kruppel-like factor 7 
(ubiquitous) 18.3 46.0 2.5 0.044 
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Srbd1 S1 RNA binding domain 1 63.1 28.7 0.5 0.044 
Phf19 PHD finger protein 19 8.5 0.7 0.1 0.044 
Itga3 integrin alpha 3 53.2 108.0 2.0 0.044 
Frat2 
frequently rearranged in 
advanced T cell lymphomas 
2 20.1 104.8 5.2 0.044 
Ska2 
spindle and kinetochore 
associated complex subunit 2 112.1 61.0 0.5 0.044 
Slc35b2 
solute carrier family 35, 
member B2 103.5 56.2 0.5 0.044 
Ankrd2 
ankyrin repeat domain 2 
(stretch responsive muscle) 0.4 8.7 20.3 0.044 
Ccl11 
chemokine (C-C motif) 
ligand 11 24.9 70.4 2.8 0.045 
Cnst 
consortin, connexin sorting 
protein 824.7 489.0 0.6 0.045 
Kcnq1 
potassium voltage-gated 
channel, subfamily Q, 
member 1 229.2 132.9 0.6 0.045 
Senp7 
SUMO1/sentrin specific 
peptidase 7 302.9 167.7 0.6 0.045 
Tube1 epsilon-tubulin 1 16.3 3.4 0.2 0.045 
Map2k3 
mitogen-activated protein 
kinase kinase 3 386.8 872.0 2.3 0.045 
Adora2b adenosine A2b receptor 35.4 75.9 2.1 0.046 
Ttc30a1 
tetratricopeptide repeat 
domain 30A1 190.4 74.6 0.4 0.046 
Srrm4 
serine/arginine repetitive 
matrix 4 89.9 29.6 0.3 0.046 
Plec plectin 
1082.
3 1976.2 1.8 0.046 
Rad51d RAD51 homolog D 121.2 62.9 0.5 0.046 
Klhl6 kelch-like 6 41.9 94.4 2.3 0.046 
Tcta 
T cell leukemia translocation 
altered gene 274.1 164.3 0.6 0.046 
Sphk1 sphingosine kinase 1 13.4 167.6 12.5 0.046 
Zfp273 zinc finger protein 273 38.0 16.1 0.4 0.047 
Swt1 
SWT1 RNA 
endoribonuclease homolog 
(S. cerevisiae) 142.1 468.2 3.3 0.047 
Ssfa2 sperm specific antigen 2 434.3 653.6 1.5 0.047 
Cd53 CD53 antigen 123.2 220.5 1.8 0.047 
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Sdr42e1 
short chain 
dehydrogenase/reductase 
family 42E, member 1 23.4 7.7 0.3 0.047 
Phlda1 
pleckstrin homology-like 
domain, family A, member 1 115.2 709.7 6.2 0.048 
Zc4h2 
zinc finger, C4H2 domain 
containing 35.5 10.7 0.3 0.048 
Kcnd3 
potassium voltage-gated 
channel, Shal-related family, 
member 3 286.2 160.7 0.6 0.048 
Nme1 
NME/NM23 nucleoside 
diphosphate kinase 1 77.0 137.9 1.8 0.048 
C3ar1 
complement component 3a 
receptor 1 36.3 79.1 2.2 0.048 
Dcbld1 
discoidin, CUB and LCCL 
domain containing 1 65.7 115.2 1.8 0.048 
Zfp944 zinc finger protein 944 150.9 79.9 0.5 0.049 
Bicd1 
bicaudal D homolog 1 
(Drosophila) 179.9 92.5 0.5 0.049 
Dpy19l1 dpy-19-like 1 (C. elegans) 178.1 101.5 0.6 0.049 
Tnfaip6 
tumor necrosis factor alpha 
induced protein 6 52.5 96.2 1.8 0.049 
Hif3a 
hypoxia inducible factor 3, 
alpha subunit 134.4 57.3 0.4 0.049 
Setdb2 SET domain, bifurcated 2 493.6 261.1 0.5 0.049 
Kctd6 
potassium channel 
tetramerisation domain 
containing 6 148.5 407.5 2.7 0.049 
Cc2d2a 
coiled-coil and C2 domain 
containing 2A 109.5 56.6 0.5 0.050 
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APPENDIX B 
RNA-SEQ DATA: GENES WITH DIFFERENTIAL EXPRESSION BETWEEN 
MESECHYMAL STEM CELLS AND THEIR EXOSOMES 
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Symbol Name MSC Exo Fold P 
Rn45s 45S pre-ribosomal RNA 38894.6 
567553
01 1459.207 8.55E-11 
Rpph1 
ribonuclease P RNA 
component H1 1.1 2988.4 2708.797 8.55E-11 
Dnm3os dynamin 3, opposite strand 1044.7 0 0 2.75E-10 
Tm4sf1 
transmembrane 4 
superfamily member 1 977.8 0 0 8.56E-10 
Ogn osteoglycin 4118.7 195.7 0.048 9.25E-10 
Ugcg 
UDP-glucose ceramide 
glucosyltransferase 890.9 0 0 3.96E-09 
Sdc2 syndecan 2 1944.7 67.2 0.035 5.50E-09 
Col6a1 collagen, type VI, alpha 1 3857.1 211.7 0.055 1.33E-08 
Fstl1 follistatin-like 1 4188.7 186.8 0.045 1.38E-08 
Dag1 dystroglycan 1 885.0 2.2 0.003 2.35E-08 
Itgav integrin alpha V 1940.6 62.5 0.032 5.10E-08 
Ogt 
O-linked N-
acetylglucosamine 
(GlcNAc) transferase  2003.1 67.0 0.033 5.10E-08 
Tmem59 transmembrane protein 59 1711.7 46.9 0.027 5.10E-08 
Aspn asporin 723.3 0 0 9.55E-08 
Col4a5 collagen, type IV, alpha 5 713.9 0 0 1.11E-07 
M6pr 
mannose-6-phosphate 
receptor, cation dependent 711.7 0 0 1.11E-07 
Rprl3 ribonuclease P RNA-like 3 0.2 2467.0 10083.803 1.11E-07 
Lamp2 
lysosomal-associated 
membrane protein 2 1846.9 92.3 0.050 3.44E-07 
Cdh2 cadherin 2 1433.9 70.2 0.049 3.44E-07 
Tmed10 
transmembrane emp24-like 
trafficking protein 10 
(yeast) 730.8 3.9 0.005 4.08E-07 
Alpl 
alkaline phosphatase, 
liver/bone/kidney 2259.8 120.5 0.053 9.30E-07 
Aplp2 
amyloid beta (A4) 
precursor-like protein 2 1284.1 35.7 0.028 9.58E-07 
Vcan versican 1401.8 46.9 0.033 1.25E-06 
Adam9 
a disintegrin and 
metallopeptidase domain 9 
(meltrin gamma) 602.9 0 0 1.25E-06 
Hmgcr 3-hydroxy-3- 787.8 6.7 0.009 1.25E-06 
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methylglutaryl-Coenzyme 
A reductase 
Adam10 
a disintegrin and 
metallopeptidase domain 
10 672.9 2.2 0.003 1.27E-06 
Atp6ap2 
ATPase, H+ transporting, 
lysosomal accessory 
protein 2 783.4 6.7 0.009 1.27E-06 
Col1a2 collagen, type I, alpha 2 33716.3 2792.9 0.083 1.27E-06 
Sema3a 
sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3A 596.2 0.0 0.000 1.27E-06 
Postn 
periostin, osteoblast 
specific factor 6227.1 464.9 0.075 1.28E-06 
Ncstn nicastrin 666.6 2.2 0.003 1.31E-06 
Fbln5 fibulin 5 582.2 0 0 1.70E-06 
Dkk3 
dickkopf homolog 3 
(Xenopus laevis) 729.6 0 0 2.01E-06 
Tmx1 
thioredoxin-related 
transmembrane protein 1 572.8 0 0 2.08E-06 
Serinc1 serine incorporator 1 1207.8 60.5 0.050 2.93E-06 
Col5a2 collagen, type V, alpha 2 8519.6 933.6 0.110 2.93E-06 
Fbn2 fibrillin 2 551.7 0 0 3.39E-06 
Derl1 
Der1-like domain family, 
member 1 551.5 0 0 3.39E-06 
Tcf4 transcription factor 4 2834.5 279.2 0.098 5.21E-06 
Pcdh18 protocadherin 18 528.7 0 0 6.18E-06 
Plod2 
procollagen lysine, 2-
oxoglutarate 5-dioxygenase 
2 528.0 0 0 6.18E-06 
Ssr3 
signal sequence receptor, 
gamma 3382.1 394.3 0.117 8.42E-06 
Hspa13 
heat shock protein 70 
family, member 13 515.6 0 0 8.42E-06 
Serinc3 serine incorporator 3 952.7 23.6 0.025 8.67E-06 
Zmpste24 
zinc metallopeptidase, 
STE24 512.3 0 0 8.88E-06 
B3gat2 
beta-1,3-
glucuronyltransferase 2 
(glucuronosyltransferase S) 511.1 0 0 9.00E-06 
Nptn neuroplastin 940.4 24.6 0.026 9.90E-06 
Cpe carboxypeptidase E 3730.2 320.7 0.086 1.02E-05 
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Cpd carboxypeptidase D 800.6 27.5 0.034 1.07E-05 
Cst3 cystatin C 501.6 0 0 1.07E-05 
Mat2a 
methionine 
adenosyltransferase II, 
alpha 1350.7 78.3 0.058 1.07E-05 
Npnt nephronectin 501.1 0 0 1.07E-05 
Cacna2d1 
calcium channel, voltage-
dependent, alpha2/delta 
subunit 1 497.6 0 0 1.15E-05 
Sned1 
sushi, nidogen and EGF-
like domains 1 497.4 0 0 1.15E-05 
Serpinf1 
serine (or cysteine) 
peptidase inhibitor, clade 
F, member 1 2277.6 233.4 0.102 1.56E-05 
Col8a1 collagen, type VIII, alpha 1 478.1 0 0 1.92E-05 
Arsb arylsulfatase B 477.9 0 0 1.92E-05 
Pdia3 
protein disulfide isomerase 
associated 3 2333.5 273.3 0.117 1.92E-05 
Edem3 
ER degradation enhancer, 
mannosidase alpha-like 3 470.1 0 0 2.36E-05 
Tmtc3 
transmembrane and 
tetratricopeptide repeat 
containing 3 466.8 0 0 2.57E-05 
Ikbip IKBKB interacting protein 465.6 0 0 2.62E-05 
Bmpr2 
bone morphogenetic 
protein receptor, type II 
(serine/threonine kinase) 1188.5 55.8 0.047 2.84E-05 
Spcs3 
signal peptidase complex 
subunit 3 homolog (S. 
cerevisiae) 951.0 47.0 0.049 2.88E-05 
Abca5 
ATP-binding cassette, sub-
family A (ABC1), member 
5 454.1 0 0 3.53E-05 
Ccnl2 cyclin L2 740.3 15.6 0.021 3.53E-05 
Ltbp2 
latent transforming growth 
factor beta binding protein 
2 450.5 0 0 3.83E-05 
Abcc5 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 5 448.9 0 0 3.96E-05 
Kif1c kinesin family member 1C 452.9 15529.0 34.291 4.02E-05 
P4ha1 
procollagen-proline, 2-
oxoglutarate 4-dioxygenase 801.1 30.8 0.038 4.45E-05 
185 
	
(proline 4-hydroxylase), 
alpha 1 polypeptide 
Insig1 insulin induced gene 1 431.4 0 0 6.45E-05 
Pdia4 
protein disulfide isomerase 
associated 4 537.8 3.5 0.006 6.45E-05 
Alg10b 
asparagine-linked 
glycosylation 10B (alpha-
1,2-glucosyltransferase) 425.4 0 0 7.57E-05 
Yipf5 
Yip1 domain family, 
member 5 521.8 7.8 0.015 8.53E-05 
Tmed5 
transmembrane emp24 
protein transport domain 
containing 5 686.1 15.6 0.023 9.62E-05 
Vasn vasorin 415.6 0 0 9.88E-05 
Slc12a2 
solute carrier family 12, 
member 2 412.2 0 0 0.0001 
Sc4mol 
sterol-C4-methyl oxidase-
like 410.6 0 0 0.0001 
Rprl2 ribonuclease P RNA-like 2 0.1 1034.8 7049.679 0.0001 
Tspan3 tetraspanin 3 409.4 0 0 0.0001 
Omd osteomodulin 1296.1 144.0 0.111 0.0001 
Lbr lamin B receptor 402.6 0 0 0.0001 
Slc7a6 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 6 400.6 0 0 0.0001 
Pam 
peptidylglycine alpha-
amidating monooxygenase 1357.9 160.8 0.118 0.0002 
Slc38a2 
solute carrier family 38, 
member 2 2069.1 282.5 0.137 0.0002 
Col4a3bp 
collagen, type IV, alpha 3 
(Goodpasture antigen) 
binding protein 391.9 0 0 0.0002 
Dnajc3 
DnaJ (Hsp40) homolog, 
subfamily C, member 3 491.3 3.5 0.007 0.0002 
Tpbg trophoblast glycoprotein 390.3 0 0 0.0002 
Tm9sf2 
transmembrane 9 
superfamily member 2 882.8 72.9 0.083 0.0002 
Zc2hc1a 
zinc finger, C2HC-type 
containing 1A 388.1 0 0 0.0002 
Zmym2 zinc finger, MYM-type 2 384.2 0 0 0.0002 
Tm9sf1 
transmembrane 9 
superfamily member 1 383.6 0 0 0.0002 
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Pmp22 
peripheral myelin protein 
22 415.7 0 0 0.0003 
Timp2 
tissue inhibitor of 
metalloproteinase 2 2705.5 313.4 0.116 0.0003 
Mmp14 
matrix metallopeptidase 14 
(membrane-inserted) 2107.3 243.5 0.116 0.0003 
Bmpr1a 
bone morphogenetic 
protein receptor, type 1A 817.4 18.7 0.023 0.0003 
Pdzd8 PDZ domain containing 8 373.4 0 0 0.0003 
Sgpl1 
sphingosine phosphate 
lyase 1 567.4 11.2 0.020 0.0003 
Vldlr 
very low density 
lipoprotein receptor 371.3 0 0 0.0003 
Hiatl1 
hippocampus abundant 
transcript-like 1 584.4 13.4 0.023 0.0004 
Mkln1 
muskelin 1, intracellular 
mediator containing kelch 
motifs 415.7 3.9 0.009 0.0004 
Elovl5 
ELOVL family member 5, 
elongation of long chain 
fatty acids (yeast) 363.5 0 0 0.0004 
Hist3h2ba histone cluster 3, H2ba 0.0 364.0 Inf 0.0004 
Zkscan3 
zinc finger with KRAB and 
SCAN domains 3 359.3 0 0 0.0004 
Ptprs 
protein tyrosine 
phosphatase, receptor type, 
S 2088.5 155.4 0.074 0.0004 
Degs1 
degenerative spermatocyte 
homolog 1 (Drosophila) 356.1 0 0 0.0005 
Camk2d 
calcium/calmodulin-
dependent protein kinase 
II, delta 354.4 0 0 0.0005 
Hs2st1 
heparan sulfate 2-O-
sulfotransferase 1 351.9 0 0 0.0005 
Rtn4 reticulon 4 2043.5 311.9 0.153 0.0006 
Azi2 
5-azacytidine induced gene 
2 348.2 0 0 0.0006 
Ibsp 
integrin binding 
sialoprotein 503.4 0 0 0.0006 
Lars2 
leucyl-tRNA synthetase, 
mitochondrial 10357.3 
447363
2.4 431.932 0.0007 
Ltbp3 
latent transforming growth 
factor beta binding protein 
3 390.8 3.9 0.010 0.0007 
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Tfrc transferrin receptor 538.1 23.5 0.044 0.0007 
Mbnl1 
muscleblind-like 1 
(Drosophila) 2590.4 347.5 0.134 0.0007 
Emilin2 
elastin microfibril 
interfacer 2 337.8 0 0 0.0008 
Ppap2a 
phosphatidic acid 
phosphatase type 2A 337.4 0 0 0.0008 
Hsp90b1 
heat shock protein 90, beta 
(Grp94), member 1 3479.4 622.8 0.179 0.0008 
Cyb5r3 cytochrome b5 reductase 3 499.2 12797.1 25.634 0.0008 
Thbs1 thrombospondin 1 33026.4 2375.4 0.072 0.0008 
Itpr1 
inositol 1,4,5-trisphosphate 
receptor 1 384.5 2.2 0.006 0.0008 
Col5a1 collagen, type V, alpha 1 2971.7 436.3 0.147 0.0009 
Alb albumin 0.0 213.2 4356.990 0.0009 
Rnf145 ring finger protein 145 330.8 0 0 0.0009 
Srsf10 
serine/arginine-rich 
splicing factor 10 1112.4 88.3 0.079 0.0009 
Pdia6 
protein disulfide isomerase 
associated 6 1370.1 141.4 0.103 0.0009 
Mir3064 microRNA 3064 328.9 0 0 0.0009 
Sypl synaptophysin-like protein 328.8 0 0 0.0009 
Satb2 
special AT-rich sequence 
binding protein 2 326.5 0 0 0.0010 
Slc41a2 
solute carrier family 41, 
member 2 325.1 0 0 0.0010 
Clk1 CDC-like kinase 1 891.6 91.3 0.102 0.0011 
Man2a1 mannosidase 2, alpha 1 806.4 46.9 0.058 0.0012 
St3gal5 
ST3 beta-galactoside 
alpha-2,3-sialyltransferase 
5 321.1 0 0 0.0012 
Acp2 
acid phosphatase 2, 
lysosomal 321.0 0 0 0.0012 
Col12a1 collagen, type XII, alpha 1 10271.0 494.7 0.048 0.0012 
Tia1 
cytotoxic granule-
associated RNA binding 
protein 1 579.2 20.1 0.035 0.0014 
Hspa5 heat shock protein 5 2652.4 340.5 0.128 0.0014 
Atp6ap1 
ATPase, H+ transporting, 
lysosomal accessory 
protein 1 315.0 0 0 0.0014 
Ssr1 
signal sequence receptor, 
alpha 1244.7 152.1 0.122 0.0014 
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Epm2aip1 
EPM2A (laforin) 
interacting protein 1 771.6 44.6 0.058 0.0015 
Heatr5a 
HEAT repeat containing 
5A 529.7 15.6 0.030 0.0015 
Btbd7 
BTB (POZ) domain 
containing 7 311.2 0.0 0.000 0.0015 
Slc35b4 
solute carrier family 35, 
member B4 310.2 0.0 0.000 0.0016 
Lrrcc1 
leucine rich repeat and 
coiled-coil domain 
containing 1 946.0 118.7 0.126 0.0016 
Ubn2 ubinuclein 2 857.5 91.3 0.106 0.0016 
Fam3c 
family with sequence 
similarity 3, member C 308.5 0 0 0.0016 
Ece1 
endothelin converting 
enzyme 1 307.9 0 0 0.0016 
Mgea5 
meningioma expressed 
antigen 5 (hyaluronidase) 585.6 22.3 0.038 0.0017 
Ift80 intraflagellar transport 80 305.4 0 0 0.0018 
Pgrmc1 
progesterone receptor 
membrane component 1 960.3 75.6 0.079 0.0018 
Otud4 OTU domain containing 4 823.3 78.3 0.095 0.0018 
Ndnf 
neuron-derived 
neurotrophic factor 302.7 0.0 0.000 0.0019 
Zfp36l1 
zinc finger protein 36, C3H 
type-like 1 1023.5 110.8 0.108 0.0020 
Adamts9 
a disintegrin-like and 
metallopeptidase 
(reprolysin type) with 
thrombospondin type 1 
motif, 9 301.1 0 0 0.0020 
Hsd17b12 
hydroxysteroid (17-beta) 
dehydrogenase 12 300.8 0 0 0.0020 
Dnajc10 
DnaJ (Hsp40) homolog, 
subfamily C, member 10 1049.2 93.8 0.089 0.0021 
Tmx3 
thioredoxin-related 
transmembrane protein 3 662.3 33.5 0.051 0.0021 
Itgb1 
integrin beta 1 (fibronectin 
receptor beta) 4483.4 557.1 0.124 0.0021 
Bmp1 
bone morphogenetic 
protein 1 642.5 31.3 0.049 0.0021 
Insig2 insulin induced gene 2 343.6 2.2 0.006 0.0022 
Tmem2 transmembrane protein 2 705.3 78.5 0.111 0.0022 
Rcn2 reticulocalbin 2 605.4 26.8 0.044 0.0022 
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Cd44 CD44 antigen 1509.0 130.7 0.087 0.0022 
Morf4l1 mortality factor 4 like 1 3209.2 810.9 0.253 0.0022 
Asah1 
N-acylsphingosine 
amidohydrolase 1 407.3 6.7 0.016 0.0022 
Heatr1 HEAT repeat containing 1 294.6 0.0 0.000 0.0023 
Gas1 growth arrest specific 1 741.5 71.1 0.096 0.0023 
Man1a2 
mannosidase, alpha, class 
1A, member 2 822.0 57.1 0.069 0.0023 
Cnst 
consortin, connexin sorting 
protein 292.9 0 0 0.0024 
Rab11a 
RAB11a, member RAS 
oncogene family 292.5 0 0 0.0024 
Gja1 
gap junction protein, alpha 
1 649.7 33.5 0.052 0.0024 
Tmem30a 
transmembrane protein 
30A 1503.9 94.7 0.063 0.0024 
Map3k2 
mitogen-activated protein 
kinase kinase kinase 2 694.8 78.5 0.113 0.0024 
Ids iduronate 2-sulfatase 881.8 104.1 0.118 0.0024 
Sdc3 syndecan 3 1050.3 114.0 0.109 0.0024 
Hmgcs1 
3-hydroxy-3-
methylglutaryl-Coenzyme 
A synthase 1 999.2 134.9 0.135 0.0025 
Slc30a7 
solute carrier family 30 
(zinc transporter), member 
7 399.2 9.1 0.023 0.0025 
Aebp2 AE binding protein 2 917.4 75.9 0.083 0.0026 
Cav2 caveolin 2 535.8 20.1 0.037 0.0026 
Cd164 CD164 antigen 1300.9 121.9 0.094 0.0026 
Ptx3 pentraxin related gene 700.3 13.4 0.019 0.0026 
Xiap 
X-linked inhibitor of 
apoptosis 674.0 38.0 0.056 0.0026 
Fads3 fatty acid desaturase 3 284.3 0.0 0.000 0.0030 
Slc35f5 
solute carrier family 35, 
member F5 284.1 0.0 0.000 0.0030 
Pcdh19 protocadherin 19 538.1 30.8 0.057 0.0030 
Ap4e1 
adaptor-related protein 
complex AP-4, epsilon 1 283.5 0.0 0.000 0.0030 
Hist1h2bn histone cluster 1, H2bn 20.7 1199.5 57.977 0.0030 
Calu calumenin 4266.0 900.4 0.211 0.0031 
Ltbp1 
latent transforming growth 
factor beta binding protein 1928.3 224.3 0.116 0.0032 
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1 
Tmem106b 
transmembrane protein 
106B 1089.0 57.3 0.053 0.0032 
Itm2a 
integral membrane protein 
2A 688.7 42.4 0.062 0.0033 
Papd5 
PAP associated domain 
containing 5 279.7 0 0 0.0033 
Fmod fibromodulin 279.7 0 0 0.0033 
Serpinh1 
serine (or cysteine) 
peptidase inhibitor, clade 
H, member 1 1558.3 185.2 0.119 0.0033 
Sh3bp4 
SH3-domain binding 
protein 4 278.7 0 0 0.0034 
Plxna2 plexin A2 277.8 0 0 0.0035 
Lmbrd1 
LMBR1 domain containing 
1 354.1 4.5 0.013 0.0037 
A730098P
11Rik 
mortality factor 4 like 1 
pseudogene 2809.8 733.1 0.261 0.0037 
Wnt10b 
wingless related MMTV 
integration site 10b 274.9 0 0 0.0038 
Cpne3 copine III 351.7 4.5 0.013 0.0039 
Fkbp10 FK506 binding protein 10 951.4 89.3 0.094 0.0039 
Gfra2 
glial cell line derived 
neurotrophic factor family 
receptor alpha 2 271.6 0 0 0.0042 
Prosc 
proline synthetase co-
transcribed 269.4 0 0 0.0045 
Rab2a 
RAB2A, member RAS 
oncogene family 1189.9 133.5 0.112 0.0046 
Atp2b1 
ATPase, Ca++ 
transporting, plasma 
membrane 1 773.1 60.3 0.078 0.0047 
Timp3 
tissue inhibitor of 
metalloproteinase 3 2185.4 359.1 0.164 0.0049 
Csgalnact
2 
chondroitin sulfate N-
acetylgalactosaminyltransf
erase 2 265.2 0 0 0.0051 
Runx2 
runt related transcription 
factor 2 1111.0 188.6 0.170 0.0051 
Mme 
membrane metallo 
endopeptidase 1096.1 122.8 0.112 0.0051 
Ptgs2 
prostaglandin-
endoperoxide synthase 2 264.4 0.0 0.000 0.0052 
191 
	
Ddx17 
DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 17 2290.9 391.6 0.171 0.0052 
Hist1h2bg histone cluster 1, H2bg 33.3 1521.6 45.678 0.0053 
Prpf39 
PRP39 pre-mRNA 
processing factor 39 
homolog (yeast) 722.3 53.6 0.074 0.0053 
Ssr2 
signal sequence receptor, 
beta 456.0 15.6 0.034 0.0054 
Smurf2 
SMAD specific E3 
ubiquitin protein ligase 2 413.3 11.2 0.027 0.0055 
Arl6ip5 
ADP-ribosylation factor-
like 6 interacting protein 5 453.7 15.6 0.034 0.0056 
Ankle2 
ankyrin repeat and LEM 
domain containing 2 260.9 0 0 0.0056 
Tnfrsf11b 
tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin) 260.8 0 0 0.0056 
Npc1 Niemann Pick type C1 260.5 0 0 0.0057 
Zfyve16 
zinc finger, FYVE domain 
containing 16 260.1 0 0 0.0057 
Lman1 lectin, mannose-binding, 1 1058.9 194.3 0.184 0.0059 
Tm2d1 TM2 domain containing 1 450.7 15.6 0.035 0.0059 
Larp4 
La ribonucleoprotein 
domain family, member 4 850.3 78.1 0.092 0.0059 
Man2a2 mannosidase 2, alpha 2 258.8 0 0 0.0059 
Fam134a 
family with sequence 
similarity 134, member A 257.6 0 0 0.0061 
Sppl2a 
signal peptide peptidase 
like 2A 655.5 44.6 0.068 0.0061 
Map4k3 
mitogen-activated protein 
kinase kinase kinase kinase 
3 406.0 11.2 0.027 0.0063 
Hist1h2bj histone cluster 1, H2bj 13.9 821.4 59.233 0.0063 
Yipf4 
Yip1 domain family, 
member 4 706.5 53.6 0.076 0.0063 
Kdelr3 
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum 
protein retention receptor 3 255.9 0.0 0.000 0.0064 
Sh3pxd2a SH3 and PX domains 2A 881.3 9843.8 11.170 0.0065 
15-Sep selenoprotein 828.0 75.9 0.092 0.0065 
Itm2c 
integral membrane protein 
2C 689.4 51.3 0.074 0.0066 
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Ptgfrn 
prostaglandin F2 receptor 
negative regulator 253.6 0.0 0.000 0.0068 
Hspg2 
perlecan (heparan sulfate 
proteoglycan 2) 3331.4 521.8 0.157 0.0070 
Prelp 
proline arginine-rich end 
leucine-rich repeat 252.5 0 0 0.0070 
Col15a1 collagen, type XV, alpha 1 251.5 0 0 0.0072 
Fnbp4 formin binding protein 4 251.2 0 0 0.0072 
Med12 
mediator of RNA 
polymerase II transcription, 
subunit 12 homolog (yeast) 324.5 4.5 0.014 0.0072 
Nipbl 
Nipped-B homolog 
(Drosophila) 935.9 146.1 0.156 0.0073 
Cers6 ceramide synthase 6 250.7 0 0 0.0073 
Nedd9 
neural precursor cell 
expressed, 
developmentally down-
regulated gene 9 250.4 0 0 0.0073 
Slc4a7 
solute carrier family 4, 
sodium bicarbonate 
cotransporter, member 7 473.7 39.2 0.083 0.0074 
Tmem57 transmembrane protein 57 249.2 0.0 0.000 0.0075 
Snx14 sorting nexin 14 249.0 0.0 0.000 0.0076 
Rad21 
RAD21 homolog (S. 
pombe) 1815.4 283.4 0.156 0.0078 
Stt3b 
STT3, subunit of the 
oligosaccharyltransferase 
complex, homolog B (S. 
cerevisiae) 908.1 96.0 0.106 0.0081 
Txndc16 
thioredoxin domain 
containing 16 246.3 0.0 0.000 0.0082 
Gabbr1 
gamma-aminobutyric acid 
(GABA) B receptor, 1 246.2 0.0 0.000 0.0082 
Anapc1 
anaphase promoting 
complex subunit 1 1185.3 156.3 0.132 0.0083 
Enpp2 
ectonucleotide 
pyrophosphatase/phosphod
iesterase 2 375.3 3.9 0.010 0.0083 
Plat 
plasminogen activator, 
tissue 245.4 0.0 0.000 0.0084 
Ptprd 
protein tyrosine 
phosphatase, receptor type, 
D 621.8 83.7 0.135 0.0084 
Colec12 collectin sub-family 1312.4 297.4 0.227 0.0087 
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member 12 
Myadm 
myeloid-associated 
differentiation marker 591.6 48.6 0.082 0.0087 
Zdhhc20 
zinc finger, DHHC domain 
containing 20 480.8 40.5 0.084 0.0087 
Laptm4a 
lysosomal-associated 
protein transmembrane 4A 1423.3 216.0 0.152 0.0089 
Hip1 
huntingtin interacting 
protein 1 478.1 22.3 0.047 0.0090 
Ddhd2 
DDHD domain containing 
2 241.6 0.0 0.000 0.0093 
Nrp2 neuropilin 2 2332.4 118.3 0.051 0.0094 
Gns 
glucosamine (N-acetyl)-6-
sulfatase 739.8 86.1 0.116 0.0094 
Pigs 
phosphatidylinositol glycan 
anchor biosynthesis, class 
S 240.6 0.0 0.000 0.0096 
Gclc 
glutamate-cysteine ligase, 
catalytic subunit 356.3 14.0 0.039 0.0097 
Itga1 integrin alpha 1 239.9 0.0 0.000 0.0097 
Mtdh metadherin 1931.4 261.1 0.135 0.0099 
Lgmn legumain 472.4 22.3 0.047 0.0099 
Mfsd1 
major facilitator 
superfamily domain 
containing 1 547.7 66.7 0.122 0.0099 
Lnp limb and neural patterns 238.9 0.0 0.000 0.0099 
Rassf3 
Ras association 
(RalGDS/AF-6) domain 
family member 3 89.3 1933.9 21.664 0.0099 
Lats1 large tumor suppressor 471.7 22.3 0.047 0.0099 
Ttc14 
tetratricopeptide repeat 
domain 14 703.5 60.3 0.086 0.0099 
Cenpb centromere protein B 302.5 6595.3 21.801 0.0099 
Tmem127 transmembrane protein 127 238.5 0.0 0.000 0.0099 
Mmp16 matrix metallopeptidase 16 238.5 0.0 0.000 0.0099 
Tgfbr2 
transforming growth factor, 
beta receptor II 567.9 44.7 0.079 0.0099 
Cln5 
ceroid-lipofuscinosis, 
neuronal 5 237.8 0.0 0.000 0.0100 
Pdgfrb 
platelet derived growth 
factor receptor, beta 
polypeptide 966.8 149.3 0.154 0.0100 
Alcam activated leukocyte cell 237.7 0.0 0.000 0.0100 
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adhesion molecule 
Ep400 E1A binding protein p400 485.5 24.6 0.051 0.0100 
Fbxo33 F-box protein 33 237.5 0.0 0.000 0.0100 
Dlx5 distal-less homeobox 5 237.3 0.0 0.000 0.0100 
Antxr1 anthrax toxin receptor 1 1148.8 116.3 0.101 0.0100 
Slc35e1 
solute carrier family 35, 
member E1 236.9 0.0 0.000 0.0101 
Hist1h2bh histone cluster 1, H2bh 20.3 919.1 45.229 0.0103 
Ano6 anoctamin 6 563.5 58.8 0.104 0.0107 
6720401G
13Rik 
RIKEN cDNA 
6720401G13 gene 234.5 0.0 0.000 0.0109 
Csnk2a2 
casein kinase 2, alpha 
prime polypeptide 234.5 0.0 0.000 0.0109 
Ccnt2 cyclin T2 234.4 0.0 0.000 0.0109 
Zbtb7a 
zinc finger and BTB 
domain containing 7a 233.9 0.0 0.000 0.0110 
Laptm4b 
lysosomal-associated 
protein transmembrane 4B 496.1 54.9 0.111 0.0119 
Gpc6 glypican 6 678.5 44.6 0.066 0.0119 
Rbbp6 
retinoblastoma binding 
protein 6 468.0 13.4 0.029 0.0119 
Marcks 
myristoylated alanine rich 
protein kinase C substrate 4577.6 1038.1 0.227 0.0119 
Man1b1 
mannosidase, alpha, class 
1B, member 1 230.2 0.0 0.000 0.0124 
Gpc4 glypican 4 472.5 24.6 0.052 0.0124 
Hiat1 
hippocampus abundant 
gene transcript 1 229.5 0.0 0.000 0.0126 
Dhx33 
DEAH (Asp-Glu-Ala-His) 
box polypeptide 33 339.8 15.7 0.046 0.0127 
Cnot8 
CCR4-NOT transcription 
complex, subunit 8 228.4 0.0 0.000 0.0131 
Rpn1 ribophorin I 831.3 104.6 0.126 0.0131 
Soat1 sterol O-acyltransferase 1 403.3 15.6 0.039 0.0132 
Cdk2 cyclin-dependent kinase 2 227.0 0.0 0.000 0.0136 
Cyth3 cytohesin 3 226.9 0.0 0.000 0.0136 
Derl2 
Der1-like domain family, 
member 2 226.0 0.0 0.000 0.0140 
Dcaf8 
DDB1 and CUL4 
associated factor 8 449.7 22.3 0.050 0.0140 
Cdh11 cadherin 11 1321.5 147.1 0.111 0.0140 
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Sec61a1 
Sec61 alpha 1 subunit (S. 
cerevisiae) 925.9 113.9 0.123 0.0140 
Olfml2b olfactomedin-like 2B 595.6 66.0 0.111 0.0140 
Zbed6 
zinc finger, BED domain 
containing 6 912.0 125.7 0.138 0.0142 
Vcl vinculin 2535.0 489.8 0.193 0.0142 
Hist1h2be histone cluster 1, H2be 35.7 1478.3 41.414 0.0147 
Syvn1 
synovial apoptosis 
inhibitor 1, synoviolin 223.8 0.0 0.000 0.0148 
Tmco1 
transmembrane and coiled-
coil domains 1 316.4 6.7 0.021 0.0149 
Ccne2 cyclin E2 223.1 0.0 0.000 0.0151 
Hist1h2bb histone cluster 1, H2bb 12.6 786.5 62.499 0.0156 
Nrp1 neuropilin 1 534.6 58.8 0.110 0.0159 
Fmnl2 formin-like 2 221.0 0.0 0.000 0.0160 
Fn1 fibronectin 1 23220.2 4837.4 0.208 0.0160 
Tlr2 toll-like receptor 2 220.8 0.0 0.000 0.0160 
Mpc2 
mitochondrial pyruvate 
carrier 2 220.5 0.0 0.000 0.0162 
Tmem19 transmembrane protein 19 220.3 0.0 0.000 0.0162 
Vaultrc5 vault RNA component 5 0.0 358.4 Inf 0.0164 
Ubr3 
ubiquitin protein ligase E3 
component n-recognin 3 777.5 83.8 0.108 0.0164 
Fam160b1 
family with sequence 
similarity 160, member B1 219.7 0.0 0.000 0.0164 
Sun1 
Sad1 and UNC84 domain 
containing 1 423.6 20.1 0.047 0.0164 
Rmnd5a 
required for meiotic 
nuclear division 5 homolog 
A (S. cerevisiae) 584.0 91.5 0.157 0.0167 
B3galtl 
beta 1,3-
galactosyltransferase-like 218.9 0.0 0.000 0.0167 
Piezo1 
piezo-type 
mechanosensitive ion 
channel component 1 632.6 55.8 0.088 0.0167 
Cd109 CD109 antigen 452.8 24.6 0.054 0.0167 
Eif4enif1 
eukaryotic translation 
initiation factor 4E nuclear 
import factor 1 218.7 0.0 0.000 0.0167 
Fnip1 
folliculin interacting 
protein 1 650.8 77.7 0.119 0.0167 
Dlg1 
discs, large homolog 1 
(Drosophila) 590.1 70.0 0.119 0.0167 
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Hexa hexosaminidase A 218.5 0.0 0.000 0.0167 
Zfx 
zinc finger protein X-
linked 770.5 84.8 0.110 0.0171 
Mbnl2 muscleblind-like 2 1271.9 257.6 0.203 0.0175 
Nfib nuclear factor I/B 1102.7 184.3 0.167 0.0175 
Ecm1 
extracellular matrix protein 
1 216.3 0.0 0.000 0.0179 
Dzip3 
DAZ interacting protein 3, 
zinc finger 466.6 54.9 0.118 0.0181 
Arf2 ADP-ribosylation factor 2 215.8 0.0 0.000 0.0181 
Gpr176 
G protein-coupled receptor 
176 253.3 2.2 0.009 0.0181 
Casd1 CAS1 domain containing 1 215.5 0.0 0.000 0.0182 
Rsbn1 
rosbin, round spermatid 
basic protein 1 215.4 0.0 0.000 0.0183 
Ttyh3 
tweety homolog 3 
(Drosophila) 215.3 0.0 0.000 0.0183 
Zc3h11a 
zinc finger CCCH type 
containing 11A 1124.1 121.3 0.108 0.0183 
Ppib peptidylprolyl isomerase B 651.9 94.0 0.144 0.0184 
Zdhhc17 
zinc finger, DHHC domain 
containing 17 214.7 0.0 0.000 0.0184 
Hexb hexosaminidase B 214.7 0.0 0.000 0.0184 
Adnp 
activity-dependent 
neuroprotective protein 473.8 29.0 0.061 0.0184 
Col6a3 collagen, type VI, alpha 3 2169.4 228.2 0.105 0.0184 
Dsel 
dermatan sulfate 
epimerase-like 214.3 0.0 0.000 0.0186 
Angptl4 angiopoietin-like 4 251.7 1.2 0.005 0.0192 
Hist1h2bk histone cluster 1, H2bk 23.0 1346.0 58.588 0.0194 
Nup155 nucleoporin 155 715.1 75.9 0.106 0.0196 
Lgr4 
leucine-rich repeat-
containing G protein-
coupled receptor 4 212.0 0.0 0.000 0.0199 
Gxylt2 
glucoside 
xylosyltransferase 2 211.8 0.0 0.000 0.0200 
Prrx1 paired related homeobox 1 3175.9 633.5 0.199 0.0200 
Naa25 
N(alpha)-acetyltransferase 
25, NatB auxiliary subunit 211.6 0.0 0.000 0.0201 
Kdelc1 
KDEL (Lys-Asp-Glu-Leu) 
containing 1 211.5 0.0 0.000 0.0201 
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Trpm7 
transient receptor potential 
cation channel, subfamily 
M, member 7 742.7 82.6 0.111 0.0201 
Qsox1 
quiescin Q6 sulfhydryl 
oxidase 1 575.2 68.3 0.119 0.0202 
Slc35a1 
solute carrier family 35 
(CMP-sialic acid 
transporter), member 1 211.1 0.0 0.000 0.0202 
C1s 
complement component 1, 
s subcomponent 300.6 6.7 0.022 0.0202 
Pcolce 
procollagen C-
endopeptidase enhancer 
protein 775.5 146.1 0.188 0.0202 
Sgms1 sphingomyelin synthase 1 210.5 0.0 0.000 0.0206 
Senp7 
SUMO1/sentrin specific 
peptidase 7 210.2 0.0 0.000 0.0207 
Tiparp 
TCDD-inducible 
poly(ADP-ribose) 
polymerase 209.2 0.0 0.000 0.0214 
Klf3 
Kruppel-like factor 3 
(basic) 208.9 0.0 0.000 0.0216 
Col11a1 collagen, type XI, alpha 1 208.6 0.0 0.000 0.0218 
Tor1aip2 
torsin A interacting protein 
2 893.1 147.0 0.165 0.0220 
Cd47 
CD47 antigen (Rh-related 
antigen, integrin-associated 
signal transducer) 317.5 8.9 0.028 0.0222 
Tmem245 transmembrane protein 245 321.1 5.0 0.016 0.0224 
Ski 
ski sarcoma viral oncogene 
homolog (avian) 505.0 45.1 0.089 0.0225 
Lamc1 laminin, gamma 1 849.0 70.7 0.083 0.0228 
Dedd 
death effector domain-
containing 271.0 4.5 0.016 0.0230 
Mylip 
myosin regulatory light 
chain interacting protein 206.4 0.0 0.000 0.0231 
Eya4 
eyes absent 4 homolog 
(Drosophila) 430.6 24.6 0.057 0.0233 
Cers5 ceramide synthase 5 205.7 0.0 0.000 0.0236 
Mark3 
MAP/microtubule affinity-
regulating kinase 3 325.5 19.6 0.060 0.0236 
Ext2 exostoses (multiple) 2 205.5 0.0 0.000 0.0236 
Sparc 
secreted acidic cysteine 
rich glycoprotein 12720.9 3340.4 0.263 0.0236 
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Hs6st2 
heparan sulfate 6-O-
sulfotransferase 2 333.5 11.2 0.033 0.0236 
Smap1 
stromal membrane-
associated protein 1 611.4 58.0 0.095 0.0236 
Ergic1 
endoplasmic reticulum-
golgi intermediate 
compartment (ERGIC) 1 507.6 38.0 0.075 0.0236 
Tcea1 
transcription elongation 
factor A (SII) 1 1704.9 448.7 0.263 0.0240 
Prpf40a 
PRP40 pre-mRNA 
processing factor 40 
homolog A (yeast) 1265.1 278.0 0.220 0.0241 
Tmem50a 
transmembrane protein 
50A 368.7 31.4 0.085 0.0245 
Prdx4 peroxiredoxin 4 631.4 60.5 0.096 0.0245 
Plxna3 plexin A3 203.7 0.0 0.000 0.0245 
Clcn7 chloride channel 7 203.7 0.0 0.000 0.0245 
Sun2 
Sad1 and UNC84 domain 
containing 2 585.2 53.6 0.092 0.0246 
Rbm12b2 
RNA binding motif protein 
12 B2 202.7 0.0 0.000 0.0252 
Sfrp2 
secreted frizzled-related 
protein 2 16768.7 309.5 0.018 0.0252 
Rprd1a 
regulation of nuclear pre-
mRNA domain containing 
1A 266.3 4.5 0.017 0.0252 
Ahr aryl-hydrocarbon receptor 201.9 0.0 0.000 0.0258 
Tmem168 transmembrane protein 168 201.7 0.0 0.000 0.0260 
Erp44 
endoplasmic reticulum 
protein 44 310.0 7.9 0.026 0.0260 
Igf2bp3 
insulin-like growth factor 2 
mRNA binding protein 3 201.3 0.0 0.000 0.0262 
Hist1h3e histone cluster 1, H3e 3.6 841.7 234.947 0.0264 
Dhx36 
DEAH (Asp-Glu-Ala-His) 
box polypeptide 36 637.3 84.4 0.132 0.0267 
Pros1 protein S (alpha) 528.2 63.8 0.121 0.0267 
Pappa2 pappalysin 2 424.9 51.0 0.120 0.0272 
Lpin2 lipin 2 199.8 0.0 0.000 0.0273 
Ppp3cb 
protein phosphatase 3, 
catalytic subunit, beta 
isoform 446.3 29.0 0.065 0.0273 
Zfp281 zinc finger protein 281 263.5 3.5 0.013 0.0274 
Lifr leukemia inhibitory factor 1265.4 253.0 0.200 0.0274 
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receptor 
Ccl7 
chemokine (C-C motif) 
ligand 7 258.3 0.0 0.000 0.0278 
Pole 
polymerase (DNA 
directed), epsilon 199.0 0.0 0.000 0.0278 
Spcs2 
signal peptidase complex 
subunit 2 homolog (S. 
cerevisiae) 198.9 0.0 0.000 0.0278 
Nxf1 
nuclear RNA export factor 
1 430.2 26.8 0.062 0.0285 
Slc30a5 
solute carrier family 30 
(zinc transporter), member 
5 415.9 24.6 0.059 0.0288 
Emc1 
ER membrane protein 
complex subunit 1 432.0 54.9 0.127 0.0288 
Nov 
nephroblastoma 
overexpressed gene 362.2 0.0 0.000 0.0294 
Ccdc88a 
coiled coil domain 
containing 88A 972.3 192.3 0.198 0.0294 
Tbk1 TANK-binding kinase 1 355.0 15.6 0.044 0.0297 
Fam114a1 
family with sequence 
similarity 114, member A1 513.1 42.4 0.083 0.0300 
Rtf1 
Rtf1, Paf1/RNA 
polymerase II complex 
component, homolog (S. 
cerevisiae) 408.8 44.4 0.109 0.0303 
Sp7 Sp7 transcription factor 7 195.9 0.0 0.000 0.0304 
Dpy19l4 dpy-19-like 4 (C. elegans) 195.3 0.0 0.000 0.0310 
Iars2 
isoleucine-tRNA 
synthetase 2, mitochondrial 450.1 31.3 0.069 0.0313 
Zfp948 zinc finger protein 948 194.9 0.0 0.000 0.0314 
Gpc1 glypican 1 724.3 88.3 0.122 0.0317 
Mzt1 
mitotic spindle organizing 
protein 1 391.2 43.2 0.110 0.0318 
Zfp955a zinc finger protein 955A 194.0 0.0 0.000 0.0321 
Atp13a1 ATPase type 13A1 193.5 0.0 0.000 0.0326 
Preb 
prolactin regulatory 
element binding 193.4 0.0 0.000 0.0326 
Eml4 
echinoderm microtubule 
associated protein like 4 394.1 22.3 0.057 0.0327 
Cd63 CD63 antigen 972.9 154.0 0.158 0.0329 
Mid2 midline 2 191.2 0.0 0.000 0.0351 
Serinc5 serine incorporator 5 191.1 0.0 0.000 0.0352 
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Kdm6a 
lysine (K)-specific 
demethylase 6A 191.0 0.0 0.000 0.0353 
Pdgfa 
platelet derived growth 
factor, alpha 190.5 0.0 0.000 0.0359 
Fzd1 
frizzled homolog 1 
(Drosophila) 216.8 0.0 0.000 0.0360 
Tomm22 
translocase of outer 
mitochondrial membrane 
22 homolog (yeast) 477.0 38.0 0.080 0.0360 
Ppp1cb 
protein phosphatase 1, 
catalytic subunit, beta 
isoform 3189.7 903.2 0.283 0.0368 
Afg3l2 
AFG3(ATPase family gene 
3)-like 2 (yeast) 189.4 0.0 0.000 0.0371 
Slc7a2 
solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 2 270.5 8.4 0.031 0.0374 
Fubp1 
far upstream element 
(FUSE) binding protein 1 600.8 114.3 0.190 0.0376 
Rer1 
RER1 retention in 
endoplasmic reticulum 1 
homolog (S. cerevisiae) 431.6 38.0 0.088 0.0376 
Crim1 
cysteine rich 
transmembrane BMP 
regulator 1 (chordin like) 309.1 11.2 0.036 0.0382 
Pdp1 
pyruvate dehyrogenase 
phosphatase catalytic 
subunit 1 188.3 0.0 0.000 0.0382 
Tfb2m 
transcription factor B2, 
mitochondrial 188.2 0.0 0.000 0.0382 
Ubtd2 
ubiquitin domain 
containing 2 371.4 20.1 0.054 0.0382 
Dnaja1 
DnaJ (Hsp40) homolog, 
subfamily A, member 1 1027.1 204.2 0.199 0.0382 
Nisch nischarin 1655.6 300.6 0.182 0.0382 
Sp1 
trans-acting transcription 
factor 1 664.6 82.3 0.124 0.0385 
Erlin1 ER lipid raft associated 1 187.5 0.0 0.000 0.0388 
Lox lysyl oxidase 12316.7 1966.6 0.160 0.0389 
Hist1h2bq histone cluster 1, H2bq 68.0 2861.1 42.075 0.0389 
Hist1h2br histone cluster 1 H2br 68.0 2861.1 42.075 0.0389 
Arhgap29 
Rho GTPase activating 
protein 29 191.3 0.0 0.000 0.0389 
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BC016423 
cDNA sequence 
BC016423 488.1 74.0 0.151 0.0389 
Ccnh cyclin H 186.4 0.0 0.000 0.0398 
Neto2 
neuropilin (NRP) and 
tolloid (TLL)-like 2 186.1 0.0 0.000 0.0402 
Hist1h3a histone cluster 1, H3a 4.1 677.8 166.280 0.0410 
Zdhhc8 
zinc finger, DHHC domain 
containing 8 185.5 0.0 0.000 0.0410 
Tmed2 
transmembrane emp24 
domain trafficking protein 
2 1256.9 378.5 0.301 0.0410 
Edem1 
ER degradation enhancer, 
mannosidase alpha-like 1 476.4 68.3 0.143 0.0412 
Usp10 
ubiquitin specific peptidase 
10 185.1 0.0 0.000 0.0412 
Dock5 dedicator of cytokinesis 5 276.2 0.0 0.000 0.0413 
Csf1 
colony stimulating factor 1 
(macrophage) 1142.6 134.0 0.117 0.0413 
Vps37a 
vacuolar protein sorting 
37A (yeast) 320.6 13.4 0.042 0.0413 
Galnt13 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide 
N-
acetylgalactosaminyltransf
erase 13 320.5 13.4 0.042 0.0413 
Fth1 ferritin heavy chain 1 1570.2 11992.4 7.637 0.0413 
Sp8 
trans-acting transcription 
factor 8 184.6 0.0 0.000 0.0413 
Snrk SNF related kinase 184.6 0.0 0.000 0.0413 
Ifnar1 
interferon (alpha and beta) 
receptor 1 245.4 3.5 0.014 0.0413 
Thbs2 thrombospondin 2 4566.0 470.4 0.103 0.0413 
Tmem184b 
transmembrane protein 
184b 184.4 0.0 0.000 0.0415 
Angptl2 angiopoietin-like 2 441.6 33.5 0.076 0.0415 
Fzd5 
frizzled homolog 5 
(Drosophila) 496.8 58.7 0.118 0.0416 
Hist1h2bf histone cluster 1, H2bf 18.0 871.8 48.557 0.0418 
Naa15 
N(alpha)-acetyltransferase 
15, NatA auxiliary subunit 1219.0 252.4 0.207 0.0418 
Met met proto-oncogene 183.6 0.0 0.000 0.0423 
Ufl1 UFM1 specific ligase 1 183.4 0.0 0.000 0.0426 
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Kctd10 
potassium channel 
tetramerisation domain 
containing 10 968.9 10082.6 10.407 0.0428 
Smad7 SMAD family member 7 183.1 0.0 0.000 0.0429 
Tm9sf4 
transmembrane 9 
superfamily protein 
member 4 183.0 0.0 0.000 0.0430 
Phf20l1 
PHD finger protein 20-like 
1 400.9 26.8 0.067 0.0441 
BC030336 
cDNA sequence 
BC030336 182.2 0.0 0.000 0.0441 
Lphn2 latrophilin 2 413.1 29.0 0.070 0.0442 
Tmem18 transmembrane protein 18 182.0 0.0 0.000 0.0442 
B4galt6 
UDP-Gal:betaGlcNAc beta 
1,4-galactosyltransferase, 
polypeptide 6 181.8 0.0 0.000 0.0445 
Col4a2 collagen, type IV, alpha 2 181.7 0.0 0.000 0.0445 
Gtf3a 
general transcription factor 
III A 181.6 0.0 0.000 0.0445 
Sepp1 selenoprotein P, plasma, 1 384.9 41.0 0.107 0.0453 
Maf 
avian musculoaponeurotic 
fibrosarcoma (v-maf) 
AS42 oncogene homolog 502.1 44.6 0.089 0.0453 
Inpp5b 
inositol polyphosphate-5-
phosphatase B 181.0 0.0 0.000 0.0453 
D4Wsu53e 
DNA segment, Chr 4, 
Wayne State University 53, 
expressed 599.8 69.2 0.115 0.0460 
Crtap cartilage associated protein 561.7 95.7 0.170 0.0460 
AU040320 
expressed sequence 
AU040320 180.5 0.0 0.000 0.0460 
AW549877 
expressed sequence 
AW549877 700.6 136.5 0.195 0.0461 
Zfp277 zinc finger protein 277 180.1 0.0 0.000 0.0465 
Tmed9 
transmembrane emp24 
protein transport domain 
containing 9 260.1 6.7 0.026 0.0467 
Rab13 
RAB13, member RAS 
oncogene family 28.9 892.4 30.840 0.0467 
Papd7 
PAP associated domain 
containing 7 179.2 0.0 0.000 0.0479 
Zmym6 zinc finger, MYM-type 6 179.0 0.0 0.000 0.0479 
Mrc2 mannose receptor, C type 2 755.3 130.8 0.173 0.0479 
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G2e3 
G2/M-phase specific E3 
ubiquitin ligase 382.0 24.6 0.064 0.0482 
Prtg 
protogenin homolog 
(Gallus gallus) 178.6 0.0 0.000 0.0486 
Rnf149 ring finger protein 149 276.5 8.9 0.032 0.0498 
Masp2 
mannan-binding lectin 
serine peptidase 2 177.8 0.0 0.000 0.0498 
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Symbol Gene Name Read Count 
Rn45s 45S pre-ribosomal RNA 56755301 
Lars2 leucyl-tRNA synthetase, mitochondrial 4473632 
Eef1a1 eukaryotic translation elongation factor 1 alpha 1 65146 
Rps2 ribosomal protein S2 25272 
Ncl nucleolin 24177 
Ftl1 ferritin light chain 1 21388 
Actb actin, beta 18815 
Eef2 eukaryotic translation elongation factor 2 18021 
Wdr92 WD repeat domain 92 15788 
Kif1c kinesin family member 1C 15529 
Rplp0 ribosomal protein, large, P0 14565 
Cyb5r3 cytochrome b5 reductase 3 12797 
Fth1 ferritin heavy chain 1 11992 
Rpsa ribosomal protein SA 11464 
Gm6548 
eukaryotic translation elongation factor 1 alpha 1 
pseudogene 10779 
Rpl41 ribosomal protein L41 10733 
Ccnd2 cyclin D2 10624 
Npm1 nucleophosmin 1 10281 
Kctd10 
potassium channel tetramerisation domain containing 
10 10083 
Anp32b 
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member B 10060 
Sh3pxd2a SH3 and PX domains 2A 9844 
Vim vimentin 9770 
Actg1 actin, gamma, cytoplasmic 1 9672 
Pabpc1 poly(A) binding protein, cytoplasmic 1 9401 
Dst dystonin 9341 
Hsp90ab1 
heat shock protein 90 alpha (cytosolic), class B 
member 1 9086 
Ddr2 discoidin domain receptor family, member 2 8866 
Eif3a eukaryotic translation initiation factor 3, subunit A 8815 
Gapdh glyceraldehyde-3-phosphate dehydrogenase 8778 
Ahnak AHNAK nucleoprotein (desmoyokin) 8325 
206 
	
Naa50 N(alpha)-acetyltransferase 50, NatE catalytic subunit 7804 
Gm12070 
glyceraldehyde-3-phosphate dehydrogenase 
pseudogene 7466 
Ubc ubiquitin C 7440 
Tpt1 tumor protein, translationally-controlled 1 7340 
Hspa8 heat shock protein 8 7221 
Ubb ubiquitin B 7083 
Gnb2l1 
guanine nucleotide binding protein (G protein), beta 
polypeptide 2 like 1 6840 
Trak2 trafficking protein, kinesin binding 2 6712 
Cenpb centromere protein B 6595 
Ppia peptidylprolyl isomerase A 6544 
Tmem38b transmembrane protein 38B 6158 
Rps27a ribosomal protein S27A 6120 
Rpl3 ribosomal protein L3 5783 
Rpl5 ribosomal protein L5 5739 
Myo10 myosin X 5739 
Ybx1 Y box protein 1 5667 
Net1 neuroepithelial cell transforming gene 1 5646 
S100a6 S100 calcium binding protein A6 (calcyclin) 5465 
Cald1 caldesmon 1 5465 
Plec plectin 5315 
Rps6 ribosomal protein S6 5285 
Rps3a1 ribosomal protein S3A1 5170 
Nedd4 
neural precursor cell expressed, developmentally 
down-regulated 4 5035 
Huwe1 HECT, UBA and WWE domain containing 1 4998 
Dynll2 dynein light chain LC8-type 2 4895 
Fn1 fibronectin 1 4837 
Acta2 actin, alpha 2, smooth muscle, aorta 4835 
Malat1 
metastasis associated lung adenocarcinoma transcript 1 
(non-coding RNA) 4823 
Rps14 ribosomal protein S14 4800 
Rps12 ribosomal protein S12 4759 
Rpl4 ribosomal protein L4 4759 
Bgn biglycan 4735 
Tuba1b tubulin, alpha 1B 4690 
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Myh9 myosin, heavy polypeptide 9, non-muscle 4668 
Rps18 ribosomal protein S18 4636 
Gm5643 
heterogeneous nuclear ribonucleoprotein A1 
pseudogene 4600 
Pkm pyruvate kinase, muscle 4587 
Rpl12 ribosomal protein L12 4359 
Tpm4 tropomyosin 4 4238 
Lgals1 lectin, galactose binding, soluble 1 4191 
Palld palladin, cytoskeletal associated protein 4150 
Set SET nuclear oncogene 4135 
Gnas 
GNAS (guanine nucleotide binding protein, alpha 
stimulating) complex locus 4102 
Csde1 cold shock domain containing E1, RNA binding 4076 
Arhgap11a Rho GTPase activating protein 11A 4045 
Rpl8 ribosomal protein L8 3912 
Wnk1 WNK lysine deficient protein kinase 1 3910 
Hsp90aa1 
heat shock protein 90, alpha (cytosolic), class A 
member 1 3902 
Tuba1c tubulin, alpha 1C 3885 
Rps24 ribosomal protein S24 3821 
Calr calreticulin 3779 
Map4 microtubule-associated protein 4 3675 
Tpm1 tropomyosin 1, alpha 3659 
Hdlbp high density lipoprotein (HDL) binding protein 3641 
Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3 3591 
Eif5a eukaryotic translation initiation factor 5A 3561 
Tmsb4x thymosin, beta 4, X chromosome 3475 
Trp53inp2 
transformation related protein 53 inducible nuclear 
protein 2 3435 
Myo1h myosin 1H 3423 
Sparc secreted acidic cysteine rich glycoprotein 3340 
Sptbn1 spectrin beta, non-erythrocytic 1 3278 
Pkp4 plakophilin 4 3276 
Rps8 ribosomal protein S8 3260 
Tuba1a tubulin, alpha 1A 3250 
Rpl23a ribosomal protein L23A 3226 
Rps23 ribosomal protein S23 3210 
Gm15772 ribosomal protein L26 pseudogene 3190 
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Rpl26 ribosomal protein L26 3190 
Rpl38 ribosomal protein L38 3153 
Rps4x ribosomal protein S4, X-linked 3135 
Ccng1 cyclin G1 3110 
Hspa9 heat shock protein 9 3104 
Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 3045 
Rpl10 ribosomal protein L10 3026 
Rplp1 ribosomal protein, large, P1 3018 
Ptma prothymosin alpha 3007 
Rpl31 ribosomal protein L31 3005 
Scd1 stearoyl-Coenzyme A desaturase 1 2999 
Ywhae 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon polypeptide 2988 
Rpph1 ribonuclease P RNA component H1 2988 
Eif4b eukaryotic translation initiation factor 4B 2967 
Cfl1 cofilin 1, non-muscle 2930 
Rpl27a ribosomal protein L27A 2893 
Pcbp2 poly(rC) binding protein 2 2876 
Hist1h2bq histone cluster 1, H2bq 2861 
Hist1h2br histone cluster 1 H2br 2861 
Rps29 ribosomal protein S29 2824 
Myl6 
myosin, light polypeptide 6, alkali, smooth muscle and 
non-muscle 2816 
Eno1 enolase 1, alpha non-neuron 2816 
Tmsb10 thymosin, beta 10 2804 
Col1a2 collagen, type I, alpha 2 2793 
Rpl23 ribosomal protein L23 2781 
Serbp1 serpine1 mRNA binding protein 1 2777 
Rpl18a ribosomal protein L18A 2757 
Rpl7 ribosomal protein L7 2731 
Rbm3 RNA binding motif protein 3 2716 
Eif1 eukaryotic translation initiation factor 1 2710 
Uba52 
ubiquitin A-52 residue ribosomal protein fusion 
product 1 2701 
Rpl13 ribosomal protein L13 2697 
Kpnb1 karyopherin (importin) beta 1 2670 
Tubb5 tubulin, beta 5 class I 2660 
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Nrd1 
nardilysin, N-arginine dibasic convertase, NRD 
convertase 1 2625 
Fat1 FAT tumor suppressor homolog 1 (Drosophila) 2603 
Pgk1 phosphoglycerate kinase 1 2584 
Zc3h13 zinc finger CCCH type containing 13 2583 
Htatsf1 HIV TAT specific factor 1 2570 
Rpl17 ribosomal protein L17 2545 
Fgd3 FYVE, RhoGEF and PH domain containing 3 2533 
Flna filamin, alpha 2490 
Rprl3 ribonuclease P RNA-like 3 2467 
Rps26 ribosomal protein S26 2460 
Rps5 ribosomal protein S5 2397 
Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 2377 
Thbs1 thrombospondin 1 2375 
Rps20 ribosomal protein S20 2323 
Atp5b 
ATP synthase, H+ transporting mitochondrial F1 
complex, beta subunit 2316 
Tagln transgelin 2311 
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 2303 
Cdv3 
carnitine deficiency-associated gene expressed in 
ventricle 3 2298 
Rpl9 ribosomal protein L9 2279 
Map2k7 mitogen-activated protein kinase kinase 7 2271 
Rps3 ribosomal protein S3 2260 
Cnn2 calponin 2 2225 
Lrrc58 leucine rich repeat containing 58 2211 
Rpl13a ribosomal protein L13A 2190 
Rpl37a ribosomal protein L37a 2184 
Eef1g eukaryotic translation elongation factor 1 gamma 2167 
Zeb1 zinc finger E-box binding homeobox 1 2162 
Ctnnb1 catenin (cadherin associated protein), beta 1 2151 
Rpl10a ribosomal protein L10A 2138 
Cltc clathrin, heavy polypeptide (Hc) 2136 
Ptpn11 protein tyrosine phosphatase, non-receptor type 11 2105 
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Hnrnpab heterogeneous nuclear ribonucleoprotein A/B 2097 
Rps9 ribosomal protein S9 2091 
Gm6682 tubulin, alpha 1C pseudogene 2087 
Macf1 microtubule-actin crosslinking factor 1 2072 
Samd4 sterile alpha motif domain containing 4 2068 
Rps19 ribosomal protein S19 2065 
Rpl11 ribosomal protein L11 2060 
Utrn utrophin 2038 
Hist1h2ap histone cluster 1, H2ap 2028 
Hist1h2ao histone cluster 1, H2ao 2028 
Rpl15 ribosomal protein L15 2004 
Eif4a1 eukaryotic translation initiation factor 4A1 2003 
Data represent the average of 3 samples collected from different passages of MSCs and 
their exosomes.  
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